{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "1c95a149",
   "metadata": {},
   "source": [
    "## Indication of Use Validator Proof of Concept"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b5739650",
   "metadata": {},
   "source": [
    "Milestones\n",
    "- Upload PDF and Extract key information including IFU\n",
    "\t- Store in vector store\n",
    "\t- Simple RAG Chain\n",
    "\t\t- extract IFU\n",
    "- Take IFU input and give back a score\n",
    "\t- Simple RAG Chain: query -> LLM with prompt to make comparison -> give structured response:\n",
    "\t\t- is_valid: bool\n",
    "\t\t- validity_score: int\n",
    "\t\t- reasoning\n",
    "\t\t\t- content\n",
    "\t\t\t- suggestion\n",
    "\t\t- suggested IFU\n",
    "- Chat with the 510K"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "42502ed9",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import getpass\n",
    "\n",
    "os.environ[\"OPENAI_API_KEY\"] = getpass.getpass(\"Enter your OpenAI API Key:\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "bae850a1",
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"TAVILY_API_KEY\"] = getpass.getpass(\"TAVILY_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "88abccca",
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"VeraMate\"\n",
    "os.environ[\"LANGSMITH_API_KEY\"] = getpass.getpass(\"Enter your Langsmith API Key:\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "04ef2f9c",
   "metadata": {},
   "source": [
    "### CREATE RETRIEVER FOR 501K GUIDELINES DOCUMENT"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "6bd90af1",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai.embeddings import OpenAIEmbeddings\n",
    "\n",
    "embedding_model = OpenAIEmbeddings(model=\"text-embedding-3-small\")\n",
    "embedding_dim = 1536"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "f2dcc1f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_qdrant import QdrantVectorStore\n",
    "from qdrant_client import QdrantClient\n",
    "from qdrant_client.http.models import Distance, VectorParams\n",
    "\n",
    "guidelines_client = QdrantClient(\":memory:\")\n",
    "\n",
    "guidelines_client.create_collection(\n",
    "    collection_name=\"guidelines\",\n",
    "    vectors_config=VectorParams(size=embedding_dim, distance=Distance.COSINE),\n",
    ")\n",
    "\n",
    "guidelines_vector_store = QdrantVectorStore(\n",
    "    client=guidelines_client,\n",
    "    collection_name=\"guidelines\",\n",
    "    embedding=embedding_model,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "4eeedc71",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 0, 'page_label': '1'}, page_content='The 510(k) Program: Evaluating \\nSubstantial Equivalence in Premarket \\nNotifications [510(k)] \\nGuidance for Industry and Food and Drug \\nAdministration Staff   \\n \\nDocument issued on: July 28, 2014 \\n \\nThe draft of th\\nis document issued on December 27, 2011.  \\n \\nThis document supersedes FDA’s Guidance on the CDRH Premarket Notification \\nReview Program, 510(k) Memorandum K86-3, dated June 30, 1986.  \\n \\n \\nFor questions for the Center for Devices and Radiological Health regarding this document, contact the \\nPremarket Notification (510(k)) Section at 301-796-5640. \\n \\nFor questions for the Center for Biologics Evaluation and Research regarding this document, contact the \\nOffice of Communication, Outreach and Development at 1-800-335-4709 or 240-402-7800. \\n \\n \\n \\nU.S. Department of Health and Human Services \\nFood and Drug Administration \\nCenter for Devices and Radiological Health \\nCenter for Biologics Evaluation and Research'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 1, 'page_label': '2'}, page_content='Contains Nonbinding Recommendations \\n \\n \\n \\nPreface \\n \\nPublic Comment \\n \\nYou may submit electronic comments and suggestions at any time for Agency consideration to \\nhttp://www.regulations.gov.  Submit written comments to the Division of Dockets Management, Food and \\nDrug Administration, 5630 Fishers Lane, Room. 1061, (HFA-305), Rockville, MD, 20852.  Identify all \\ncomments with the docket number FDA-2011-D-0652. Comments may not be acted upon by the Agency \\nuntil the document is next revised or updated. \\n \\nAdditional Copies \\n \\nCDRH \\nAdditional copies are available from the Internet. You may also send an e-mail request to CDRH-\\nGuidance@fda.hhs.gov to receive a copy of the guidance.  Please use the document number 1766 to \\nidentify the guidance you are requesting. \\n \\nCBER \\nAdditional copies are available from the Center for Biologics Evaluation and Research (CBER) by written \\nrequest to the address below, by email request to the email address below, by calling the phone number \\nbelow, or from the Internet at the webpage below: \\n \\n \\nCenter for Biologics Evaluation and Research (CBER),  \\nOffice of Communication, Outreach and Development,  \\n10903 New Hampshire Ave, Bldg. 71, Room 3128 \\nSilver Spring, MD 20993, or by calling 1-800-835-4709 or 240-402-7800, by email ocod@fda.hhs.gov, or \\nfrom the Internet at \\nhttp://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 2, 'page_label': '3'}, page_content='Contains Nonbinding Recommendations \\n \\n \\n \\nTable of Contents \\n \\nI. Introduction _____________________________________________________________________ 1 \\nII. Background _____________________________________________________________________ 2 \\nA. The Medical Device Amendments and Device Classification _________________________________ 2 \\nB. The 510(k) Classification Process ________________________________________________________ 3 \\nC. Evolution of the 510(k) Program ________________________________________________________ 4 \\nIII. Scope ________________________________________________________________________ 5 \\nIV. The 510(k) Decision-Making Process ______________________________________________ 5  \\nA. The 510(k) Review Standard ___________________________________________________________ 6 \\nB. The Flowchart ______________________________________________________________________ 10 \\nC. Predicate Device(s) ___________________________________________________________________ 10 \\nD. Intended Use ________________________________________________________________________ 15 \\nE. Technological Characteristics __________________________________________________________ 18 \\nF. Requests for Performance Data ________________________________________________________ 22 \\nG. The 510(k) Summary _________________________________________________________________ 26 \\nAppendix A.  510(k) Decision-Making Flowchart __________________________________________ 27 \\nAppendix B.  The 510(k) Summary Document Requirements ________________________________ 28  \\nAppendix C. Sample of 510(k) Summary Complying with 21 CFR 807.92 ______________________ 33 \\nAppendix D.  Glossary of Significant Terminology _________________________________________ 39'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 3, 'page_label': '4'}, page_content=\"Contains Nonbinding Recommendations \\n \\n 1 \\nThe 510(k) Program: Evaluating Substantial \\nEquivalence in Premarket Notifications \\n[510(k)] \\n \\nGuidance for Industry and Food and Drug \\nAdministration Staff \\n \\nThis guidance represents the Food and Drug Administration's (FDA's) current thinking on this \\ntopic.  It does not create or confer any rights for or on any person and does not operate to bind \\nFDA or the public.  You can use an alternative approach if the approach satisfies the requirements \\nof the applicable statutes and regulations.  If you want to discuss an alternative approach, contact \\nthe FDA staff responsible for implementing this guidance.  If you cannot identify the appropriate \\nFDA staff, call the appropriate number listed on the title page of this guidance.  \\n \\nI. Introduction \\nFDA developed this document to provide guidance to industry and FDA staff about current review \\npractices for premarket notification (510(k)) submissions.  The intent of this guidance is to identify, \\nexplain, and clarify each of the critical decision points in the decision-making process FDA uses to \\ndetermine substantial equivalence.  This guidance is not intended to implement significant policy \\nchanges to the current 510(k) review process.  Rather, the intent of this guidance is to enhance the \\npredictability, consistency, and transparency of the 510(k) program by describing in greater detail the \\nregulatory framework, policies, and practices underlying FDA’s 510(k) review.   \\n \\nThe draft of this guidance document contained sections addressing FDA’s Special and Abbreviated \\n510(k) programs.  FDA intends to finalize those sections separately.  Until FDA issues new final \\nrecommendations on the Special and Abbreviated 510(k) programs, the recommendations for Special \\nand Abbreviated 510(k)s contained in “The New 510(k) Paradigm - Alternate Approaches to \\nDemonstrating Substantial Equivalence in Premarket Notifications,” dated March 20, 1998, \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0801\\n87.htm) remain in effect. \\n \\nFDA's guidance documents, including this guidance, do not establish legally enforceable \\nresponsibilities.  Instead, guidances describe the Agency's current thinking on a topic and should be \\nviewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The \\nuse of the word should in Agency guidances means that something is suggested or recommended, but \\nnot required.\"), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='Contains Nonbinding Recommendations \\n \\n 2 \\nII. Background \\nA. The Medical Device Amendments and Device Classification \\nThe Medical Device Amendments (MDA) (Pub. L. 94-295) to the Federal Food, Drug, and Cosmetic \\n(FD&C) Act were enacted on May 28, 1976.  The MDA directed FDA to issue regulations that \\nclassify all devices that were in commercial distribution at that time into one of three regulatory \\ncontrol categories:  Class I, II, or III, depending upon the degree of regulation necessary to provide \\nreasonable assurance of their safety and effectiveness.  The class into which a device is placed \\ndetermines the requirements that a medical device manufacturer must meet prior to distributing a \\ndevice in interstate commerce.  According to section 513(a)(1) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)), the three device classes are defined as follows: \\n\\uf0b7 Class I:  Devices are subject to a comprehensive set of regulatory authorities called general \\ncontrols that are applicable to all classes of devices.\\n1 \\n   \\n\\uf0b7 Class II:  Devices for which general controls, by themselves, are insufficient to provide \\nreasonable assurance of the safety and effectiveness of the device, and for which there is \\nsufficient information to establish special controls to provide such assurance.\\n2 \\n \\n\\uf0b7 Class III:  Devices for which general controls, by themselves, are insufficient and for which \\nthere is insufficient information to establish special controls to provide reasonable assurance \\nof the safety and effectiveness of the device.  Class III devices typically require premarket \\napproval.\\n3   \\n                                                 \\n1 General controls apply to all classes of medical devices and provide FDA with the means of regulating devices to assure their safety \\nand effectiveness. General controls include but are not limited to provisions that relate to establishment registration and device listing; \\npremarket notification, although most class I devices are exempt by regulation from this requirement; prohibitions against adulteration \\nand misbranding; records and reports; and good manufacturing practices.  Section 513(a)(1)(A) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)(A)). \\n \\n2 The original definition of a class II device in the Medical Device Amendments of 1976 (Pub. L. 94-295) identified performance \\nstandards rather than special controls as the mechanism by which FDA could establish reasonable assurance of safety and effectiveness. \\nThe Safe Medical Devices Act of 1990 (Pub. L. 101-629) added “special controls,” which can include the promulgation of performance \\nstandards as well as postmarket surveillance, patient registries, development and dissemination of guidelines (including guidelines for \\nthe submission of clinical data in premarket notification submissions), and other appropriate actions as FDA deems necessary to \\nprovide such assurance.  Section 513(a)(1)(B) of the FD&C Act (21 U.S.C. § 360c(a)(1)(B)). \\n \\n3 Certain types of devices classified into class III that were in commercial distribution in the United States before May 28, 1976, and \\nthose determined to be substantially equivalent to such devices, may be cleared through the 510(k) process until FDA issues an \\nadministrative order requiring them to go through the premarket approval process.  Section 515(b)(1) of the FD&C Act (21 U.S.C. \\n§ 360e(b)(1)).  Prior to the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144) on \\nJuly 9, 2012, FDA had to publish regulations to require such devices to go through the premarket approval process.  Section 608(b) of \\nFDASIA (126 Stat. 1056) changed the process from rulemaking to administrative order. \\n  \\n \\n4 For the purpose of this guidance document, a “new device” means a device within the meaning of section 201(h) of the FD&C Act \\nthat is not legally marketed.  It can be either a completely new device or a modification of a legally marketed device that would require \\na new 510(k).   \\n \\n5 By contrast, an unclassified devices, as defined in FDA’s Guidance for Industry and Food and Drug Administration Staff, “Medical \\nDevice Classification Product Codes” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm285317.htm), is a pre-amendments \\nPremarket notification is the process by which a new device,4 i.e., a post-amendments device, is \\nclassified into one of these three device classes.5 A manufacturer who intends to market in the United'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='Contains Nonbinding Recommendations \\n \\n                                                                                                                                                                     \\ndevice for which a classification regulation has not been promulgated. Unclassified devices require submission of a 510(k) premarket \\nnotification to FDA. A not-classified device is a post-amendments device for which the Agency has not yet reviewed a marketing \\napplication or for which the Agency has not made a final decision on such a marketing application. A pre-amendments device is a \\ndevice that was on the market prior to the enactment of the Medical Device Amendments to the FD&C Act on May 28, 1976.   \\n \\n6 The three device classes are described in section 513(a) of the FD&C Act (21 U.S.C. § 360c(a)): \\n(1) There are established the following classes of devices intended for human use: \\n(A) CLASS I, GENERAL CONTROLS.— \\n(i) A device for which the controls . . . are sufficient to provide reasonable assurance of the safety and effectiveness of the \\ndevice. \\n(ii) A device for which insufficient information exists to determine that the controls referred to in clause (i) are sufficient to \\nprovide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such \\nassurance, but because it— \\n(I) is not purported or represented to be for a use in supporting or sustaining human life or for a use which is of substantial \\nimportance in preventing impairment of human health, and \\n(II) does not present a potential unreasonable risk of illness or injury,  \\nis to be regulated by the controls referred to in clause (i). \\n 3 \\nStates a Class I, II, or III device intended for human use, for which a Premarket Approval application \\n(PMA) is not required, must submit to FDA a premarket notification submission (often referred to as \\na 510(k)), unless the device is exempt from the 510(k) requirements of the FD&C Act and does not \\nexceed the limitations of exemptions for each of the device classification regulations (Section .9 of 21 \\nCFR Parts 862 through 892, e.g., 21 CFR 862.9, 21 CFR 864.9, etc.).  Under section 510(k) of the \\nFD&C Act, a manufacturer must submit a 510(k) to FDA at least 90 days before introducing, or \\ndelivering for introduction, a device into interstate commerce for commercial distribution so the \\nAgency can determine whether or not the device meets the criteria for market clearance (Sections \\n510(k) and (n) of the FD&C Act (21 U.S.C. §§ 360(k) & (n))).  The Agency bases its decision on \\nwhether the device is substantially equivalent (SE) to a legally marketed (predicate) device (Section \\n513(i) of the FD&C Act (21 U.S.C. § 360c(i))).  The device cannot be commercialized until FDA \\nissues an order (510(k) clearance) stating that the device has been determined to be SE (Section \\n513(f)(1) of the FD&C Act (21 U.S.C. § 360c(f)(1))). \\nB. The 510(k) Classification Process \\nAccording to section 513(f) of the FD&C Act, a new (i.e., post-amendments) device is automatically \\nin Class III and must undergo premarket approval or reclassification before it can be marketed, unless \\nit is a type of device that was in commercial distribution prior to May 28, 1976, and is SE to another \\nsuch device; or it is within a type of device introduced after May 28, 1976, that has been reclassified \\ninto Class I or II and is SE to another device within such classification.  For information about how \\nFDA’s classification product codes assist in accurate identification and tracking of current medical \\ndevices, please see FDA’s Guidance for Industry and Food and Drug Administration Staff, “Medical \\nDevice Classification Product Codes” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm2853\\n17.htm).  \\nWhen FDA determines under sections 510(k), 513(f)(1), and 513(i) of the FD&C Act that a new \\ndevice is SE to a legally marketed (predicate) device, the new device is classified into the same class \\nand subject to the same requirements as the predicate device.  (See Section IV.C.)  A determination \\nthat a new device is not substantially equivalent (NSE) to a predicate device results in the new device \\nbeing classified into Class III.  Thus, 510(k) review is both the mechanism by which a manufacturer \\nseeks marketing authorization for a new device and by which FDA classifies devices into their \\nappropriate regulatory category.  Because devices are classified according to the level of regulatory \\ncontrol necessary to provide a reasonable assurance of safety and effectiveness,\\n6 classification of a'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='Contains Nonbinding Recommendations \\n \\n                                                                                                                                                                     \\n(B) CLASS II, SPECIAL CONTROLS.—A device which cannot be classified as a class I device because the general controls \\nby themselves are insufficient to provide reasonable assurance of the safety and effectiveness of the device, and for which \\nthere is sufficient information to establish special controls to provide such assurance . . . \\n(C) CLASS III, PREMARKET APPROVAL.—A device which because— \\n(i) it (I) cannot be classified as a class I device because insufficient information exists to determine that the application of \\ngeneral controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device, and (II) cannot be \\nclassified as a class II device because insufficient information exists to determine that the special controls described in \\nsubparagraph (B) would provide reasonable assurance of its safety and effectiveness, and \\n(ii)(I) is purported or represented to be for a use in supporting or sustaining human life or for a use which is of substantial \\nimportance in preventing impairment of human health, or \\n(II) presents a potential unreasonable risk of illness or injury, \\nis to be subject, in accordance with section 515, to Premarket approval to provide reasonable assurance of its safety and \\neffectiveness. \\n \\n7 If FDA has established special controls applicable to the device type, the 510(k) would need to adequately address the issues covered \\nby the special controls for the device to be classified into Class II.  See Section 513(a)(1)(B) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)(B)).   \\n \\n8 See CDRH Preliminary Internal Evaluations – Volume I: 510(k) Working Group Preliminary Report and Recommendations \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf).  See also CDRH Preliminary \\nInternal Evaluations – Volume II: Task Force on the Utilization of Science in Regulatory Decision Making Preliminary Report and \\nRecommendations (http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220783.pdf).  See also \\n510(k) and Science Report Recommendations: Summary and Overview of Comments and Next Steps \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pdf). \\n \\n 4  \\nnew device through the 510(k) process requires FDA to determine the issues of safety and \\neffectiveness presented by the new device, and the regulatory controls necessary to address those \\nissues.7 \\nC. Evolution of the 510(k) Program \\nSince its inception, the 510(k) program has undergone a number of statutory changes.  Notably, the \\nSafe Medical Devices Act of 1990 (Pub. L. 101-629) added section 513(i), which codified FDA \\nreview practice in applying the “substantial equivalence” review standard.  In addition, FDA has \\nmodified its implementation of the program to adapt to changing circumstances and to accommodate \\nthe evolving medical device landscape.  For example, the alternative options of a Special 510(k) or an \\nAbbreviated 510(k) still exist today.  Additional information regarding these alternative options can \\nbe found in FDA’s guidance, “The New 510(k) Paradigm – Alternative Approaches to Demonstrating \\nSubstantial Equivalence in Premarket Notifications” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/ucm080189.pdf).  The current 510(k) program reflects the current statutory framework and FDA’s \\nimplementation of that framework through regulation, guidance, and administrative practice.  A \\nhistory of the 510(k) program has been summarized in other documents that FDA has published.\\n8 \\nThis guidance document provides updated information to the existing guidance document entitled \\n“Guidance on the CDRH Premarket Notification Review Program, 510(k) Memorandum K86-3” \\n(K86-3 Guidance), issued on June 30, 1986.  The K86-3 Guidance was written and issued as final \\nguidance prior to the February 27, 1997 implementation of FDA’s Good Guidance Practices (GGPs), \\nand has not been updated since its initial publication date.  This guidance replaces the K86-3 \\nGuidance.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8'}, page_content='Contains Nonbinding Recommendations \\n \\n 5 \\nIII. Scope \\nThis guidance provides recommendations to industry and FDA staff about the content of 510(k) \\nsubmissions and the decision-making process for determining substantial equivalence of devices \\nreviewed under the 510(k) program.  The guidance has been organized to coincide with the critical \\ndecision points outlined in the 510(k) Decision-Making Flowchart (See Appendix A), which has \\nbeen updated to track section 513(i) of the FD&C Act and relevant regulations more closely.  This \\ndocument provides guidance on the following issues: \\n \\n\\uf0b7 the appropriate use of multiple predicates (See Section IV.C); \\n\\uf0b7 the processes associated with determining whether a new device with new indications for use \\nhas a new intended use (See Section IV.D); \\n\\uf0b7 the process for determining whether different technological characteristics raise different \\nquestions of safety and effectiveness (See Section IV.E); \\n\\uf0b7 when performance data, with special emphasis on clinical performance data, may be \\nnecessary to support an SE determination (See Section IV.F); and  \\n\\uf0b7 how to develop 510(k) Summaries to promote greater transparency in the 510(k) decision-\\nmaking process (See Section IV.G).   \\n \\nThe overarching principles in this guidance are applicable to devices that are subject to 510(k) review \\nby CDRH, including the Office of Device Evaluation (ODE) and the Office of In Vitro Diagnostics \\nand Radiological Health (OIR), as well as devices that are subject to 510(k) review by the Center for \\nBiologics Evaluation and Research (CBER).  This guidance is not intended to supplant existing \\ndevice-specific guidance, but may cover broader areas not addressed in device-specific guidance \\ndocuments.  If you have questions about how this guidance and a device-specific guidance apply to a \\nparticular issue, please contact FDA to discuss.  In addition, this guidance does not address review \\nissues unique to combination products.  For information on combination products, please refer to the \\nOffice of Combination Products webpage \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScien\\nceandHealthCoordination/ucm2018184.htm). \\n \\nIV. The 510(k) Decision-Making Process \\nA 510(k) is a premarket submission made to FDA to demonstrate that the new device to be marketed \\nis “substantially equivalent” to a legally marketed device\\n9 (21 U.S.C. §§ 360(k), 360(n), 360c(f)(1) & \\n360c(i); 21 CFR 807.92(a)(3)) which is not subject to PMA.  Manufacturers must compare their new \\ndevice to a similar legally marketed device to support its substantial equivalence (21 U.S.C. \\n§ 360c(i); 21 CFR 807.92(a)(3)). \\n                                                 \\n9 Under 21 CFR 807.92(a)(3), a legally marketed device to which a new device may be compared for a determination \\nregarding substantial equivalence is a device that was legally marketed prior to May 28, 1976, or a device which has been \\nreclassified from class III to class II or I, or a device which has been found to be substantially equivalent through the \\n510(k) premarket notification process.   \\n \\nThe most commonly used method of demonstrating substantial equivalence is through the submission \\nand FDA review and clearance of a Traditional 510(k).  Under 21 CFR 807.87, FDA established \\nbasic content requirements for 510(k)s to be submitted by device manufacturers in support of \\nsubstantial equivalence.  The Agency has provided a general framework on how to format an original \\nsubmission for a Traditional 510(k) in FDA’s Guidance for Industry and FDA Staff, “Format for'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 8, 'page_label': '9'}, page_content='Contains Nonbinding Recommendations \\n \\n 6 \\nTraditional and Abbreviated 510(k)s” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0843\\n65.htm).  Although the basic content requirements apply to all 510(k)s, the type of data and \\ninformation necessary to establish substantial equivalence varies by the type of device and the \\ndifferences between the new device and the predicate device.  FDA has issued many device-specific \\nguidance documents that clarify the data that should be included in 510(k)s for particular device \\ntypes.  If a manufacturer is unsure of what information to include within a 510(k) submission, the \\nmanufacturer may contact FDA and submit a pre-submission to seek additional feedback to ensure \\nsubmissions contain appropriate data elements.  For more information on the pre-submission process, \\nsee FDA’s Guidance for Industry and FDA Staff, “Requests for Feedback on Medical Device \\nSubmissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/UCM311176.pdf).   \\n \\nPlease note that the use of the Standards Data Report for 510(k)s (Form 3654) \\n(http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM081667.pdf), \\nrecognized consensus standards, and device-specific guidance documents is not limited to \\nAbbreviated 510(k) submissions.  Appropriate reliance on these documents can facilitate the review \\nof all 510(k) submissions and can help to make the review process more consistent.  Medical device \\nmanufacturers should consider relying on and citing to standards and device-specific guidance \\ndocuments wherever appropriate, regardless of the type of 510(k) submission.   \\n \\nA new device does not need to be identical to the predicate device for it to be found substantially \\nequivalent to the predicate device.  In FDA’s experience, it is rare for a new device to be identical to \\na predicate device.  Given the diversity of technologies evaluated under this review standard, this \\nguidance adopts a flexible approach to determining “substantial equivalence” to accommodate \\nevolving technology while maintaining predictability and consistency to promote confidence among \\ndevice developers, practitioners, and patients.   \\nA. The 510(k) Review Standard \\n1. The Statutory Standard \\nThe 510(k) review standard (substantial equivalence of a new device to a legally marketed (predicate) \\ndevice) differs from the PMA review standard (reasonable assurance of safety and effectiveness).  \\nThe 510(k) review standard is comparative, whereas the PMA standard relies on an independent \\ndemonstration of safety and effectiveness.  Nonetheless, the principles of safety and effectiveness \\nunderlie the substantial equivalence determination in every 510(k) review.  The standard for a \\ndetermination of substantial equivalence in a 510(k) review is set out in section 513(i) of the FD&C \\nAct, which states: \\nSubstantial Equivalence \\n(i)(1)(A) For purposes of determinations of substantial equivalence under subsection (f) and \\nsection 520(l), the term \"substantially equivalent\" or \"substantial equivalence\" means, with \\nrespect to a device being compared to a predicate device, that the device has the same \\nintended use as the predicate device and that the Secretary by order has found that the device'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10'}, page_content='Contains Nonbinding Recommendations \\n \\n 7 \\n(i) has the same technological characteristics as the predicate device, or \\n(ii)(I) has different technological characteristics and the information submitted that the device \\nis substantially equivalent to the predicate device contains information, including appropriate \\nclinical or scientific data if deemed necessary by the Secretary or a person accredited under \\nsection 523, that demonstrates that the device is as safe and effective as a legally marketed \\ndevice, and (II) does not raise different questions of safety and effectiveness than the \\npredicate device. \\n(B) For purposes of subparagraph (A), the term “different technological characteristics” \\nmeans, with respect to a device being compared to a predicate device, that there is a \\nsignificant change in the materials, design, energy source, or other features of the device from \\nthose of the predicate device. \\nSafety and effectiveness factor into both parts of the FDA’s review.  First, FDA must find that the \\nintended use of the device and its predicate are “the same.”  As discussed in the Intended Use Section \\nof this guidance, differences in the indications for use, such as the population for which a device is \\nintended or the disease a device is intended to treat do not necessarily result in a new intended use.  \\nSuch differences result in a new intended use when they affect (or may affect) the safety and/or \\neffectiveness of the new device as compared to the predicate device and the differences cannot be \\nadequately evaluated under the comparative standard of substantial equivalence. (See Section IV.D.)  \\n \\nSecond, when comparing a new device to a predicate device, FDA must find that the two devices \\nhave “the same technological characteristics,” or that a “significant change in the materials, design, \\nenergy source or other features of the device” does not raise different questions of safety and \\neffectiveness and that the device is as safe and effective as a legally marketed device.   \\n \\nAlthough the 510(k) process involves a comparison of a new device to a predicate device rather than \\nan independent demonstration of the new device’s safety and effectiveness, as is required for \\napproval of a PMA, in both cases FDA’s review decision reflects a determination of the level of \\ncontrol necessary to provide a “reasonable assurance of safety and effectiveness.”\\n10  The evidentiary \\nstandard, however, is different.  In the 510(k) context, FDA generally relies, in part, on FDA’s prior \\ndetermination that a reasonable assurance of safety and effectiveness exists for the predicate device.  \\nDemonstrating basic similarities between a new device and a predicate device typically requires \\nmanufacturers to provide descriptive information such as a comparison of specifications, materials, \\nand technology.  In contrast, FDA generally evaluates differences between the new device and the \\npredicate device to determine their effect on safety and effectiveness.  It follows that the evidence \\nnecessary to show substantial equivalence will increase as differences between the new device and \\nthe predicate device increase if those differences significantly affect, or may significantly affect, \\nsafety or effectiveness (21 CFR 807.81). \\n                                                 \\n10 Under section 513(a)(2) of the FD&C Act, the safety and effectiveness of a device are to be determined: \\n(A) with respect to the persons for whose use the device is represented or intended, \\n(B) with respect to the conditions of use prescribed, recommended, or suggested in the labeling of the device, and \\n(C) weighing any probable benefit to health from the use of the device against any probable risk of injury or illness from \\nsuch use.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 10, 'page_label': '11'}, page_content='Contains Nonbinding Recommendations \\n \\n 8 \\n2. The Least Burdensome Principle \\nThe FDA Modernization Act of 1997 (FDAMA) added two provisions, commonly known as “the \\nleast burdensome provisions,” to the FD&C Act; these were amended by the FDA Safety and \\nInnovation Act of 2012 (FDASIA) (Pub. L. 112-144; 126 Stat. 1051).  The provision relating to \\nsubstantial equivalence, section 513(i)(1)(D), states: \\n \\n(i) Whenever the Secretary requests information to demonstrate that devices with \\ndiffering technological characteristics are substantially equivalent, the Secretary shall \\nonly request information that is necessary to making substantial equivalence \\ndeterminations. In making such request, the Secretary shall consider the least \\nburdensome means of demonstrating substantial equivalence and request information \\naccordingly. \\n(ii) For purposes of clause (i), the term “necessary” means the minimum required \\ninformation that would support a determination of substantial equivalence between a \\nnew device and a predicate device. \\n(iii) Nothing in this subparagraph shall alter the standard for determining substantial \\nequivalence between a new device and a predicate device. \\n \\nAlthough the statutory provision refers only to information requests related to determining the \\nsubstantial equivalence of technological characteristics of a device and its predicate, the underlying \\nprinciple that information requests should relate to the review standard is a basic principle of good \\nregulatory practice with broad applicability to the 510(k) decision-making process. \\n \\nFDA’s guidances, “The Least Burdensome Provisions of the FDA Modernization Act of 1997: \\nConcept and Principles” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0859\\n94.htm) and “Suggested Format for Developing and Responding to Deficiencies in Accordance with \\nthe Least Burdensome Provisions of FDAMA” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0736\\n79.htm) (“the Least Burdensome Guidances”), explain how FDA intends to apply the least \\nburdensome provisions.  “The Least Burdensome Provisions of the FDA Modernization Act of 1997: \\nConcept and Principles” interprets least burdensome as “a successful means of addressing a \\npremarket issue that involves the most appropriate investment of time, effort, and resources on the \\npart of industry and FDA,” and specifies that the least burdensome provisions do not affect the \\nstatutory premarket review standards for devices.  The recommendations discussed in this guidance \\nfor evaluating substantial equivalence are consistent with the principles discussed in the Least \\nBurdensome Guidances, but applies them by discussing the considerations that may affect the type of \\ninformation necessary to demonstrate substantial equivalence at different decision points in the \\nreview of a 510(k). \\n3. Categories of NSE Determinations \\nThe K86-3 Guidance stated:  “If it is clear from an initial review that a new device has a[n] intended \\nuse or technological feature that makes it NSE, the Center will not review or require performance \\ninformation in the 510(k). Instead the applicant will be notified that the device is NSE, and any \\nperformance data will be reviewed in a PMA or reclassification petition.”  The same is not true for \\nNSE decisions based on a lack of performance data, which do not preclude submission of a new \\n510(k) containing different or additional data to support a finding of substantial equivalence.  Thus, it'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='Contains Nonbinding Recommendations \\n \\n 9 \\nhas been FDA’s longstanding policy to treat NSE determinations as falling into two categories: (1) \\nthose that reflect FDA’s affirmative determination that the device is a Class III device and cannot be \\nreviewed in a 510(k) submission, and (2) those that reflect inadequacies in the evidence that preclude \\na finding of substantial equivalence.  \\nThe first category of NSE determinations includes a variety of different decisions, such as a finding \\nof a lack of a predicate device, a new intended use, or different technological characteristics that raise \\ndifferent questions of safety or effectiveness when the new device is compared to the cited predicate \\ndevice, that as a matter of law results in an NSE determination.  In most cases, FDA will provide the \\nopportunity for the manufacturer to respond to initial concerns regarding the equivalency of the new \\ndevice’s intended use or technology to a predicate device via response to a request for additional \\ninformation.  When FDA issues an NSE letter for a reason in this first category, the letter will \\ntypically not identify performance-based deficiencies.  Consequently, the device is automatically \\nclassified into Class III and will require PMA approval,\\n11 or if eligible, granting of a De Novo before \\nmarketing.  If FDA believes that the device found NSE may be eligible for the De Novo program, the \\nNSE letter will typically indicate FDA’s recommendation.  More information regarding the De Novo \\nprogram can be found in FDA’s Guidance for Industry and CDRH Staff, “New Section 513(f)(2) - \\nEvaluation of Automatic Class III Designation” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/ucm080197.pdf). \\n                                                 \\n11 Alternatives to PMAs include submission of a Product Development Protocol (PDP) (Section 515(f) of the FD&C Act) or a \\nHumanitarian Device Exemption (HDE) (Section 520(m)(2) of the FD&C Act and 21 CFR 814.104).  An HDE may be an appropriate \\noption if the device has been determined by the Office of Orphan Products Development to be eligible for an HDE through a \\nHumanitarian Use Device (HUD) designation (21 CFR 814.100 and 814.102).  Unlike other regulatory submissions, given the limited \\npatient population, an HDE only has to demonstrate a reasonable assurance of safety and probable benefit (Section 520(m)(2) of the \\nFD&C Act and 21 CFR 814.104).  For more information on HUD designations, please see FDA’s guidance “Humanitarian Use Device \\n(HUD) Designations” (http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM336515.pdf). \\n \\n12 The passage of FDASIA (Pub. L. 112-144) on July 9, 2012, included the Medical Device User Fee Amendments of 2012 (MDUFA \\nIII), Title II of FDASIA (126 Stat. 1002), which reauthorized the device user fee program for another five years.  The MDUFA III \\nCommitment Letter (http://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM295454.pdf) outlines \\nchanges to the review timeframes and/or expected interactions for many premarket submissions.   \\n \\nThe second category of NSE determinations is for those devices for which FDA has not affirmed that \\nthe new device has a different intended use or that the different technological characteristics raise \\ndifferent questions of safety or effectiveness when compared to the cited predicate device, but rather \\nthat the information provided in the submission is insufficient to demonstrate substantial equivalence \\nto the predicate device.  In this situation, FDA generally first identifies the specific additional \\ninformation – typically related to performance testing – that needs to be provided so that FDA may \\ncomplete its evaluation of substantial equivalence.  Upon receipt of FDA’s request for additional \\ninformation (either through a formal letter, email, phone call or fax), the manufacturer has the \\nopportunity to respond to FDA’s request.  If the manufacturer in its response does not provide the \\nrequested information or a substantive justification for not providing the requested information, FDA \\nwill consider the response incomplete and place the submission immediately back on hold as an \\nincomplete response.  Once a complete response is received, FDA will work with the manufacturer to \\ntry to resolve identified deficiencies in an interactive capacity following the timeframes and \\ninteractions instituted with the passage of the Medical Device User Fee Amendments of 2012 \\n(MDUFA III).\\n12  For more information on communications during the review of a 510(k) submission, \\nsee FDA’s Guidance for Industry and FDA Staff, “Types of Communication During the Review of \\nMedical Device Submissions”'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 12, 'page_label': '13'}, page_content='Contains Nonbinding Recommendations \\n \\n 10 \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm3419\\n18.htm).  If the manufacturer does not respond at all to FDA’s requests for additional information, the \\nsubmission will be subsequently withdrawn by FDA within the timeframe specified by FDA’s \\nGuidance for Industry and FDA Staff, “FDA and Industry Actions on Premarket Notification \\n(510(k)) Submissions: Effect on FDA Review Clock and Goals” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/UCM089738.pdf).  If a 510(k) is withdrawn due to a lack of response, the manufacturer may submit \\na new 510(k) with additional information that addresses the outstanding deficiencies communicated \\nby FDA based on the review of the prior 510(k).  If the manufacturer provides the requested \\ninformation after the withdrawal date, it will be considered and processed as a new 510(k) (21 CFR \\n807.87(l)); therefore, all information previously submitted would have to be resubmitted so that the \\nnew 510(k) is complete.  If a new 510(k) is submitted to address deficiencies raised in this type of \\nNSE letter, as explained in FDA’s Guidance for Industry and FDA Staff, “Refuse to Accept Policy \\nfor 510(k)s” (http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-\\ngen/documents/document/ucm315014.pdf), the new 510(k) should clearly identify how the \\noutstanding issues have been addressed and cross-reference where the new information is provided \\nwithin the newly submitted 510(k).  Failure to cite the prior 510(k) number may result in a Refuse to \\nAccept decision.     \\nB. The Flowchart \\nThe 510(k) Substantial Equivalence Decision-Making Process Flowchart (K86-3 Flowchart) was \\noriginally presented in the K86-3 Guidance and has served as the overarching “framework” for \\n510(k) decision-making for decades.  The K86-3 Flowchart has provided a concise summary of the \\n510(k) decision-making process and serves as a common frame of reference for scientific and \\nregulatory discussions related to the 510(k) process.  However, the K86-3 Flowchart has not been \\nupdated since 1986 and, consequently, does not incorporate certain terminology set out in subsequent \\namendments to the FD&C Act.  Furthermore, the K86-3 Flowchart’s visual structure may be more \\ncomplex than necessary.  To specifically address these issues, a modified Flowchart is provided that \\nboth more closely tracks the language of section 513(i) of the FD&C Act and relevant regulations, \\nand visually simplifies our presentation of the decision-making algorithm.   \\nIt should be noted that the 510(k) Decision-Making Flowchart (the Flowchart) (see Appendix A) is \\nmeant to be used in conjunction with this guidance document and not as a “stand-alone” document \\nwithout appropriate references to the context of each critical decision point.    \\nC. Predicate Device(s) \\nAs discussed in Section IV.A, the 510(k) review standard is substantial equivalence of a new device \\nto a legally marketed device.  Under 21 CFR 807.92(a)(3), a legally marketed device is a device that \\n(i) was legally marketed prior to May 28, 1976 (preamendments device13) and for which a PMA is \\nnot required; or (ii) has been reclassified from Class III to Class II or I; or (iii) has been found SE \\nthrough the 510(k) process.  For purposes of determining substantial equivalence, the legally \\nmarketed device is commonly referred to as the “predicate device” or “predicate.”  While \\nmanufacturers may identify more than one predicate device, only one is required.  FDA encourages \\n                                                 \\n13 See Preamendment Status \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ComplianceActivities/ucm072746.htm).'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 13, 'page_label': '14'}, page_content='Contains Nonbinding Recommendations \\n \\n 11 \\nmanufacturers to identify a single predicate device to simplify and facilitate the decision-making \\nprocess.  When a manufacturer does identify multiple predicates, the primary predicate refers to \\nthe one with indications for use and technological characteristics most similar to the device under \\nreview.  Although using a single predicate is optimal, when multiple predicates are appropriate (as \\ndescribed in the examples below), FDA recommends identifying a primary predicate in the \\nsubmission to facilitate a timely, well-supported decision.   \\nSection 513(i) of the FD&C Act and 21 CFR 807.100(b) state that, for a new device to be considered \\nsubstantially equivalent to a predicate device, the new device must have the same intended use as the \\npredicate device and the same technological characteristics or different technological characteristics \\nthat do not raise different questions of safety and effectiveness than the predicate device.  Therefore, \\nthe use of a “split predicate” is inconsistent with the 510(k) regulatory standard.  “Split predicate” \\nrefers to a situation in which a manufacturer is attempting to “split” the 510(k) decision making \\nprocess by demonstrating that a new device has the same intended use as one marketed device while \\ncomparing the new device’s technological characteristics with a second marketed device that has a \\ndifferent intended use.  As a general matter, to find a device substantially equivalent, FDA must be \\nable to address Decision Points 1 through 4 in the Flowchart using one predicate device identified by \\nthe manufacturer.  FDA may use one or more additional devices proposed by the manufacturer in \\ncertain instances to help support substantial equivalence, as described below.     \\n1. Multiple Predicates \\nA manufacturer may use multiple predicate devices\\n14 to help demonstrate substantial equivalence in \\ncertain circumstances.  Manufacturers sometimes choose to do this when combining features from \\ntwo or more predicate devices with the same intended use into a single new device, when seeking to \\nmarket a device with more than one intended use, or when seeking more than one indication for use \\nunder the same intended use, as described in the examples below.  \\n                                                 \\n14 See 510(k) and Science Report Recommendations: Summary and Overview of Comments and Next Steps.  \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pdf).     \\n \\n \\nMultiple Predicates Example 1:   \\nA manufacturer submits a 510(k) for a new hemodialysis catheter.  This new catheter has an \\nextension (the portion of the device outside the body) design that is similar to predicate A and a \\ntip (the portion of the device inside the body) design similar to predicate B.  Both predicates A \\nand B have the same intended use as the new device. In this example, the manufacturer is relying \\non both predicate A and predicate B, which have the same intended use as the new device, to \\nsupport substantial equivalence with respect to technological characteristics.  The manufacturer \\nmay choose either predicate as the primary predicate in this example.   \\n \\nMultiple Predicates Example 2:   \\nA manufacturer submits a 510(k) for a plate indicated for fixation of both diaphyseal (the shaft of \\na long bone) and epiphyseal (the ends of a long bone) fractures, i.e., the plate can be used to set a \\nlong bone, such as the femur or thigh bone, that is broken in the middle or at the ends.  The \\nmanufacturer cites a predicate device that is a plate indicated for middle bone fractures only and \\nanother predicate device that is indicated specifically for bone tip fractures.  While the indications \\nfor use of each predicate device are different, both devices have the same intended use, namely,'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 14, 'page_label': '15'}, page_content='Contains Nonbinding Recommendations \\n \\n 12 \\nfracture fixation of the long bone.15  Thus, although the manufacturer could have used a single \\npredicate device, in cases where a manufacturer intends to market a device for more than one \\nindication and a different predicate exists to support each specific indication, the manufacturer \\nmay cite more than one relevant predicate device to support an SE determination.  In this case, \\nusing two appropriate predicates clearly identified by the manufacturer helped to facilitate \\nclearance of the new device, which was indicated to treat both types of fractures treated by the \\npredicates.   \\n                                                 \\n15 It is important to note that if multiple predicates are used to support the same intended use, any different technological characteristics \\nbetween the new device and the cited predicate devices must not raise different questions of safety and effectiveness.  Section 513(i) of \\nthe FD&C Act (21 U.S.C. § 360c(i)). \\n \\nMultiple Predicates Example 3:   \\nA manufacturer submits a 510(k) for a laser platform that consists of two hand pieces:  an \\nEr:YAG laser hand piece and a Q-Switch Nd:YAG laser hand piece.  The manufacturer cites two \\npredicates to support substantial equivalence for both of their requested proposed indications for \\nuse.  In this case, each predicate cited does not share the same indications for use as the other \\npredicate because each predicate consists of only one hand piece in which the indications \\ncorrespond to the indications for one of the hand pieces included in the new device.  However, the \\nindications for both hand pieces fall within the scope of the general intended use of lasers, \\n“incision, excision, ablation, vaporization of soft tissue.”  The Er:YAG laser hand piece is \\nindicated for the incision, excision, ablation, vaporization of soft tissue; and the Q-Switch \\nNd:YAG laser hand piece is indicated for tattoo removal.  The new device is found substantially \\nequivalent to the predicate devices because it has the same intended use and the new device’s \\ntechnological characteristics are similar to the cited predicates. \\n \\nIn each example above, a single predicate could have been used to establish substantial equivalence \\nof the new device, but the manufacturer used multiple predicates to show that FDA had found similar \\ntechnology or indications to be substantially equivalent.     \\n \\nMultiple Predicates Example 4:   \\nA manufacturer submits a 510(k) for a multi-parameter monitor.  The monitor includes different \\ntechnologies that can stand alone independently, but can also be used together for the general \\nintended use of measuring patient vital information.  If there is a predicate device for each of the \\nparameters, then the combination of these parameters, assuming that monitoring of each \\nindividual parameter does not interfere with the others, can be found substantially equivalent.   \\n \\nIt should be noted that in Examples 2, 3, and 4 above, the specific indications of the new device may \\nnecessitate new performance testing, but they do not change the overall intended use of the device \\nrelative to the predicates.  These types of situations will need to be assessed on a case-by-case basis; \\nin some situations, a specific indication may actually alter the overall intended use of the device in \\nwhich case the multiple predicates concept may not be applicable.  More information regarding when \\na specific indication is reasonably included within a general indication can be found in FDA’s \\nGuidance for Industry, “General/Specific Intended Use” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0739\\n44.htm). \\n \\nFeatures can also be added to a new device to increase convenience of use and/or functionality, \\nwithout altering the intended use or risk profile (relative to a predicate) of the new device.  Under'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 15, 'page_label': '16'}, page_content='Contains Nonbinding Recommendations \\n \\n 13 \\nsuch circumstances, the device with the added feature can be reviewed in a 510(k), even if the added \\nfeature consists of a component that may fall under a different classification regulation.  A catheter-\\nthermometer construct is useful in illustrating this concept.   \\n \\nMultiple Predicates Example 5:   \\nA manufacturer submits a 510(k) for a urinary catheter with a thermometer.  The \\nthermometer/temperature-measuring feature is not affecting the intended use or risks of using the \\ncatheter (assuming it is integrated appropriately), nor is the catheter affecting the performance or \\nrisk profile of the thermometer.  The temperature-measuring feature is a convenience component \\nthat is added to the catheter, with the intended use of the device still being that of the catheter to \\npass fluids to or from the urinary tract, so it is appropriate to have a legally marketed catheter \\nserving as the primary predicate. \\n \\nThere are obvious limitations to feature/component additions in the 510(k) program.  If a feature is \\nadded which alters the intended use of the new device and/or alters the safety profile (i.e., introduces \\nnew or additional risk factors) such that comparison to a predicate cannot be made, the new device is \\nineligible for the 510(k) program.  A new device with a new design feature or added component must \\nmeet the SE standard with at least a single predicate from the same classification regulation.   \\n2. Reference Devices \\nWhen demonstrating substantial equivalence in a 510(k) submission, manufacturers sometimes direct \\nattention to similar situations FDA has encountered in the past.  If a manufacturer successfully \\nnavigates through Decision Point 4 on the Flowchart using a single predicate device, other legally \\nmarketed devices, which FDA calls “reference devices,” may be used to support scientific \\nmethodology or standard reference values at Decision Point 5a.   \\nIt is important to note that a reference device is not considered a predicate device and it cannot be \\nused to address Decision Points 1 – 4 on the Flowchart.  Additionally, the applicability of a reference \\ndevice will need to be reviewed by FDA for its appropriateness.  If a selected reference device is used \\nin an anatomical location or for a physiological purpose that is considerably different than that of the \\nnew device, its utility as a reference device may be limited. \\nIf a manufacturer intends to use a reference device, the manufacturer should provide a scientific \\nrationale that justifies its use.  This concept is illustrated in the Reference Device Examples below. \\nWe recommend that you read these examples side-by-side with the Flowchart in Appendix A so that \\nyou can follow the decision-making process. \\nReference Device Example 1:  A manufacturer submits a 510(k) for a total knee implant with \\ncoating X (the new device).  Other coated knee implants with the same intended use with coatings \\nA, B, and C are legally marketed.  In addition, a total hip implant with coating X is legally \\nmarketed.  The manufacturer cites the legally marketed knee implant with coating A as the \\npredicate device.  FDA determines that the new device has an appropriate predicate device (thus, \\nanswering “yes” at Decision Point 1) and the new device has the same intended use as the \\npredicate device (thus, answering “yes” at Decision Point 2 in the Flowchart).\\n16  However, FDA \\n                                                 \\n16 The answer at Decision Point 2 may possibly be “no” if the predicate device is uncoated.  Introducing a coated arthroplasty device \\ninto an anatomical location which previously only had non-coated devices would likely create a new intended use due to the different \\nfixation methods.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='Contains Nonbinding Recommendations \\n \\n 14 \\ndetermines that the new device does not have the same technological characteristics as the \\npredicate device (thus, answering “no” at Decision Point 3 in the Flowchart), because the new \\ndevice (knee implant with coating X) has a chemical profile different from the chemical profile of \\nthe cited predicate device (knee implant with coating A).  There are no other technological \\ndifferences between the new device and the cited predicate device (knee implant with coating A).  \\nFDA determines that the new device does not raise different questions of safety and effectiveness.  \\nIn this case, FDA determines that the safety and effectiveness questions regarding the coating \\nmaterial are whether it is biocompatible and whether it affects the fixation of the implant and \\nthese questions apply to both the new device and predicate device (thus, answering “no” at \\nDecision Point 4 in the Flowchart).   \\n \\nAfter Decision Point 4 in the Flowchart, if appropriate, the manufacturer may refer to the \\nreference device (the hip implant with coating X in this situation) to support the appropriate \\nscientific methods for the characterization of coating X on the new knee implant device.  In this \\nparticular example, the manufacturer provided an adequate scientific rationale to support that the \\nmethods used to characterize the biocompatibility and characteristics of the coating (e.g., \\nstrength, abrasion, etc.) on the hip implant are applicable to the knee implant.\\n17  The reference \\ndevice (hip implant with coating X) is used in this case solely to assist with the characterization of \\nthe coating on the new device (knee implant with coating X).    \\n                                                 \\n17 The applicability of the scientific methodology used to characterize certain aspects of a legally marketed device will depend upon the \\nspecific scenario.  In this example, it is determined that the duration of contact, which affects the biocompatibility testing, and the \\nmechanical testing conducted to fully characterize the coating on the hip implant are directly relevant and informative for the same \\ncoating applied to the knee implant.  However, if the manufacturer wanted to rely on the scientific methodology for a coating used in a \\ndifferent type of implant (e.g., cardiovascular), it may not be appropriate to exercise this approach.    \\n \\n \\nReference Device Example 2:  A manufacturer submits a 510(k) for an over-the-counter blood \\nglucose test system (glucose meter).  Other glucose meters with the same intended use are legally \\nmarketed.  The manufacturer cites a legally marketed glucose meter as the predicate device.  FDA \\ndetermines that the new device has an appropriate predicate device (thus, answering “yes” at \\nDecision Point 1) and the new device has the same intended use as the predicate device (thus, \\nanswering “yes” at Decision Point 2 in the Flowchart).  The manufacturer has not demonstrated \\nthat the new device has the same technological characteristics as the predicate device (thus, \\nanswering “no” at Decision Point 3 in the Flowchart), but the new device does not raise different \\nquestions of safety and effectiveness (thus, answering “no” at Decision Point 4 in the Flowchart).   \\n \\nBecause glucose meters of this type typically have relatively high inherent total error due to \\nlimitations in their technology and other factors, in order to sufficiently characterize the analytical \\nperformance of the new device (and answer “yes” at Decision Point 5a in the Flowchart), the new \\ndevice uses the same approach to characterize analytical performance as the predicate device.  \\nSpecifically, the accuracy of the new device is evaluated by comparing its blood glucose results \\nto reference values generated on a laboratory-based glucose measurement device that has been \\nwell-validated for precision and accuracy, and that is traceable to a higher order, e.g., \\ninternationally recognized standard.  If the performance of the new device (including accuracy \\ncompared to the reference values from a reference device) is equivalent to the performance of the \\npredicate device (including accuracy of the predicate compared to the reference values from a \\nreference device), the FDA would determine that the data demonstrate equivalence (thus \\nanswering “yes” at Decision Point 5b in the Flowchart).'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='Contains Nonbinding Recommendations \\n \\n 15 \\n3. Lack of Predicate Device \\nIf a predicate device with the same intended use cannot be identified, or if the new device’s different \\ntechnological characteristics raise different questions of safety or effectiveness, a manufacturer may \\nsubmit a De Novo request, either after receipt of an NSE letter or directly requesting classification \\nthrough the De Novo process.18  For high risk devices, a PMA (or alternative submission type) may \\nbe required.  \\n                                                 \\n18 Section 607 of FDASIA (Pub. L. 112-144; 126 Stat. 1054), which was enacted on July 9, 2012, amended section 513(f)(2) of the \\nFD&C Act by providing the option of directly submitting a request for De Novo classification without the need for an NSE \\ndetermination.  A manufacturer who intends to submit a direct De Novo request is encouraged to engage in dialogue with FDA through \\nthe pre-submission process to obtain additional feedback related to whether a valid predicate exists for the new device and appropriate \\nperformance data that will be necessary to support a reasonable assurance of safety and effectiveness.  For more information on the pre-\\nsubmission process, see FDA’s Guidance for Industry and FDA Staff, “Requests for Feedback on Medical Device Submissions: The \\nPre-Submission Program and Meetings with Food and Drug Administration Staff” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM311176.pdf). \\n \\n19 Although devices recently cleared under the 510(k) program are often selected as the predicate device to which substantial \\nequivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2) \\nof the FD&C Act provides that a predicate device may not have been removed from the market at the initiative of the Commissioner of \\nFood and Drugs or been determined to be misbranded or adulterated by a judicial order.  See also 21 CFR 807.100. \\n \\n20 This guidance is not intended to supplant either of the following guidance documents:  “Determination of Intended Use for 510(k) \\nDevices; Guidance for CDRH Staff (Update to K98-1)” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082162.htm) or “General/Specific \\nIntended Use” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm). \\n \\n21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations” \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm259173.htm). \\n \\n4. Identification and Documentation of the Predicate(s) \\nAlthough manufacturers may cite more than one predicate device in a 510(k), FDA recommends that \\nthe manufacturer clearly identify the primary predicate device to which substantial equivalence is \\nbeing claimed.\\n19  Further, as part of the decision-making process, FDA should clearly cite the \\npredicate device relied upon in determining substantial equivalence for the new device in its review \\ndocumentation.  If multiple predicates or reference devices are used in accordance with this guidance, \\nthe manufacturer should identify each device and explain why more than one predicate or a reference \\ndevice is necessary and appropriate to support substantial equivalence.  Manufacturers should choose \\nthe most appropriate single or primary predicate for their new device, and should limit the multiple \\npredicates to those most helpful in facilitating review of the new device and to the minimum number \\nnecessary to support substantial equivalence.  Predicate device(s) relied upon for SE must be \\naccurately cited in the 510(k) Summary (see Appendix B) according to 21 CFR 807.92 (a)(3).  \\nReference devices also may be cited in the 510(k) Summary.   \\nD. Intended Use \\nUnder section 513(i) of the FD&C Act, FDA may only determine that a device is substantially \\nequivalent to a predicate device if it has the same intended use.20  (Refer to the 510(k) Decision-\\nMaking Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE \\ndetermination generally reflects a finding that a change in the indications for use of a device creates a'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19'}, page_content='Contains Nonbinding Recommendations \\n \\n 16 \\nnew intended use.  This section of the guidance provides further clarification about the terms \\n“intended use” and “indications for use,” describes how FDA determines what the intended use of a \\ndevice is, and provides examples of changes in indications for use that may constitute a new intended \\nuse making the device ineligible for review under the 510(k) program.     \\n1. Explanation of Intended Use and Indications for Use \\nFor purposes of substantial equivalence, the term intended use means the general purpose of the \\ndevice or its function, and encompasses the indications for use.  The term indications for use, as \\ndefined in 21 CFR 814.20(b)(3)(i), describes the disease or condition the device will diagnose, treat, \\nprevent, cure or mitigate, including a description of the patient population for which the device is \\nintended.\\n22  The intended use of a device is one criterion that determines whether a device can be \\ncleared for marketing through the 510(k) process or must be evaluated in a PMA (or alternative \\nsubmission type), or if appropriate, a De Novo request.  The proposed labeling in a 510(k) is used to \\ndetermine a device’s intended use (Section 513(i)(1)(E) of the FD&C Act).  The indications for use \\nstatement in a 510(k) is also a factor in determining a device’s intended use.  Consistency between \\nthe indications for use statement and the proposed labeling will facilitate the review of the 510(k). \\n \\n                                                 \\n22 We have a long-standing policy of applying the definition of indications for use in the PMA regulation at 21 CFR 814.20(b)(3)(i) in \\nthe same way in the 510(k) context. \\n \\n23 For purposes of Section IV.D, the term “new” in describing indications for use refers to an indication that is new or differs from that \\nof the predicate device. \\nA finding of substantial equivalence means that the indications for use of the new device fall within \\nthe intended use of the predicate device and, therefore, the two devices have the same intended use.  \\nFor devices with general indications for use that do not specify a disease, condition, or population (or \\nan anatomical site from which a disease state or population may be inferred), the indications for use \\nand intended use are the same.  Such indications for use are referred to as “tool type” indications for \\nuse.  Examples of devices with “tool type” indications for use include devices such as scalpels, which \\nare often indicated for cutting tissue, or imaging devices, which are often indicated for taking images \\nof the body.  A scalpel indicated for removing a particular type of cancerous cell, however, has \\nindications for use specific to the identified disease, condition, or population, and therefore, does not \\nhave “tool type” indications for use. \\n2. Determining Intended Use \\nSection 513(i)(1)(E)(i) of the FD&C Act provides that the FDA’s determination of intended use of a \\ndevice “shall be based upon the proposed labeling” submitted in a 510(k).  When a review of the \\nindications for use and all other information in the proposed labeling submitted with a 510(k) \\nsupports an intended use that is the same as that of the predicate device, FDA will determine that the \\nnew device and predicate device have the same intended use.  This guidance does not address FDA’s \\nauthority to consider information outside the labeling in reviewing a 510(k) and issue an “SE with \\nlimitations” under section 513(i)(l)(E) of the FD&C Act because “there is a reasonable likelihood that \\nthe device will be used for an intended use not identified in the proposed labeling” and such use \\n“could cause harm.”  For information on “SE with limitations,” please see the guidance document, \\n“Determination of Intended Use for 510(k) Devices; Guidance for CDRH Staff (Update to K98-1 )” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0821\\n62.htm).  When a review of the labeling submitted with a 510(k) shows that the indications for use of \\na new device and predicate device differ, FDA must evaluate whether the new23 indications for use'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='Contains Nonbinding Recommendations \\n \\n                                                                                                                                                                     \\n \\n24 See 21 CFR 807.92(a)(5); see also FDA guidance “General/Specific Intended Use” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm) which implements section \\n513(i)(1)(F) of the FD&C Act.   \\n 17 \\nfall within the same intended use as that of the predicate device.  As described in Section IV.A, \\nbecause the substantial equivalence determination is grounded in safety and effectiveness, this \\ndetermination depends upon the safety and effectiveness of the new device for the new indications \\nrelative to the safety and effectiveness of the predicate device. \\nOnce FDA has determined the indications for use of the new device upon review of the proposed \\nlabeling, FDA may rely upon relevant clinical and/or scientific information, that does not appear in \\nthe proposed labeling submitted with the 510(k), regarding the safety and effectiveness of the new \\nindications for use.  For example, FDA may rely upon publicly-available scientific information or \\nAgency knowledge about how a disease progresses to determine whether indications for use to treat a \\ncertain disease or anatomical site constitute a new intended use.   \\n3. Determining When Indications for Use Result in a New Intended Use \\nNot every change in indications for use that may affect safety or effectiveness will result in a finding \\nof a new intended use.  Only a change in the indications for use that raises different questions of \\nsafety and effectiveness and therefore, precludes a meaningful comparison with the predicate device \\nconstitutes a new intended use.  FDA may find changes in indications for use of a device to constitute \\na new intended use when the changes raise a safety or effectiveness issue that was not raised by the \\npredicate device, or the changes have the potential to significantly increase a safety or effectiveness \\nconcern raised by the predicate device.\\n24  In the first case, reliance on a predicate device is inadequate \\nbecause the safety or effectiveness issue was not considered in reviewing the 510(k) for the predicate \\ndevice.  In the second case, although the safety or effectiveness issue may have been considered in \\nthe 510(k) for the predicate device, the finding of substantial equivalence for the predicate device \\ncannot be generalized to the new indications for use because of a probable, significant change in the \\nincidence or severity of the issue.  In both cases, the predicate device is not an adequate “proxy” for \\nan independent determination of safety and effectiveness.   \\nIllustrative Example 1:  A new device’s instructions for use describe using a general surgery \\ndevice in a body cavity, but the predicate device is used only to treat external injuries.  A \\ncomparison to the predicate device may not be adequate to address the risk of infection posed by \\ninternal use of the device.  Because of the need for an independent assessment of an issue that \\nwas not evaluated or was of significantly less concern during FDA’s review of the 510(k) for the \\npredicate device, FDA may determine that the indication for use of the new device constitutes a \\nnew intended use and a PMA (or alternative submission type), or if appropriate, a De Novo \\nrequest, is required.   \\n \\nIllustrative Example 2:  A 510(k) for an existing surgical ablation device cleared for ablation of \\ncardiac tissue has now been submitted for the treatment of atrial fibrillation. While the devices are \\nsimilar in technology, additional clinical testing has been conducted to demonstrate that not only \\ncan the device ablate cardiac tissue, but also that doing so can treat atrial fibrillation safely and \\neffectively.  While the question of whether or not cardiac tissue can be safely and effectively \\nablated was raised by the predicate device, FDA has determined that the specific indication for \\nthe treatment of atrial fibrillation constitutes a new intended use because it raises questions of \\nboth safety and effectiveness not raised by the predicate device.  Specifically, treatment of atrial'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21'}, page_content='Contains Nonbinding Recommendations \\n \\n 18 \\nfibrillation requires extensive ablation to create linear lines of conduction block in a maze-like \\npattern that eliminates fibrillatory conduction in the atria.  The effectiveness assessment for the \\ntreatment of atrial fibrillation warrants a clinical outcome study.  Furthermore, the risks of \\niatrogenic heart block and collateral cardiac or extra-cardiac damage are either raised or increased \\nwhen such a complex and extensive lesion set is created.  As a result, a PMA (or alternative \\nsubmission type) is required. \\n4. Changes in Indications for Use that May Result in a New Intended Use \\nAll new indications for use should be evaluated to determine whether they reflect a new intended use.  \\nCertain types of changes, however, warrant particular attention in evaluating whether the new \\nindications for use result in a new intended use because they are more likely to significantly affect \\nsafety or effectiveness: \\n \\n\\uf0b7 a change from a functional/performance indication to a treatment or aesthetic indication; \\n \\n\\uf0b7 a change from a diagnostic indication to a screening indication, or vice versa; \\n \\n\\uf0b7 a change in the anatomical structure of use; \\n \\n\\uf0b7 a change in the patient population (e.g., adult versus pediatric; different disease populations);  \\n \\n\\uf0b7 a change in the clinical context or setting (e.g., periodic monitoring versus continuous \\nmonitoring; hospital versus home use). \\nE. Technological Characteristics \\nAfter FDA has determined that a valid predicate device exists for a new device and that both devices \\nhave the same intended use, FDA will move to Decision Points 3 and 4 of the Flowchart (see \\nAppendix A).  In these steps of the 510(k) review process, FDA compares the technological \\ncharacteristics of the new device and the predicate device to determine whether the new device has \\nthe same technological characteristics as the predicate, and if not, whether the different technological \\ncharacteristics raise different questions of safety and effectiveness.\\n25  Devices reviewed under the \\n510(k) program commonly have different technological characteristics from their predicate device(s); \\nhowever, FDA rarely makes a finding of NSE at Decision Point 4.\\n26   \\n                                                 \\n25 Section 513(i)(1)(A) of the FD&C Act and 21 CFR 807.100(b)(2).  “Different technological characteristics” are defined as \\n“significant change in the materials, design, energy source, or other features of the device from those of the predicate device.”  Section \\n513(i)(1)(B) of the FD&C Act and 21 CFR 807.100(b)(2)(ii)(A). \\n \\n26 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”  \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm259173.htm).  \\n \\n1. Step 1 – Identification of Technological Characteristics of the New and Predicate \\nDevice \\nFor FDA to evaluate whether differences exist between the technological characteristics of the new \\ndevice and the predicate device(s), the manufacturer should clearly identify the technological \\ncharacteristics of each device individually.  Technological characteristics include materials, design,'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content=\"Contains Nonbinding Recommendations \\n \\n 19 \\nenergy source, and other device features, as defined in section 513(i)(1)(B) of the FD&C Act and 21 \\nCFR 807.100(b)(2)(ii)(A). \\n  \\nTo facilitate FDA’s review of a device’s technological characteristics, the device description in a \\n510(k)\\n27 should include the information necessary to explain the new device’s technological \\ncharacteristics, including similarities in materials, design, energy source, and other device features.  \\nThis information will be evaluated by FDA to determine whether the technological characteristics of \\nthe new device are different and, if so, whether they raise different questions of safety and \\neffectiveness as compared to the predicate(s).  Examples of key characteristics that should be \\nprovided as part of a 510(k) submission include, but are not limited to, the following features: \\n                                                 \\n27 FDA’s regulations require manufacturers to include in their 510(k)s “[a] description of the device that is the subject of the premarket \\nnotification submission, such as might be found in the labeling or promotional material for the device, including an explanation of how \\nthe device functions, the scientific concepts that form the basis for the device, and the significant physical and performance \\ncharacteristics of the device, such as device design, material used, and physical properties.” 21 CFR 807.92(a)(4); see also 21 CFR \\n807.87(f). \\n \\n28 The original Flowchart from the K86-3 Guidance included a decision point related to whether or not “descriptive characteristics” \\nwere precise enough to ensure equivalence.  However, the term “descriptive characteristics” does not appear in the statute or \\nregulations.  The 510(k) Decision-Making Flowchart described in Appendix A specifically addresses this to reflect the statute more \\nclosely and minimize confusion. \\n \\n29 For additional considerations, refer to the FDA guidance, “Use of International Standard ISO-10993, 'Biological Evaluation of \\nMedical Devices Part 1: Evaluation and Testing' (Replaces #G87-1 #8294) (blue book memo)” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080735.htm).  See also Draft Guidance \\nfor Industry and FDA Staff, “Use of International Standard ISO-10993, ‘Biological Evaluation of Medical Devices Part 1: Evaluation \\nand Testing’” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM348890.pdf). FDA’s draft \\nguidance represents the Agency’s proposed approach on this topic.      \\n \\n \\n\\uf0b7 An overall description of the device design.  A complete description of the device may be \\nfacilitated by the submission of engineering drawings or other figures.  If the device consists \\nof multiple components, a diagram identifying how the different components of the device \\nsystem work together may be beneficial.  The device description should also include a \\ndiscussion of the physical specifications, dimensions and design tolerances that are critical to \\nthe new device.\\n28  Significant features of the new device should have a clear purpose within \\nthe context of the overall design and intended use.  In cases where this is not apparent, it is \\nimportant for the 510(k) submission to provide a discussion of how a particular device design \\nor component contributes to the overall use and function of the new device.  \\n \\n\\uf0b7 Materials.  For many devices, a complete identification of the detailed chemical formulation \\nused in the materials of construction, especially for those materials that come into contact \\nwith the patient, should be provided.  Note that the FDA does not clear/approve materials.\\n29  \\nAny additives, including color additives, coatings, or other surface modifications should also \\nbe identified.  For some devices, the processing of the material (e.g., forged vs. cast) or the \\nstate of the material (e.g., amorphous vs. crystalline) may also significantly contribute to or \\naffect the overall safety or function of the device, and so should be included as part of the \\ndevice description, as applicable.   \\n \\n\\uf0b7 Energy sources.  This not only includes energy delivery to the device, including the use of \\nbatteries, but also energy delivery that is part of the functional aspect of the device (e.g., laser, \\nradiofrequency, ultrasound, etc.) and that affects the patient and/or the health care\"), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 22, 'page_label': '23'}, page_content='Contains Nonbinding Recommendations \\n \\n 20 \\nprofessional using the device.  Where applicable, a discussion of this characteristic should be \\nprovided.    \\n \\n\\uf0b7 Other key technological features.  These include, but are not limited to, software/hardware \\nfeatures, density, porosity, degradation characteristics, nature of reagents (recombinant, \\nplasma derived, etc.), principle of the assay method, etc., that are not explicitly included as \\npart of the materials, design or energy source characteristics.  These technological features \\nshould be included as part of the device description in the 510(k) submission, as appropriate \\nfor the specific device technology.\\n30   \\n                                                 \\n30 We encourage manufacturers to determine whether there is an applicable device-specific guidance or special controls for the device \\ntype as provided in a special controls document or classification regulation.   \\n \\nA 510(k) submission must also contain information about the technological characteristics of the \\npredicate device (21 CFR 807.87(f), 807.92(a)(3) and (a)(6)).  The manufacturer of the new device \\nshould provide information necessary and sufficient to fully and clearly identify and describe the \\ntechnological characteristics of the predicate device so that FDA can conduct a comparative \\nassessment of the technological characteristics, as further described in Step 2. \\n2. Step 2 – Identification of Differences in Technological Characteristics Between the \\nNew and Predicate Device \\nOnce the technological characteristics of the new and predicate device(s) have been clearly identified, \\nthe next step involves a comparison of these characteristics to identify any differences.  This may \\ninvolve a comparison of detailed specifications as well as a comparison of the system-level \\ntechnological characteristics of the devices.  FDA relies upon information provided about the \\npredicate device, in addition to the information in our files as appropriate, and the new device to \\ndetermine whether the new device has different technological characteristics (Decision Point 3) in \\ncomparison to the predicate(s). \\n \\nAt this point, FDA will assess whether the similarities/differences in technological characteristics \\nbetween the new and predicate device(s) have been appropriately identified.  FDA highly \\nrecommends that the manufacturer summarize this information in tabular format to facilitate this step \\nof review.   \\n3. Step 3 – Determination of Whether the Differences in Technological Characteristics \\nRaise Different Questions of Safety and Effectiveness \\nIf FDA determines that there are differences in the technological characteristics of the new device \\nand the predicate device, FDA will review and evaluate all relevant information bearing on any such \\ndifferences in technological characteristics to determine whether they raise different questions of \\nsafety and effectiveness for the new device as compared to the predicate device (Decision Point 4 on \\nthe Flowchart).  A “different question of safety or effectiveness” is a question raised by the \\ntechnological characteristics of the new device that was not applicable to the predicate device, and \\nposes a significant safety or effectiveness concern for the new device.   \\n \\nSome examples are provided below to illustrate cases where the response to this general question was \\n“yes,” i.e., the new device was determined to raise different safety and effectiveness questions in \\ncomparison to the predicate device, and the new device was found NSE.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 23, 'page_label': '24'}, page_content='Contains Nonbinding Recommendations \\n \\n 21 \\n \\nIllustrative Example 1   \\nPredicate:  A biological indicator utilizing natural bacterial spores with recognized resistance \\ncharacteristics as organisms for the biological indicator, where the presence of a color change or \\nfluorescent signal is indicative of bacterial viability. \\nNew Device: A biological indicator based on recombinant technology/genetic engineering, where \\nthe fluorescent signal is not indicative of bacterial viability; it is indicative of plasmid enzyme \\nexpression. \\nIntended Use:  Same   \\nDifferent questions of safety and effectiveness?  Yes \\nWhy:  Due to the engineering of a plasmid into the biological indicator, it is possible to have \\nviable bacteria that do not contain the plasmid in sufficient amounts to generate a signal.  In this \\ncase, the biological indicator could falsely indicate that the monitored load was sterilized properly \\ndue to the absence of fluorescent signal, while there are viable non-expressing bacteria in the \\nindicator (development of false negatives).  This technological difference raises different types of \\nsafety and effectiveness concerns for using a recombinant-DNA plasmid that codes for antibiotic \\nresistance and a signaling enzyme in the spores of a biological indicator.  Appropriate test \\nmethodologies and risk assessments need to be determined to address the properties of the \\nintroduced plasmid and host bacterial spore that could affect indicator performance.  Because \\nthese types of questions were not necessary to take into account for the predicate device, the new \\ndevice would be found NSE.   \\n \\nIllustrative Example 2   \\nPredicate:  A mechanical device used for embryo dissection \\nNew Device:  An electrical device used for embryo dissection \\nIntended Use:  Same  \\nDifferent questions of safety and effectiveness?  Yes \\nWhy:  In this example, changing the process from a mechanical process to an electrical energy \\nsource (e.g., laser) changes the way the device operates and raises different safety concerns \\nregarding how the heating aspect of the electrical mechanism affects the embryo.  Because these \\ntypes of questions were not necessary to take into account for the predicate device, the new \\ndevice would be found NSE.   \\n \\nIllustrative Example 3 \\nPredicate:  A device inserted into the patient’s pharynx through the mouth to provide a patent \\nairway by mechanically moving the soft tissue. \\nNew Device:  A device placed externally on the mandible and neck to apply a vacuum to move \\nthe soft tissue forward and thus “open” the airway.  \\nIntended Use:  Same   \\nDifferent questions of safety and effectiveness?  Yes \\nWhy:  The predicate device is invasive and placed midline in the oropharynx and does not exert \\npressure on the vascular, respiratory, or nerve structures in the neck, whereas the new device \\nexerts continuous external negative pressure on these areas, raising different types of safety \\nquestions, such as the risks and potential adverse events associated with the stimulation of the \\nnerve structures in the neck.  Because these types of questions were not necessary to take into \\naccount for the predicate device, the new device would be found NSE.\\n      \\n  \\nIn the event the answer to Decision Point 4 is “No” and the differences between the new device and \\nthe predicate device do not raise different questions of safety and effectiveness, then the scientific'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 24, 'page_label': '25'}, page_content='Contains Nonbinding Recommendations \\n \\n 22 \\nreview of the performance data will proceed.  However, if the answer to Decision Point 4 is “Yes” \\nand the differences between the new device and predicate device raise different questions of safety \\nand effectiveness, then the new device will be found NSE.  Upon receipt of this type of NSE letter, \\nthe manufacturer may submit a PMA (or alternative submission type), or if appropriate, a De Novo \\nrequest.  \\nF. Requests for Performance Data \\nAlthough FDA may rely upon descriptive information alone to address the critical questions in the \\nFlowchart (Decision Points 1 through 4), performance data are typically needed in a Traditional \\n510(k) to demonstrate the substantial equivalence of a new device to a predicate device.  In addition, \\ninformation on device performance described in labeling or other sections of the 510(k) should be \\nsupported with appropriate performance data.  The type and quantity of performance data necessary \\nto support a determination of substantial equivalence depend upon the device and/or device type.\\n31  \\nPerformance data may be needed to address a variety of safety and effectiveness issues and may be \\ngenerated from different types of tests and studies.   \\n                                                 \\n31 Manufacturers should also determine whether there is an applicable device-specific guidance or special controls for the device type \\nas provided in a special controls document or classification regulation.   \\n \\n32 FDA follows the “least burdensome” provisions.  See Final Guidance for FDA and Industry, “The Least Burdensome Provisions of \\nthe FDA Modernization Act of 1997: Concept and Principles” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085994.htm). \\n \\n \\nFDA’s data requests typically follow a stepwise analytical process to ensure the information \\nrequested reflects the least burdensome approach to establishing substantial equivalence.\\n32  First, \\nFDA considers whether descriptive information about the technological characteristics, such as the \\nmaterials, design, and specifications, of the new device is sufficient.  Very few 510(k) submissions \\nrely solely on descriptive information about materials, design, specifications, and other technological \\ncharacteristics (see 21 CFR 807.87(f) and (g)).  When this information is not sufficient to support a \\nsubstantial equivalence determination, FDA then considers whether non-clinical bench performance \\ntesting or analytical studies using clinical samples would be sufficient.  For in vitro diagnostic \\ndevices (IVDs), analytical studies include, but are not limited to, evaluations of accuracy, precision, \\nspecificity, and sensitivity.  Non-clinical bench performance testing includes a wide variety of test \\nmodalities that will be dependent upon the specifics of the actual device, including, but not limited to: \\n \\n\\uf0b7 mechanical, electrical, and biological engineering performance, such as fatigue, wear, tensile \\nstrength, compression, flowrate, burst pressure;  \\n\\uf0b7 electromagnetic compatibility (EMC); \\n\\uf0b7 sterility; \\n\\uf0b7 stability/shelf life; \\n\\uf0b7 software validation; \\n\\uf0b7 other forms of non-clinical, including device-specific. \\nNon-clinical animal and/or biocompatibility studies are typically requested when other forms of non-\\nclinical bench performance testing are not sufficient to demonstrate substantial equivalence.  Non-\\nclinical laboratory studies that support the safety of medical devices must be conducted in \\ncompliance with 21 CFR Part 58, Good Laboratory Practice (GLP) for Nonclinical Laboratory'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='Contains Nonbinding Recommendations \\n \\n 23 \\nStudies, as applicable, to ensure the quality, reliability, and integrity of study data.33 For more \\ninformation on this topic, see FDA’s Draft Guidance for Industry and Food and Drug Administration \\nStaff, “The Applicability of Good Laboratory Practice in Premarket Device Submissions: Questions \\n& Answers” \\n(http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm366338.h\\ntm).  FDA’s draft guidance represents FDA’s proposed approach on this topic.   \\n                                                 \\n33 The applicability of GLPs to non-clinical studies in a 510(k) submission is also mentioned in FDA’s Guidance “Refuse to Accept \\nPolicy for 510(k)s” in the Performance Data – General section of the checklist \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm315014.pdf). \\n \\n34 21 CFR 860.7(c)(2): Valid scientific evidence is evidence from well-controlled investigations, partially controlled studies, studies \\nand objective trials without matched controls, well-documented case histories conducted by qualified experts, and reports of significant \\nhuman experience with a marketed device, from which it can fairly and responsibly be concluded by qualified experts that there is \\nreasonable assurance of the safety and effectiveness of a device under its conditions of use. The evidence required may vary according \\nto the characteristics of the device, its conditions of use, the existence and adequacy of warnings and other restrictions, and the extent \\nof experience with its use. Isolated case reports, random experience, reports lacking sufficient details to permit scientific evaluation, \\nand unsubstantiated opinions are not regarded as valid scientific evidence to show safety or effectiveness. Such information may be \\nconsidered, however, in identifying a device the safety and effectiveness of which is questionable. \\n \\n35 In the U.S., clinical studies/investigations (see 21 CFR 812.3(h)) involving one or more human subjects to determine the safety or \\neffectiveness of a device must be conducted in accordance with the Investigational Device Exemptions (IDE) regulations, 21 CFR Part \\n812, as applicable.  In addition, such studies/investigations must comply with the regulations governing institutional review boards (21 \\nCFR Part 56), informed consent (21 CFR Part 50), and financial disclosure (21 CFR Part 54).  See also Guidance for Clinical \\nInvestigators, Industry, and FDA Staff, “Financial Disclosure by Clinical Investigators” \\n(http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM341008.pdf). Studies conducted outside the U.S. generally do \\nnot have to comply with the IDE regulations, but FDA recommends that such studies be conducted in accordance with good clinical \\npractice.  For information on good clinical practice, see 78 FR 12664 (Feb. 25, 2013). \\n \\n36 The acceptability or level of data necessary to support an SE determination is product specific and therefore, not discussed in this \\nguidance.  Manufacturers should determine whether there is an applicable device-specific guidance or special controls for the device \\ntype as provided in a special controls document or classification regulation as these sources may provide further information about \\nperformance data that may be necessary in a 510(k) submission.       \\n \\nWhen analytical or non-clinical bench performance testing data, or non-clinical animal and/or \\nbiocompatibility studies are insufficient, or available scientific methods are not acceptable, e.g., the \\nscientific methods are deemed unacceptable because they are not clinically validated or are not \\nsupported by a valid scientific rationale, FDA may request clinical performance data to support a \\nsubstantial equivalence determination.  For 510(k)s reviewed in the Office of Device Evaluation, \\nFDA currently requests clinical data for less than 10 percent of the 510(k) submissions.  In some \\ninstances, clinical data may be a less burdensome means of demonstrating substantial equivalence \\nthan other means of performance testing, and 510(k)s reviewed in CBER for products intended to \\nensure the safety and effectiveness of blood and blood products typically include clinical data.  \\nClinical data provided in support of any marketing application, including a 510(k) when those data \\nare relevant to a substantial equivalence determination, should constitute valid scientific evidence as \\ndefined in 21 CFR 860.7(c)(2)\\n34 and must comply with the Investigational Device Exemptions (IDE) \\nregulations as applicable.35   \\n \\nAlthough not an exhaustive list of instances in which FDA may request clinical data to demonstrate \\nsubstantial equivalence,\\n36 the following scenarios illustrate the most common situations in which \\nclinical data may be requested.  As explained in the Scope Section (see Section III), the information \\nin this guidance and the examples below do not take the place of any device-specific guidance.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 26, 'page_label': '27'}, page_content='Contains Nonbinding Recommendations \\n \\n 24 \\nNote:  The examples provided below distinguish between examples that are only applicable to \\ndiagnostic devices, including IVDs, and therapeutic devices.  This is because there are significant \\ndifferences in the clinical data requirements for these two categories of devices.  \\n1. New or Modified Indications for Use – Same Intended Use \\nIn rare instances, FDA may rely upon clinical data to determine that new or modified indications for \\nuse fall within the same intended use as a predicate device.   \\nIllustrative Examples:  \\n\\uf0b7 The new device is an IVD that is indicated for over-the-counter use, whereas the predicate \\ndevice is indicated for prescription use in the home or prescription use in a clinical setting.  \\nThe newly indicated test population might fall within the intended use of the predicate device.  \\nClinical data (demonstrating that the user can collect the sample, generate an accurate result, \\nand adequately interpret the result) might establish that the indication for use for the new \\ndevice falls within the intended use of the predicate device. \\n\\uf0b7 The new IVD is indicated for use with patients who have symptoms and signs of illness from \\nany member of a specified set of closely related diseases.  The indications for use for the \\npredicate IVD do not include one of the diseases addressed by the new IVD.  Clinical data \\n(concerning all diseases in the newly specified set) might establish that the indications for use \\nfor the new device fall within the intended use of the predicate device. \\n\\uf0b7 The manufacturer modifies the indications for use, explicitly or implicitly, by proposing a \\ndifferent surgical implantation method which also affects the indications for use, e.g., a \\nminimally invasive procedure in place of an open procedure, and the safety and effectiveness \\nof the new device cannot be adequately replicated or otherwise characterized in a non-clinical \\nperformance (including animal) test environment to adequately support substantial \\nequivalence to the predicate.  Although on its face a minimally invasive procedure would \\nappear to involve less serious risks than an open procedure, the minimally invasive procedure \\nmay be less effective or may present different but still serious risks. \\n2. Technological Differences \\nFDA may request clinical data for a 510(k) when the technological differences between the new \\ndevice and predicate device are significant but do not support an immediate NSE determination due \\nto different questions of safety and effectiveness.  In these limited situations, clinical data may be \\nneeded to evaluate the safety and effectiveness of the new device as compared to the predicate \\ndevice. \\n \\nIllustrative Examples: \\n \\n\\uf0b7 A new IVD uses the same analyte-specific chemistry as the predicate, but with a different \\nread-out technology (e.g., chemiluminescence instead of colorimetry).  Clinical data may be \\nnecessary to demonstrate that the new device performs equivalent to the predicate. \\n \\n\\uf0b7 Performance characteristics of the new device in comparison to the predicate are significantly \\ndifferent in non-clinical performance testing, e.g., the predicate is rigid whereas the new'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 27, 'page_label': '28'}, page_content='Contains Nonbinding Recommendations \\n \\n 25 \\ndevice is designed to be more flexible.  Clinical data may be necessary to demonstrate that the \\nnew device performs equivalent to the predicate.   \\n \\n\\uf0b7 Some devices that display data about the patient’s anatomy or physiology, e.g., glucose \\nmeters, pulse oximeters, blood pressure cuffs, are supported by software.  If there is a change \\nin the software that relates to how the software analyzes the patient’s anatomy or physiology, \\nthe device may need to be tested on actual patients to assure that the software performs in a \\nmanner that is equivalent to the previous version.  In this case, non-clinical data may not \\nsuffice.   \\n \\n\\uf0b7 The technological characteristics of the new device raise a question concerning whether its \\nclinical performance can be expected to be equivalent to the clinical performance of the \\npredicate.  Clinical data may be necessary to demonstrate that the new device performs \\nequivalent to the predicate.  For IVDs, an example is a new prothrombin time (clotting) test \\nusing thromboplastin that is a recombinant product instead of a naturally occurring material.     \\n3. Non-clinical Testing Methods are Limited or Inappropriate Because of the \\nIndications for Use or Device Technology  \\nFDA requests clinical data for a 510(k) submission to address issues that cannot be adequately \\naddressed using non-clinical test methods because of the indications for use or device technology.  \\nFor instance, for certain indications or technologies, FDA may request clinical data when non-clinical \\ntesting methods are not validated, are limited or are inappropriate, because of either their scope or \\ntheir applicability, to demonstrate substantial equivalence.   \\n \\nIllustrative Examples:  \\n \\n\\uf0b7 For some devices, the way they are used and the environment in which they are used affect \\nthe way they perform.  For example, the non-clinical performance testing on the new device \\nmay be insufficient to support a substantial equivalence determination if the testing cannot \\nreplicate the way the device will be used or the way similar devices have been demonstrated \\nto fail in a clinical setting. Although the non-clinical testing for these devices might be \\ninformative for many other aspects of the device, it may be necessary to supplement the non-\\nclinical data with clinical simulation performance data or clinical performance data.   \\n \\n\\uf0b7 If the non-clinical testing of a device raises safety concerns that cannot be mitigated or \\nanswered through non-clinical testing, such a device may require clinical testing to assure that \\nthe safety questions are not greater than those raised by the predicate device.  \\n \\nNew scientific information may affect FDA’s expectations concerning the type and level of \\nperformance data included in a 510(k) submission.  For device types with long histories of safe use \\nand well understood mechanisms of action, more limited performance testing data may be sufficient.  \\nOn the other hand, a pattern of adverse events or published literature documenting poor clinical \\noutcomes with a particular technology may lead FDA to reconsider its regulatory approach to \\npremarket submissions for such technology.\\n 37  Should FDA change its scientific decision making \\n                                                 \\n37 See SOP: Decision Authority for Additional or Changed Data Needs for Premarket Submissions  \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm279288.htm).'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 28, 'page_label': '29'}, page_content='Contains Nonbinding Recommendations \\n \\n 26 \\nwith regard to a particular device, FDA will consider its options (e.g., guidance, advisory panel \\nmeeting, etc.), for explaining such change and the basis for the decision to ensure transparency in the \\nchange in policy.  FDA also intends to consider any pending 510(k) submissions that may be affected \\nby the change or allow for an appropriate transition period, in certain situations that may affect the \\nindustry at large. \\nG. The 510(k) Summary \\nThe 510(k) Summary38 is a document that provides a high-level discussion of the content of a 510(k) \\nand must include all the elements identified in 21 CFR 807.92.  A 510(k) Summary must be in \\nsufficient detail to provide an understanding of the basis for a determination of substantial \\nequivalence (21 CFR 807.92(a)). \\n                                                 \\n38 As specified in 21 CFR 807.87(h), a 510(k) Statement as described in 21 CFR 807.93 may be provided in lieu of a 510(k) Summary.  \\nHowever, in order to facilitate transparency, FDA encourages all submitters to utilize the 510(k) Summary option. \\n \\nIn an effort to improve the transparency and predictability of the 510(k) program and to ensure that \\nthe 510(k) Summary reflects the information provided in a 510(k) submission to support a substantial \\nequivalence determination, FDA intends to verify the accuracy and completeness of the information \\nincluded in a 510(k) Summary.   \\nAlthough the 510(k) Summary is a document created by the manufacturer and is included in the \\n510(k), revisions to the 510(k) Summary may be necessary to accurately reflect the FDA’s decision-\\nmaking process.  For example, manufacturers may have identified several devices as potential \\npredicate devices, whereas, in the course of FDA’s substantial equivalence evaluation, FDA may \\nhave determined that only one of these devices is an appropriate predicate device.  In addition, it is \\npossible during the course of FDA’s review of the 510(k), that additional information or testing may \\nbe requested and submitted.  Consequently, the manufacturer may be requested to update the 510(k) \\nSummary to accurately include and convey the information identified in 21 CFR 807.92 and which \\nwas used to support the final decision-making process.   \\nIn Appendix B, FDA describes the requirements of the content to be included in a 510(k) Summary, \\nin accordance with 21 CFR 807.92, and provides guidance on the information to be included in a \\n510(k) Summary to ensure compliance with 21 CFR 807.92 and consistency in the level of \\ninformation conveyed and captured in the 510(k) Summaries which are available to the public on \\nFDA’s website.  In Appendix C, FDA has provided a hypothetical 510(k) Summary in order to \\ndemonstrate the recommended level of detail for each section.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 29, 'page_label': '30'}, page_content='Contains Nonbinding Recommendations \\n \\nIdentify the new device and the \\npredicate device.\\nDecision 1\\nIs the \\npredicate device legally \\nmarketed?\\nNSENO\\nReview all labeling and assure \\nthat it is consistent with IFU \\nstatements.\\nYES\\nDecision 2\\nDo the devices\\nhave the same\\nintended use?\\nNSENO\\nReview design, materials, energy \\nsource and other features of the \\ndevices.\\nYES\\nDecision 3\\nDo the devices\\nhave the same\\ntechnological \\ncharacteristics?\\nSE\\nYES\\nDetermine what questions of \\nsafety and effectiveness the \\ndifferent technological \\ncharacteristics raise.\\nNO\\nDecision 4\\nDo the different \\ntechnological characteristics \\nof the devices raise different \\nquestions \\nof safety and \\neffectiveness?\\nNSE YES\\nNO\\nReview the proposed scientific \\nmethods for evaluating new/\\ndifferent characteristics’ effects \\non safety and effectiveness.\\nDecision 5a\\nAre the methods \\nacceptable?\\nNSE NO\\nYES\\nEvaluate performance data.\\nDecision 5b\\nDo the data \\ndemonstrate substantial \\nequivalence?\\nNSE\\nSE\\nYES\\nSE = “Substantially Equivalent”\\nNSE = “Not Substantially Equivalent”\\nIFU = “Indications For Use”\\nThis Flowchart is not intended to be used as a ‘stand-alone’ document and should only be considered in conjunction with the accompanying text in \\nthis guidance.\\n Refer to Section IV.D. \\n(Intended Use) and\\n21 CFR 807.100(b)(1).  \\nRefer to Section IV.C. \\n(Predicate Devices) and \\n21 CFR 807.100(b)(3).\\nRefer to Section IV.E. \\n(Technological \\nCharacteristics) and 21 \\nCFR 807.100(b)(2)(i) and \\n(ii)(A). \\nNO\\nRefer to Section IV. \\nF (Requests for \\nPerformance Data) \\nand\\n21 CFR \\n807.100(b)(2)(ii)(B).\\nRefer to Section IV. \\nF (Requests for \\nPerformance Data) \\nand 21 CFR\\n807.100(b)(2)(ii)(B). \\nRefer to Sections \\nIV.E. (Technological \\nCharacteristics) and \\nIV.F. (Requests for \\nPerformance Data) \\nand\\n21 CFR \\n807.100(b)(2)(ii)(C). \\n 27 \\nAppendix A.  510(k) Decision-Making Flowchart'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 30, 'page_label': '31'}, page_content=\"Contains Nonbinding Recommendations \\n \\n 28 \\nAppendix B.  The 510(k) Summary Document Requirements \\nIn Appendix B, FDA provides further clarification and guidance to facilitate compliance with the \\nrequirements set forth in 21 CFR 807.92 and consistency in the information conveyed in the 510(k) \\nSummaries which are available to the public on FDA’s website.  As noted earlier in this guidance \\ndocument, if during the course of review, additional testing or information are requested, the \\nmanufacturer should submit a revised 510(k) Summary to reflect the additional information.  The \\nfollowing identifies the information that must be included in the 510(k) Summary under 21 CFR \\n807.92, information that we recommend be included in the 510(k) Summary, and other \\nconsiderations.   \\n   \\n\\uf0b7 807.92(a)(1): “The submitter's name, address, telephone number, a contact person, and the \\ndate the summary was prepared.”   \\no The “submitter” or manufacturer should be the holder of the 510(k), not a consultant \\nor law firm. \\n \\n\\uf0b7 807.92(a)(2): “The name of the device, including the trade or proprietary name if applicable, \\nthe common or usual name, and the classification name, if known.”   \\no FDA recommends that the manufacturer list all applicable names and model numbers, \\nif known. \\no If the submission is bundled\\n39, the 510(k) Summary should list all applicable \\nclassification regulations and product codes.   \\n                                                 \\n39 See Guidance for Industry and FDA Staff, “Bundling Multiple Devices or Multiple Indications in a Single Submission”  \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089732.pdf).  \\n \\n\\uf0b7 807.92(a)(3): “An identification of the legally marketed device to which the submitter claims \\nequivalence.  A legally marketed device to which a new device may be compared for a \\ndetermination regarding substantial equivalence is a device that was legally marketed prior to \\nMay 28, 1976, or a device which has been reclassified from class III to class II or I (the \\npredicate), or a device which has been found to be substantially equivalent through the 510(k) \\npremarket notification process.”\\n \\no FDA recommends that the manufacturer provide the 510(k) number of the device used \\nas the predicate device in support of the current 510(k) submission.   \\no If using an exempt device as a predicate, the manufacturer should list the classification \\nregulation and the product code.   \\no If using a device that has been reclassified from Class III to II as a predicate, where a \\n510(k) has not been submitted, please list the PMA number. \\no If the manufacturer lists an inappropriate predicate device, FDA will request that such \\ninformation be removed and the 510(k) Summary updated accordingly by the \\nmanufacturer.   \\n \\n\\uf0b7 807.92(a)(4): “A description of the device that is the subject of the premarket notification \\nsubmission, such as might be found in the labeling or promotional material for the device, \\nincluding an explanation of how the device functions, the scientific concepts that form the \\nbasis for the device, and the significant physical and performance characteristics of the \\ndevice, such as device design, material used, and physical properties.”\"), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 31, 'page_label': '32'}, page_content='Contains Nonbinding Recommendations \\n \\n 29 \\nThe description of the device attributes should include the following details: \\no Device Identification: \\n\\uf0a7 List all key device components included in the submission (e.g., catheter, cable \\nwire, leads) \\n\\uf0a7 List all model numbers (if known) and briefly explain the differences among \\nmodels \\n \\no Device Characteristics (address all that apply): \\n\\uf0a7 software \\n\\uf0a7 biologics \\n\\uf0a7 drugs \\n\\uf0a7 any patient-contacting materials  \\n\\uf0a7 coatings \\n\\uf0a7 additives \\n\\uf0a7 single-use \\n\\uf0a7 sterile \\n\\uf0a7 sterilization method [specify] \\n \\no Environment of Use (address all that apply): \\n\\uf0a7 healthcare facility/hospital \\n\\uf0a7 home \\n\\uf0a7 other [specify] \\n \\no Brief Written Description of the Device: \\n\\uf0a7 Explanation of how the device works/principle of operation \\n\\uf0a7 Mechanism of action \\n\\uf0a7 Any necessary feature to determine SE or device performance \\n\\uf0a7 Energy source (if applicable) \\n \\no Materials of Use  \\n\\uf0a7 General type of material used (e.g., polysulfone, stainless steel) \\n\\uf0a7 If material conforms to an FDA recognized consensus standard for medical \\nuse, include the applicable number (e.g., ASTM FXXXX-last 2 numbers of the \\nyear) \\n\\uf0a7 Duration and type of contact \\n \\no Key Performance Specifications/Characteristics of the Device \\n \\n\\uf0b7 807.92(a)(5): “A statement of the intended use of the device that is the subject of the \\npremarket notification submission, including a general description of the diseases or \\nconditions that the device will diagnose, treat, prevent, cure, or mitigate, including a \\ndescription, where appropriate, of the patient population for which the device is intended. If \\nthe indication statements are different from those of the legally marketed device identified in \\nparagraph (a)(3) of this section, the 510(k) summary shall contain an explanation as to why \\nthe differences are not critical to the intended therapeutic, diagnostic, prosthetic, or surgical \\nuse of the device, and why the differences do not affect the safety and effectiveness of the \\ndevice when used as labeled.”'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 32, 'page_label': '33'}, page_content='Contains Nonbinding Recommendations \\n \\n 30 \\no The 510(k) Summary should include the Indications for Use, which should be \\nidentical to that proposed on the Indications for Use Sheet and the labeling. \\no If the Indications for Use are different from those of the predicate device, a brief \\nexplanation is required to address why the differences in the Indications do not affect \\nthe safety and effectiveness of the device and do not alter the intended therapeutic, \\ndiagnostic, prosthetic, or surgical use of the device.   \\n \\n\\uf0b7 807.92(a)(6): “If the device has the same technological characteristics (i.e., design, material, \\nchemical composition, energy source) as the predicate device identified in paragraph (a)(3) of \\nthis section, a summary of the technological characteristics of the new device in comparison \\nto those of the predicate device.  If the device has different technological characteristics from \\nthe predicate device, a summary of how the technological characteristics of the device \\ncompare to a legally marketed device identified in paragraph (a)(3) of this section.”  \\n \\n\\uf0b7 807.92(b): “510(k) summaries for those premarket submissions in which a determination of \\nsubstantial equivalence is also based on an assessment of performance data shall contain the \\nfollowing information:”  \\n“(1) A brief discussion of the nonclinical tests submitted, referenced, or relied on in the \\npremarket notification submission for a determination of substantial equivalence,” \\no A high level summary of the tests that were used to demonstrate substantial \\nequivalence should be included (e.g., fatigue testing, biocompatibility, etc.). \\no If a guidance document was referenced/used for the testing, the guidance document \\nshould be referenced in this section. \\no If an FDA recognized consensus standard (e.g., test method or guide) was used/relied \\nupon for testing, please list the standard connotation (e.g., ASTM FXXXX-last 2 \\nnumbers of the year). \\n \\n“(2) A brief discussion of the clinical tests submitted, referenced, or relied on in the premarket \\nnotification submission for a determination of substantial equivalence. This discussion shall \\ninclude, where applicable, a description of the subjects upon whom the device was tested, a \\ndiscussion of the safety or effectiveness data obtained from the testing, with specific reference \\nto adverse effects and complications, and any other information from the clinical testing \\nrelevant to a determination of substantial equivalence,”  \\no FDA is interested in collecting an appropriate degree of detail within this section to be \\ninformative regarding the level of evidence that was necessary to support an SE \\ndetermination. \\no As applicable, FDA recommends the following details be included regarding the \\nclinical evidence provided to support an SE determination: \\n \\n\\uf0b7 Level of Evidence (identify one) \\n\\uf0a7 Randomized, multi-arm, “blinded” study with concurrent sham (placebo) \\ncontrol \\n\\uf0a7 Randomized, multi-arm, “blinded” study with concurrent (“active”) control \\n\\uf0a7 Randomized, multi-arm, un“blinded” study with a control (control that is either \\nactive or consists of no treatment) \\n\\uf0a7 Non-randomized study with concurrent (“active”) control \\n\\uf0a7 Single-arm study with patient serving as own control (include designed single-\\narm crossover) \\n\\uf0a7 Single-arm study with Historical Control (using patient-level data)'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 33, 'page_label': '34'}, page_content='Contains Nonbinding Recommendations \\n \\n 31 \\n\\uf0a7 Single-arm study with Literature Control (historical control) \\n\\uf0a7 Single-arm study with Objective Performance Criteria \\n\\uf0a7 Single-arm study with Performance Goals  \\n\\uf0a7 Registry  \\n\\uf0a7 Observational study \\n\\uf0a7 Systematic review (meta-analysis with patient-level data) \\n\\uf0a7 Meta-analysis based on summary information only  \\n\\uf0a7 Literature Summary \\n\\uf0a7 Uncertain \\n \\n\\uf0b7 Location of Study (specify one of the following) \\no United States only \\no outside of United States only \\no both in United States and outside of United States \\no Identify applicable IDE number [Gxxxxxx]   \\n \\n\\uf0b7 Primary Safety Endpoint Identified?  \\n\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Primary Effectiveness Endpoint Identified?   \\n\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Primary Composite Safety/Effectiveness Endpoint Identified, if applicable?   \\n\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Patient Accountability (Enter number of patients reported at each stage): \\n \\nStage Investigational \\nDevice Arm Total \\nControl Arm \\nTotal \\nTotal \\nEnrollment    \\nTreatment    \\nPrimary Safety Endpoint \\nAnalysis \\n   \\nPrimary Effectiveness \\nEndpoint Analysis \\n   \\nPrimary Composite \\nSafety/Effectiveness (if app) \\n   \\nThe content of the table may need to be modified depending upon the specifics of the clinical data provided and the \\nendpoints studied.   \\n \\n\\uf0b7 Identify whether the study met the primary endpoint  \\n\\uf0a7 Whether Yes or No, describe \\n \\n\\uf0b7 Describe the study results in appropriate parameters \\n \\n\\uf0b7 Identify the adverse events and complications observed in the study, including \\nthose associated with the device.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 34, 'page_label': '35'}, page_content='Contains Nonbinding Recommendations \\n \\n 32 \\n“(3) The conclusions drawn from the nonclinical and clinical tests that demonstrate that the \\ndevice is as safe, as effective, and performs as well as or better than the legally marketed \\ndevice identified in paragraph (a)(3) of this section.” \\no A brief summary of why the device is substantially equivalent to the predicate. \\n \\n\\uf0b7 807.92(c): “The summary should be in a separate section of the submission, beginning on a \\nnew page and ending on a page not shared with any other section of the premarket notification \\nsubmission, and should be clearly identified as a ‘510(k) summary’.” \\n \\n\\uf0b7 807.92(d): “Any other information reasonably deemed necessary by the agency.”  \\no If the FDA determines that other information needs to be included within the 510(k) \\nSummary, such information must be included within this document.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 35, 'page_label': '36'}, page_content='Contains Nonbinding Recommendations \\n \\n 33 \\nAppendix C. Sample of 510(k) Summary Complying with 21 CFR \\n807.92 \\n \\n510(k) Summary \\n \\nI. SUBMITTER \\n \\nDevice Submitter, Inc. \\n123 Main Street \\nAnywhere, MD 01234 \\n \\nPhone: 555-555-1234 \\nFax: 555-555-0123 \\n \\nContact Person: John Contact \\nDate Prepared: May 16, 2013 \\n \\nII. DEVICE \\n \\nName of Device: Brand X Endoscopic Stapling System, Model x123, Model y456 \\nCommon or Usual Name: Endoscopic Stapling System \\nClassification Name: Endoscope and Accessories (21 CFR 876.1500) \\nRegulatory Class: II \\nProduct Code: ODE \\n \\nIII. PREDICATE DEVICE \\n \\nBrand Z Endoscopic Plication System, KXXXXXX \\nThis predicate has not been subject to a design-related recall.\\n40 \\n                                                 \\n40 On July 9, 2012, section 605 of FDASIA (Pub. L. 112-144) added section 518A to the FD&C Act, which directs FDA to establish a \\nprogram to routinely and systematically assess information regarding device recalls, and to use that information to proactively identify \\nstrategies for mitigating health risks presented by defective or unsafe devices.  FDA believes that one way to carry out this directive is \\nto provide greater transparency on recalled devices.  Identifying whether a predicate was recalled is optional, but doing so would help \\nthe Agency achieve this FDASIA directive. \\n \\nNo reference devices were used in this submission. \\n \\nIV. DEVICE DESCRIPTION \\n \\nThe Brand X Endoscopic Stapling System consists of a flexible endoscope, an endoscopy suite, and a \\nnumber of associated accessories. The endoscope and staples are provided sterile (EtO). \\n \\nBrand X uses an implant (surgical staple) that is delivered by a flexible endoscope by a surgeon or \\ngastroenterologist for approximating adjoining portions of the esophageal and gastric tissues at the \\ngastroesophageal junction, thereby creating a permanent surgical fundoplication. The system includes \\nan ultrasonic transducer that operates as a range finder for measuring the relative alignment and the \\ndistance between the transducer at the tip of the endoscope (the anvil) and the ultrasonic mirror in the'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 36, 'page_label': '37'}, page_content='Contains Nonbinding Recommendations \\n \\n 34 \\ncartridge (that includes the staples). The device deploys sets of implantable staples for performing the \\nfundoplication procedure. \\n \\nThe system combines a video camera, an ultrasonic range finder and a surgical stapler in a single \\nunit. The flexible endoscope includes light guides, irrigation, air insufflation and suction channels \\nthat terminate at the endoscope tip.  The stapler portion includes a cartridge that contains sterile 4.8 \\nmm standard \"B\" shaped titanium surgical staples. Model x123 includes five (5) staples per cartridge, \\nwhile Model y456 contains only four (4). The tip of the endoscope contains an anvil for the staples, \\nas well as two small stainless steel screws that are extracted from the tip of the endoscope and engage \\ninto nuts positioned in the cartridge. The ultrasonic range finder measures the distance between an \\nultrasonic mirror in the cartridge and the tip of the endoscope. It also verifies alignment between the \\ncartridge and the anvil, before insertion of the screws. \\n \\nThe endoscopy suite includes the ISL (Insufflation, Suction and Light) console, the CCU (Camera \\nControl Unit) console and a monitor. The ISL console provides suction, insufflation and a white light \\n(Xenon) source for illumination. The CCU console contains a controller for the camera, ultrasonic \\nrange finder and sensors that indicate status of the bending angle, screws and fire. The monitor \\ndisplays patient information, the video image, and the processed data from the controllers such as \\nultrasonic data, fire status, degree of bending and screw position.  A keyboard for entering data \\nduring the procedure is also included.  The System includes three software applications: the video \\ncontroller software, the ultrasound controller software, and the ISL controller software.  The software \\nsystems work in conjunction with the hardware consoles listed above in order to visualize the \\nprocedure and deliver the staples.  The endoscope is designed for single-patient use, and it is \\nconnected to the CCU and ISL consoles via a multi-connector.  The endoscope handle contains the \\ncontrols used by the operator to manipulate the endoscope. \\n \\nThe associated accessories include: \\n\\uf0b7 Irrigation bottle with liquids for irrigation of the camera lens \\n\\uf0b7 Suction canister for extracting liquids during the procedure \\n\\uf0b7 Silicon tubes for connecting the ISL and other accessories to the endoscope \\n\\uf0b7 Disposable air filter of the suction ISL input channel \\n\\uf0b7 Overtube for protecting patient\\'s pharynx \\n \\nV. INDICATIONS FOR USE \\n \\nThe Brand X Stapling System is indicated for the endoscopic placement of surgical staples in the soft \\ntissue of the esophagus and stomach in order to create anterior partial fundoplication for treatment of \\nsymptomatic chronic Gastro Esophageal Reflux Disease (GERD) in patients who require and respond \\nto pharmacological therapy. \\n \\nThe Indications for Use statement for the Brand X device is not identical to the predicate device; \\nhowever, the differences do not alter the intended therapeutic use of the device nor do they affect the \\nsafety and effectiveness of the device relative to the predicate.  Both the subject and predicate devices \\nhave the same intended use for the treatment of GERD, by approximating tissue in the esophagus and \\nstomach.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 37, 'page_label': '38'}, page_content='Contains Nonbinding Recommendations \\n \\n 35 \\nVI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE \\nDEVICE \\n \\nTransoral endoscopic fundoplication is the technological principle for both the subject and predicate \\ndevices. It is based on the use of endoscopic instrumentation for approximating and permanently \\nadjoining gastric and esophageal tissues, creating plications at the level of the gastroesophageal valve \\nand thereby restoring valvular functionality and reducing gastric reflux into the esophagus.  \\nAt a high level, the subject and predicate devices are based on the following same technological \\nelements: \\n\\uf0b7 Endoscope – used to reach the target tissue \\n\\uf0b7 Device inserted through an overtube – to protect the esophagus \\n\\uf0b7 Creation of a gastric (or gastroesophageal) plication in close proximity to the \\ngastroesophageal junction by the retroflexed device  \\n\\uf0b7 Use of a permanent implant to secure tissue  \\n\\uf0b7 Use of a mechanical component for positioning and launching the implant \\n\\uf0b7 User-controlled mechanical trigger (or knob) to launch the fastener (implant) \\n\\uf0b7 Mechanically securing the plication by a permanent implant fastener \\n \\nThe following technological differences exist between the subject and predicate devices: \\n\\uf0b7 Use of an ultrasound range finder  \\n\\uf0b7 Use of a staple as a fastener  \\n\\uf0b7 Use of different tissue capture and fixation mechanisms  \\n\\uf0b7 The predicate device must be used in conjunction with a flexible endoscope whereas the \\nsubject device has a flexible endoscope incorporated into the system. \\n \\nVII. PERFORMANCE DATA \\n \\nThe following performance data were provided in support of the substantial equivalence \\ndetermination. \\n \\nBiocompatibility testing \\nThe biocompatibility evaluation for the Brand X device was conducted in accordance with the FDA \\nBlue Book Memorandum #G95-1 “Use of International Standard ISO-10993, ‘Biological Evaluation \\nof Medical Devices Part 1: Evaluation and Testing,’” May 1, 1995, and International Standard ISO \\n10993-1 “Biological Evaluation of Medical Devices − Part 1: Evaluation and Testing Within a Risk \\nManagement Process,” as recognized by FDA.  The battery of testing included the following tests: \\n \\n\\uf0b7 Cytotoxicity \\n\\uf0b7 Sensitization \\n\\uf0b7 Irritation \\n\\uf0b7 Systemic toxicity \\n\\uf0b7 Pyrogen Testing \\n \\nThe endoscopic delivery system is considered tissue contacting for a duration of less than 24 hours, \\nwhile the staples are considered permanent implants.  The titanium staple material conforms to \\nASTM F-67-06 for chemical composition.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 38, 'page_label': '39'}, page_content='Contains Nonbinding Recommendations \\n \\n 36 \\nElectrical safety and electromagnetic compatibility (EMC) \\nElectrical safety and EMC testing were conducted on the Brand X device, consisting of the ISL \\nconsole, CCU console and endoscope.  The system complies with the IEC 60601-1, IEC 60601-2-18 \\nand IEC 60601-2-37 standards for safety and the IEC 60601-1-2 standard for EMC. \\n \\nSoftware Verification and Validation Testing  \\nSoftware verification and validation testing were conducted and documentation was provided as \\nrecommended by FDA’s Guidance for Industry and FDA Staff, “Guidance for the Content of \\nPremarket Submissions for Software Contained in Medical Devices.”  The software for this device \\nwas considered as a “major” level of concern, since a failure or latent flaw in the software could \\ndirectly result in serious injury or death to the patient or operator. \\n \\nMechanical and acoustic testing \\n\\uf0b7 Acoustic Testing \\n\\uf0b7 Elongation of the bending cable \\n\\uf0b7 Torque on the handle wheel and force on cable \\n\\uf0b7 Crimp assembly, cable tensile strength, cable flexibility, minimum bending radius of the \\ncables \\n\\uf0b7 Staple verification \\n\\uf0b7 Simulated use testing \\n \\nAnimal Study \\nIn the animal study conducted, 16 pigs underwent endoscopy with the Brand X System. Twelve pigs \\nunderwent fundoplication, and 4 pigs served as a sham (control) group. There were no procedure \\nrelated complications or premature deaths in this study, at the 2, 4 and 6 week follow-up (4 pigs in \\neach group). \\n \\nThe safety and feasibility of the Brand X device were evaluated by macroscopic and histological \\nevaluation of the tissue in the treatment stapled areas. These studies demonstrated that the Brand X \\ndevice can safely create an anterior partial fundoplication, similar to that which is constructed using \\nother endoscopic suturing devices.  \\n \\nClinical Studies \\nClinical testing of the Brand X device included an initial feasibility study of 6 patients, a pilot study \\nconsisting of 13 patients and a pivotal study of 72 patients. Substantial equivalence was based in part \\non the pivotal study. \\n \\nPivotal Study \\nThe pivotal study was a prospective, multi-center, open label, non-randomized, single arm study of \\n72 patients, of which 66 were available for primary endpoint analysis; 3 subjects did not complete the \\nprocedure, and 3 were excluded from the effectiveness analysis.  The device was used to staple the \\nfundus of the stomach to the esophagus, using standard B shaped surgical staples. Stapling was \\nperformed in two or three locations at least 1.5 cm above the GE junction, separated by at least 90 \\ndegrees. The procedure was intended to create a partial anterior fundoplication as a reflux barrier. \\nPatients were followed for a period of six months at 6 sites both in the United States and outside of \\nthe United States under IDE G070136.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 39, 'page_label': '40'}, page_content='Contains Nonbinding Recommendations \\n \\n 37 \\nPrimary effectiveness endpoint: \\nGERD health related quality of life score (GERD-HRQL) off proton pump inhibitor (PPI) was \\nimproved from baseline by > 50%, at six months post procedure in at least 53% of the patients (53% \\nis the lower boundary of the 95% confidence interval). \\n \\nPrimary safety endpoint: \\nThe primary safety endpoint consisted of all treatment-related adverse events, during and after the \\nprocedure. “Treatment-related” events were conventionally defined as those which occurred in the \\nfirst 30 days post-procedure. \\n \\nEffectiveness \\nThe primary endpoint for the Brand X study focused on the GERD-HRQL score. The study results \\ndemonstrated that 75% of the patients had a >50% improvement in their GERD-HRQL score off PPI \\nat six months compared to baseline. Hence the study met its primary endpoint with the required 95% \\nconfidence level. \\n \\nThe reduction in the median score for the Brand X device of 23.0 units (from 29.0 to 6.0) represents a \\n79.3% improvement. This value is almost identical to the published result for the pivotal trial of the \\npredicate device (79.2%). Therefore, the effectiveness of the Brand X system in successfully treating \\nchronic symptoms of GERD is similar to the effectiveness reported for the predicate device. \\n \\nThe median value of the percent of time pH < 4.0 decreased from an initial value of 8.3% at baseline \\nto 6.75%. Therefore, the study met its secondary endpoint related to the acid exposure test. A \\ncomparison to results reported in the literature revealed that the change in the median values of the \\nBrand X device showed a decrease of 19%, while the predicate showed a decrease of 18%.  Hence, \\nthe Brand X results in reducing the exposure to gastric acids are similar to those reported for the \\npredicate system. \\n \\nSafety \\nThe study reported nine patients with a total of nine serious adverse events (SAEs). Four events were \\nconsidered mild in intensity, involving pain and fever. Three events were classified as moderate in \\nintensity, involving pneumothorax, pneumomediastinum, and pneumoperitoneum (all resolved \\nspontaneously). Two events were considered severe in intensity: one involved esophageal perforation \\n(required drainage) and another had suicidal thoughts (non-device/procedure related). \\n \\nSix of the SAEs were considered related to the device: one definitely (esophageal perforation) and the \\nothers possibly. Three events were considered not related to the device. The median time from \\nprocedure to SAE was 1.5 days for events related to the device. None of the patients with SAEs \\nrequired any operation or re-operation. Adverse events reported that occurred in greater than the 5% \\nlevel were postoperative pain or discomfort in 33% of patients, postoperative nausea in \\napproximately 10%, and sore throat in 21%. The adverse events were mild or insignificant in most \\ncases.  \\n \\nThe SAEs and overall safety profile were similar to the predicate device for which two perforations \\nand one bleeding event were reported. The number of AEs was similar to those reported for the \\npredicate device. Three cases of fever were reported in the current study (for 72 patients), similar to \\nthe 3 cases of fever reported for the predicate. There were 23 cases of chest pain (23/72 = 32%) vs. \\n17% reported for the predicate; abdominal pain was recorded for 5% of the patients in the current'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 40, 'page_label': '41'}, page_content='Contains Nonbinding Recommendations \\n \\n 38 \\nstudy vs. 44% of the patients for the predicate. Sore throat was reported for 15 patients (15/72 = 21%) \\nvs. 15% for the predicate. \\n \\nSummary \\nBased on the clinical performance as documented in the pivotal clinical study, the Brand X system \\nwas found to have a safety and effectiveness profile that is similar to the predicate device. \\n \\nVIII. CONCLUSIONS \\n \\nSince the predicate device was cleared based in part on the results of clinical studies, and since the \\ncomparison of bench testing to clinical outcomes is still not well understood for this type of device, \\nclinical testing was required to support substantial equivalence.  The non-clinical data support the \\nsafety of the device and the hardware and software verification and validation demonstrate that the \\nBrand X device should perform as intended in the specified use conditions.  The clinical data \\ndemonstrate that the Brand X device performs comparably to the predicate device that is currently \\nmarketed for the same intended use.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 41, 'page_label': '42'}, page_content='Contains Nonbinding Recommendations \\n \\n 39 \\nAppendix D.  Glossary of Significant Terminology  \\n \\nThe following terms are defined for purposes of this guidance: \\n \\nClassification regulation – The classification regulations are Agency-defined categories of medical \\ndevices based on intended use and technology. Each device classification regulation defines the class \\n(i.e., Class I, II, or III) for the device category which in turn determines the regulatory requirements.  \\nDevice classification regulations are codified by rule or order in 21 CFR Parts 862-892.   \\n \\nIndications for use – The disease or condition the device will diagnose, treat, prevent, cure or \\nmitigate, including a description of the patient population for which the device is intended. \\n \\nIntended use – The general purpose of the device or its function.  The intended use of a device \\nencompasses the indications for use.   \\n \\nMultiple Predicate Devices – Two or more predicate devices that have been provided to support an \\nSE determination.  If using multiple predicate devices to demonstrate substantial equivalence, each \\npredicate device must have the same intended use as the new device, and any different technological \\ncharacteristics between the new device and the predicate devices must not raise different questions of \\nsafety and effectiveness.   \\n \\nPerformance Data – Performance data can be any data, including non-clinical (e.g., data from \\nengineering testing, such as fatigue, wear, corrosion, etc., biocompatibility, functional animal studies, \\ncadaver, etc.) and/or clinical, that are provided to support the substantial equivalence of a device that \\nis intended to be marketed.   \\n \\nPredicate Device – A legally marketed device (as defined in 21 CFR 807.92(a)(3)) to which a new \\ndevice may be compared for a determination regarding substantial equivalence because the devices \\nhave the same intended use and the same technological characteristics or different technological \\ncharacteristics that do not raise different questions of safety and effectiveness.   \\n \\nPrimary Predicate Device – A predicate device with indications for use and technological \\ncharacteristics that are most similar to the new device.  The primary predicate should be identified \\nwithin a 510(k) submission.   \\n \\nReference Device – A legally marketed device that is intended to provide scientific and/or technical \\ninformation (e.g., test methodology) to help address the safety and effectiveness of a new \\ntechnological characteristic.  Reference devices are not predicate devices and may only be used after \\nDecision Point 4 on the 510(k) Decision-Making Flowchart. \\n \\nSplit Predicate – Using one legally marketed device for intended use and a different legally \\nmarketed device for technological characteristics to demonstrate substantial equivalence.  The use of \\na “split predicate” is inconsistent with the 510(k) regulatory standard.')]\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "\n",
    "loader = PyPDFLoader(\"./data/510K - Evaluating Substantial Equivalence.pdf\")\n",
    "fda_guidelines_doc = loader.load()\n",
    "\n",
    "print(fda_guidelines_doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "75538e4d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 0, 'page_label': '1'}, page_content='The 510(k) Program: Evaluating \\nSubstantial Equivalence in Premarket \\nNotifications [510(k)] \\nGuidance for Industry and Food and Drug \\nAdministration Staff   \\n \\nDocument issued on: July 28, 2014 \\n \\nThe draft of th\\nis document issued on December 27, 2011.  \\n \\nThis document supersedes FDA’s Guidance on the CDRH Premarket Notification \\nReview Program, 510(k) Memorandum K86-3, dated June 30, 1986.  \\n \\n \\nFor questions for the Center for Devices and Radiological Health regarding this document, contact the \\nPremarket Notification (510(k)) Section at 301-796-5640. \\n \\nFor questions for the Center for Biologics Evaluation and Research regarding this document, contact the \\nOffice of Communication, Outreach and Development at 1-800-335-4709 or 240-402-7800. \\n \\n \\n \\nU.S. Department of Health and Human Services \\nFood and Drug Administration \\nCenter for Devices and Radiological Health \\nCenter for Biologics Evaluation and Research'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 1, 'page_label': '2'}, page_content='Contains Nonbinding Recommendations \\n \\n \\n \\nPreface \\n \\nPublic Comment \\n \\nYou may submit electronic comments and suggestions at any time for Agency consideration to \\nhttp://www.regulations.gov.  Submit written comments to the Division of Dockets Management, Food and \\nDrug Administration, 5630 Fishers Lane, Room. 1061, (HFA-305), Rockville, MD, 20852.  Identify all \\ncomments with the docket number FDA-2011-D-0652. Comments may not be acted upon by the Agency \\nuntil the document is next revised or updated. \\n \\nAdditional Copies \\n \\nCDRH \\nAdditional copies are available from the Internet. You may also send an e-mail request to CDRH-\\nGuidance@fda.hhs.gov to receive a copy of the guidance.  Please use the document number 1766 to \\nidentify the guidance you are requesting. \\n \\nCBER \\nAdditional copies are available from the Center for Biologics Evaluation and Research (CBER) by written \\nrequest to the address below, by email request to the email address below, by calling the phone number'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 1, 'page_label': '2'}, page_content='request to the address below, by email request to the email address below, by calling the phone number \\nbelow, or from the Internet at the webpage below: \\n \\n \\nCenter for Biologics Evaluation and Research (CBER),  \\nOffice of Communication, Outreach and Development,  \\n10903 New Hampshire Ave, Bldg. 71, Room 3128 \\nSilver Spring, MD 20993, or by calling 1-800-835-4709 or 240-402-7800, by email ocod@fda.hhs.gov, or \\nfrom the Internet at \\nhttp://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 2, 'page_label': '3'}, page_content='Contains Nonbinding Recommendations \\n \\n \\n \\nTable of Contents \\n \\nI. Introduction _____________________________________________________________________ 1 \\nII. Background _____________________________________________________________________ 2 \\nA. The Medical Device Amendments and Device Classification _________________________________ 2 \\nB. The 510(k) Classification Process ________________________________________________________ 3 \\nC. Evolution of the 510(k) Program ________________________________________________________ 4 \\nIII. Scope ________________________________________________________________________ 5 \\nIV. The 510(k) Decision-Making Process ______________________________________________ 5  \\nA. The 510(k) Review Standard ___________________________________________________________ 6 \\nB. The Flowchart ______________________________________________________________________ 10 \\nC. Predicate Device(s) ___________________________________________________________________ 10'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 2, 'page_label': '3'}, page_content='B. The Flowchart ______________________________________________________________________ 10 \\nC. Predicate Device(s) ___________________________________________________________________ 10 \\nD. Intended Use ________________________________________________________________________ 15 \\nE. Technological Characteristics __________________________________________________________ 18 \\nF. Requests for Performance Data ________________________________________________________ 22 \\nG. The 510(k) Summary _________________________________________________________________ 26 \\nAppendix A.  510(k) Decision-Making Flowchart __________________________________________ 27 \\nAppendix B.  The 510(k) Summary Document Requirements ________________________________ 28  \\nAppendix C. Sample of 510(k) Summary Complying with 21 CFR 807.92 ______________________ 33 \\nAppendix D.  Glossary of Significant Terminology _________________________________________ 39'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 3, 'page_label': '4'}, page_content=\"Contains Nonbinding Recommendations \\n \\n 1 \\nThe 510(k) Program: Evaluating Substantial \\nEquivalence in Premarket Notifications \\n[510(k)] \\n \\nGuidance for Industry and Food and Drug \\nAdministration Staff \\n \\nThis guidance represents the Food and Drug Administration's (FDA's) current thinking on this \\ntopic.  It does not create or confer any rights for or on any person and does not operate to bind \\nFDA or the public.  You can use an alternative approach if the approach satisfies the requirements \\nof the applicable statutes and regulations.  If you want to discuss an alternative approach, contact \\nthe FDA staff responsible for implementing this guidance.  If you cannot identify the appropriate \\nFDA staff, call the appropriate number listed on the title page of this guidance.  \\n \\nI. Introduction \\nFDA developed this document to provide guidance to industry and FDA staff about current review\"),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 3, 'page_label': '4'}, page_content='FDA staff, call the appropriate number listed on the title page of this guidance.  \\n \\nI. Introduction \\nFDA developed this document to provide guidance to industry and FDA staff about current review \\npractices for premarket notification (510(k)) submissions.  The intent of this guidance is to identify, \\nexplain, and clarify each of the critical decision points in the decision-making process FDA uses to \\ndetermine substantial equivalence.  This guidance is not intended to implement significant policy \\nchanges to the current 510(k) review process.  Rather, the intent of this guidance is to enhance the \\npredictability, consistency, and transparency of the 510(k) program by describing in greater detail the \\nregulatory framework, policies, and practices underlying FDA’s 510(k) review.   \\n \\nThe draft of this guidance document contained sections addressing FDA’s Special and Abbreviated \\n510(k) programs.  FDA intends to finalize those sections separately.  Until FDA issues new final'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 3, 'page_label': '4'}, page_content=\"The draft of this guidance document contained sections addressing FDA’s Special and Abbreviated \\n510(k) programs.  FDA intends to finalize those sections separately.  Until FDA issues new final \\nrecommendations on the Special and Abbreviated 510(k) programs, the recommendations for Special \\nand Abbreviated 510(k)s contained in “The New 510(k) Paradigm - Alternate Approaches to \\nDemonstrating Substantial Equivalence in Premarket Notifications,” dated March 20, 1998, \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0801\\n87.htm) remain in effect. \\n \\nFDA's guidance documents, including this guidance, do not establish legally enforceable \\nresponsibilities.  Instead, guidances describe the Agency's current thinking on a topic and should be \\nviewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The \\nuse of the word should in Agency guidances means that something is suggested or recommended, but \\nnot required.\"),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='Contains Nonbinding Recommendations \\n \\n 2 \\nII. Background \\nA. The Medical Device Amendments and Device Classification \\nThe Medical Device Amendments (MDA) (Pub. L. 94-295) to the Federal Food, Drug, and Cosmetic \\n(FD&C) Act were enacted on May 28, 1976.  The MDA directed FDA to issue regulations that \\nclassify all devices that were in commercial distribution at that time into one of three regulatory \\ncontrol categories:  Class I, II, or III, depending upon the degree of regulation necessary to provide \\nreasonable assurance of their safety and effectiveness.  The class into which a device is placed \\ndetermines the requirements that a medical device manufacturer must meet prior to distributing a \\ndevice in interstate commerce.  According to section 513(a)(1) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)), the three device classes are defined as follows: \\n\\uf0b7 Class I:  Devices are subject to a comprehensive set of regulatory authorities called general'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='§ 360c(a)(1)), the three device classes are defined as follows: \\n\\uf0b7 Class I:  Devices are subject to a comprehensive set of regulatory authorities called general \\ncontrols that are applicable to all classes of devices.\\n1 \\n   \\n\\uf0b7 Class II:  Devices for which general controls, by themselves, are insufficient to provide \\nreasonable assurance of the safety and effectiveness of the device, and for which there is \\nsufficient information to establish special controls to provide such assurance.\\n2 \\n \\n\\uf0b7 Class III:  Devices for which general controls, by themselves, are insufficient and for which \\nthere is insufficient information to establish special controls to provide reasonable assurance \\nof the safety and effectiveness of the device.  Class III devices typically require premarket \\napproval.\\n3   \\n                                                 \\n1 General controls apply to all classes of medical devices and provide FDA with the means of regulating devices to assure their safety'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='3   \\n                                                 \\n1 General controls apply to all classes of medical devices and provide FDA with the means of regulating devices to assure their safety \\nand effectiveness. General controls include but are not limited to provisions that relate to establishment registration and device listing; \\npremarket notification, although most class I devices are exempt by regulation from this requirement; prohibitions against adulteration \\nand misbranding; records and reports; and good manufacturing practices.  Section 513(a)(1)(A) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)(A)). \\n \\n2 The original definition of a class II device in the Medical Device Amendments of 1976 (Pub. L. 94-295) identified performance \\nstandards rather than special controls as the mechanism by which FDA could establish reasonable assurance of safety and effectiveness.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='standards rather than special controls as the mechanism by which FDA could establish reasonable assurance of safety and effectiveness. \\nThe Safe Medical Devices Act of 1990 (Pub. L. 101-629) added “special controls,” which can include the promulgation of performance \\nstandards as well as postmarket surveillance, patient registries, development and dissemination of guidelines (including guidelines for \\nthe submission of clinical data in premarket notification submissions), and other appropriate actions as FDA deems necessary to \\nprovide such assurance.  Section 513(a)(1)(B) of the FD&C Act (21 U.S.C. § 360c(a)(1)(B)). \\n \\n3 Certain types of devices classified into class III that were in commercial distribution in the United States before May 28, 1976, and \\nthose determined to be substantially equivalent to such devices, may be cleared through the 510(k) process until FDA issues an'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='those determined to be substantially equivalent to such devices, may be cleared through the 510(k) process until FDA issues an \\nadministrative order requiring them to go through the premarket approval process.  Section 515(b)(1) of the FD&C Act (21 U.S.C. \\n§ 360e(b)(1)).  Prior to the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144) on \\nJuly 9, 2012, FDA had to publish regulations to require such devices to go through the premarket approval process.  Section 608(b) of \\nFDASIA (126 Stat. 1056) changed the process from rulemaking to administrative order. \\n  \\n \\n4 For the purpose of this guidance document, a “new device” means a device within the meaning of section 201(h) of the FD&C Act \\nthat is not legally marketed.  It can be either a completely new device or a modification of a legally marketed device that would require \\na new 510(k).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 4, 'page_label': '5'}, page_content='that is not legally marketed.  It can be either a completely new device or a modification of a legally marketed device that would require \\na new 510(k).   \\n \\n5 By contrast, an unclassified devices, as defined in FDA’s Guidance for Industry and Food and Drug Administration Staff, “Medical \\nDevice Classification Product Codes” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm285317.htm), is a pre-amendments \\nPremarket notification is the process by which a new device,4 i.e., a post-amendments device, is \\nclassified into one of these three device classes.5 A manufacturer who intends to market in the United'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='Contains Nonbinding Recommendations \\n \\n                                                                                                                                                                     \\ndevice for which a classification regulation has not been promulgated. Unclassified devices require submission of a 510(k) premarket \\nnotification to FDA. A not-classified device is a post-amendments device for which the Agency has not yet reviewed a marketing \\napplication or for which the Agency has not made a final decision on such a marketing application. A pre-amendments device is a \\ndevice that was on the market prior to the enactment of the Medical Device Amendments to the FD&C Act on May 28, 1976.   \\n \\n6 The three device classes are described in section 513(a) of the FD&C Act (21 U.S.C. § 360c(a)): \\n(1) There are established the following classes of devices intended for human use: \\n(A) CLASS I, GENERAL CONTROLS.—'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='(1) There are established the following classes of devices intended for human use: \\n(A) CLASS I, GENERAL CONTROLS.— \\n(i) A device for which the controls . . . are sufficient to provide reasonable assurance of the safety and effectiveness of the \\ndevice. \\n(ii) A device for which insufficient information exists to determine that the controls referred to in clause (i) are sufficient to \\nprovide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such \\nassurance, but because it— \\n(I) is not purported or represented to be for a use in supporting or sustaining human life or for a use which is of substantial \\nimportance in preventing impairment of human health, and \\n(II) does not present a potential unreasonable risk of illness or injury,  \\nis to be regulated by the controls referred to in clause (i). \\n 3 \\nStates a Class I, II, or III device intended for human use, for which a Premarket Approval application'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='is to be regulated by the controls referred to in clause (i). \\n 3 \\nStates a Class I, II, or III device intended for human use, for which a Premarket Approval application \\n(PMA) is not required, must submit to FDA a premarket notification submission (often referred to as \\na 510(k)), unless the device is exempt from the 510(k) requirements of the FD&C Act and does not \\nexceed the limitations of exemptions for each of the device classification regulations (Section .9 of 21 \\nCFR Parts 862 through 892, e.g., 21 CFR 862.9, 21 CFR 864.9, etc.).  Under section 510(k) of the \\nFD&C Act, a manufacturer must submit a 510(k) to FDA at least 90 days before introducing, or \\ndelivering for introduction, a device into interstate commerce for commercial distribution so the \\nAgency can determine whether or not the device meets the criteria for market clearance (Sections \\n510(k) and (n) of the FD&C Act (21 U.S.C. §§ 360(k) & (n))).  The Agency bases its decision on'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='Agency can determine whether or not the device meets the criteria for market clearance (Sections \\n510(k) and (n) of the FD&C Act (21 U.S.C. §§ 360(k) & (n))).  The Agency bases its decision on \\nwhether the device is substantially equivalent (SE) to a legally marketed (predicate) device (Section \\n513(i) of the FD&C Act (21 U.S.C. § 360c(i))).  The device cannot be commercialized until FDA \\nissues an order (510(k) clearance) stating that the device has been determined to be SE (Section \\n513(f)(1) of the FD&C Act (21 U.S.C. § 360c(f)(1))). \\nB. The 510(k) Classification Process \\nAccording to section 513(f) of the FD&C Act, a new (i.e., post-amendments) device is automatically \\nin Class III and must undergo premarket approval or reclassification before it can be marketed, unless \\nit is a type of device that was in commercial distribution prior to May 28, 1976, and is SE to another \\nsuch device; or it is within a type of device introduced after May 28, 1976, that has been reclassified'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='such device; or it is within a type of device introduced after May 28, 1976, that has been reclassified \\ninto Class I or II and is SE to another device within such classification.  For information about how \\nFDA’s classification product codes assist in accurate identification and tracking of current medical \\ndevices, please see FDA’s Guidance for Industry and Food and Drug Administration Staff, “Medical \\nDevice Classification Product Codes” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm2853\\n17.htm).  \\nWhen FDA determines under sections 510(k), 513(f)(1), and 513(i) of the FD&C Act that a new \\ndevice is SE to a legally marketed (predicate) device, the new device is classified into the same class \\nand subject to the same requirements as the predicate device.  (See Section IV.C.)  A determination \\nthat a new device is not substantially equivalent (NSE) to a predicate device results in the new device'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 5, 'page_label': '6'}, page_content='that a new device is not substantially equivalent (NSE) to a predicate device results in the new device \\nbeing classified into Class III.  Thus, 510(k) review is both the mechanism by which a manufacturer \\nseeks marketing authorization for a new device and by which FDA classifies devices into their \\nappropriate regulatory category.  Because devices are classified according to the level of regulatory \\ncontrol necessary to provide a reasonable assurance of safety and effectiveness,\\n6 classification of a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='Contains Nonbinding Recommendations \\n \\n                                                                                                                                                                     \\n(B) CLASS II, SPECIAL CONTROLS.—A device which cannot be classified as a class I device because the general controls \\nby themselves are insufficient to provide reasonable assurance of the safety and effectiveness of the device, and for which \\nthere is sufficient information to establish special controls to provide such assurance . . . \\n(C) CLASS III, PREMARKET APPROVAL.—A device which because— \\n(i) it (I) cannot be classified as a class I device because insufficient information exists to determine that the application of \\ngeneral controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device, and (II) cannot be \\nclassified as a class II device because insufficient information exists to determine that the special controls described in'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='classified as a class II device because insufficient information exists to determine that the special controls described in \\nsubparagraph (B) would provide reasonable assurance of its safety and effectiveness, and \\n(ii)(I) is purported or represented to be for a use in supporting or sustaining human life or for a use which is of substantial \\nimportance in preventing impairment of human health, or \\n(II) presents a potential unreasonable risk of illness or injury, \\nis to be subject, in accordance with section 515, to Premarket approval to provide reasonable assurance of its safety and \\neffectiveness. \\n \\n7 If FDA has established special controls applicable to the device type, the 510(k) would need to adequately address the issues covered \\nby the special controls for the device to be classified into Class II.  See Section 513(a)(1)(B) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)(B)).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='by the special controls for the device to be classified into Class II.  See Section 513(a)(1)(B) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)(B)).   \\n \\n8 See CDRH Preliminary Internal Evaluations – Volume I: 510(k) Working Group Preliminary Report and Recommendations \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf).  See also CDRH Preliminary \\nInternal Evaluations – Volume II: Task Force on the Utilization of Science in Regulatory Decision Making Preliminary Report and \\nRecommendations (http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220783.pdf).  See also \\n510(k) and Science Report Recommendations: Summary and Overview of Comments and Next Steps \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pdf). \\n \\n 4  \\nnew device through the 510(k) process requires FDA to determine the issues of safety and \\neffectiveness presented by the new device, and the regulatory controls necessary to address those'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='4  \\nnew device through the 510(k) process requires FDA to determine the issues of safety and \\neffectiveness presented by the new device, and the regulatory controls necessary to address those \\nissues.7 \\nC. Evolution of the 510(k) Program \\nSince its inception, the 510(k) program has undergone a number of statutory changes.  Notably, the \\nSafe Medical Devices Act of 1990 (Pub. L. 101-629) added section 513(i), which codified FDA \\nreview practice in applying the “substantial equivalence” review standard.  In addition, FDA has \\nmodified its implementation of the program to adapt to changing circumstances and to accommodate \\nthe evolving medical device landscape.  For example, the alternative options of a Special 510(k) or an \\nAbbreviated 510(k) still exist today.  Additional information regarding these alternative options can \\nbe found in FDA’s guidance, “The New 510(k) Paradigm – Alternative Approaches to Demonstrating \\nSubstantial Equivalence in Premarket Notifications”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='be found in FDA’s guidance, “The New 510(k) Paradigm – Alternative Approaches to Demonstrating \\nSubstantial Equivalence in Premarket Notifications” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/ucm080189.pdf).  The current 510(k) program reflects the current statutory framework and FDA’s \\nimplementation of that framework through regulation, guidance, and administrative practice.  A \\nhistory of the 510(k) program has been summarized in other documents that FDA has published.\\n8 \\nThis guidance document provides updated information to the existing guidance document entitled \\n“Guidance on the CDRH Premarket Notification Review Program, 510(k) Memorandum K86-3” \\n(K86-3 Guidance), issued on June 30, 1986.  The K86-3 Guidance was written and issued as final \\nguidance prior to the February 27, 1997 implementation of FDA’s Good Guidance Practices (GGPs),'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7'}, page_content='(K86-3 Guidance), issued on June 30, 1986.  The K86-3 Guidance was written and issued as final \\nguidance prior to the February 27, 1997 implementation of FDA’s Good Guidance Practices (GGPs), \\nand has not been updated since its initial publication date.  This guidance replaces the K86-3 \\nGuidance.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8'}, page_content='Contains Nonbinding Recommendations \\n \\n 5 \\nIII. Scope \\nThis guidance provides recommendations to industry and FDA staff about the content of 510(k) \\nsubmissions and the decision-making process for determining substantial equivalence of devices \\nreviewed under the 510(k) program.  The guidance has been organized to coincide with the critical \\ndecision points outlined in the 510(k) Decision-Making Flowchart (See Appendix A), which has \\nbeen updated to track section 513(i) of the FD&C Act and relevant regulations more closely.  This \\ndocument provides guidance on the following issues: \\n \\n\\uf0b7 the appropriate use of multiple predicates (See Section IV.C); \\n\\uf0b7 the processes associated with determining whether a new device with new indications for use \\nhas a new intended use (See Section IV.D); \\n\\uf0b7 the process for determining whether different technological characteristics raise different \\nquestions of safety and effectiveness (See Section IV.E);'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8'}, page_content='has a new intended use (See Section IV.D); \\n\\uf0b7 the process for determining whether different technological characteristics raise different \\nquestions of safety and effectiveness (See Section IV.E); \\n\\uf0b7 when performance data, with special emphasis on clinical performance data, may be \\nnecessary to support an SE determination (See Section IV.F); and  \\n\\uf0b7 how to develop 510(k) Summaries to promote greater transparency in the 510(k) decision-\\nmaking process (See Section IV.G).   \\n \\nThe overarching principles in this guidance are applicable to devices that are subject to 510(k) review \\nby CDRH, including the Office of Device Evaluation (ODE) and the Office of In Vitro Diagnostics \\nand Radiological Health (OIR), as well as devices that are subject to 510(k) review by the Center for \\nBiologics Evaluation and Research (CBER).  This guidance is not intended to supplant existing \\ndevice-specific guidance, but may cover broader areas not addressed in device-specific guidance'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8'}, page_content='Biologics Evaluation and Research (CBER).  This guidance is not intended to supplant existing \\ndevice-specific guidance, but may cover broader areas not addressed in device-specific guidance \\ndocuments.  If you have questions about how this guidance and a device-specific guidance apply to a \\nparticular issue, please contact FDA to discuss.  In addition, this guidance does not address review \\nissues unique to combination products.  For information on combination products, please refer to the \\nOffice of Combination Products webpage \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScien\\nceandHealthCoordination/ucm2018184.htm). \\n \\nIV. The 510(k) Decision-Making Process \\nA 510(k) is a premarket submission made to FDA to demonstrate that the new device to be marketed \\nis “substantially equivalent” to a legally marketed device\\n9 (21 U.S.C. §§ 360(k), 360(n), 360c(f)(1) &'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8'}, page_content='is “substantially equivalent” to a legally marketed device\\n9 (21 U.S.C. §§ 360(k), 360(n), 360c(f)(1) & \\n360c(i); 21 CFR 807.92(a)(3)) which is not subject to PMA.  Manufacturers must compare their new \\ndevice to a similar legally marketed device to support its substantial equivalence (21 U.S.C. \\n§ 360c(i); 21 CFR 807.92(a)(3)). \\n                                                 \\n9 Under 21 CFR 807.92(a)(3), a legally marketed device to which a new device may be compared for a determination \\nregarding substantial equivalence is a device that was legally marketed prior to May 28, 1976, or a device which has been \\nreclassified from class III to class II or I, or a device which has been found to be substantially equivalent through the \\n510(k) premarket notification process.   \\n \\nThe most commonly used method of demonstrating substantial equivalence is through the submission \\nand FDA review and clearance of a Traditional 510(k).  Under 21 CFR 807.87, FDA established'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8'}, page_content='The most commonly used method of demonstrating substantial equivalence is through the submission \\nand FDA review and clearance of a Traditional 510(k).  Under 21 CFR 807.87, FDA established \\nbasic content requirements for 510(k)s to be submitted by device manufacturers in support of \\nsubstantial equivalence.  The Agency has provided a general framework on how to format an original \\nsubmission for a Traditional 510(k) in FDA’s Guidance for Industry and FDA Staff, “Format for'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 8, 'page_label': '9'}, page_content='Contains Nonbinding Recommendations \\n \\n 6 \\nTraditional and Abbreviated 510(k)s” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0843\\n65.htm).  Although the basic content requirements apply to all 510(k)s, the type of data and \\ninformation necessary to establish substantial equivalence varies by the type of device and the \\ndifferences between the new device and the predicate device.  FDA has issued many device-specific \\nguidance documents that clarify the data that should be included in 510(k)s for particular device \\ntypes.  If a manufacturer is unsure of what information to include within a 510(k) submission, the \\nmanufacturer may contact FDA and submit a pre-submission to seek additional feedback to ensure \\nsubmissions contain appropriate data elements.  For more information on the pre-submission process, \\nsee FDA’s Guidance for Industry and FDA Staff, “Requests for Feedback on Medical Device'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 8, 'page_label': '9'}, page_content='submissions contain appropriate data elements.  For more information on the pre-submission process, \\nsee FDA’s Guidance for Industry and FDA Staff, “Requests for Feedback on Medical Device \\nSubmissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/UCM311176.pdf).   \\n \\nPlease note that the use of the Standards Data Report for 510(k)s (Form 3654) \\n(http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM081667.pdf), \\nrecognized consensus standards, and device-specific guidance documents is not limited to \\nAbbreviated 510(k) submissions.  Appropriate reliance on these documents can facilitate the review \\nof all 510(k) submissions and can help to make the review process more consistent.  Medical device \\nmanufacturers should consider relying on and citing to standards and device-specific guidance'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 8, 'page_label': '9'}, page_content='of all 510(k) submissions and can help to make the review process more consistent.  Medical device \\nmanufacturers should consider relying on and citing to standards and device-specific guidance \\ndocuments wherever appropriate, regardless of the type of 510(k) submission.   \\n \\nA new device does not need to be identical to the predicate device for it to be found substantially \\nequivalent to the predicate device.  In FDA’s experience, it is rare for a new device to be identical to \\na predicate device.  Given the diversity of technologies evaluated under this review standard, this \\nguidance adopts a flexible approach to determining “substantial equivalence” to accommodate \\nevolving technology while maintaining predictability and consistency to promote confidence among \\ndevice developers, practitioners, and patients.   \\nA. The 510(k) Review Standard \\n1. The Statutory Standard \\nThe 510(k) review standard (substantial equivalence of a new device to a legally marketed (predicate)'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 8, 'page_label': '9'}, page_content='A. The 510(k) Review Standard \\n1. The Statutory Standard \\nThe 510(k) review standard (substantial equivalence of a new device to a legally marketed (predicate) \\ndevice) differs from the PMA review standard (reasonable assurance of safety and effectiveness).  \\nThe 510(k) review standard is comparative, whereas the PMA standard relies on an independent \\ndemonstration of safety and effectiveness.  Nonetheless, the principles of safety and effectiveness \\nunderlie the substantial equivalence determination in every 510(k) review.  The standard for a \\ndetermination of substantial equivalence in a 510(k) review is set out in section 513(i) of the FD&C \\nAct, which states: \\nSubstantial Equivalence \\n(i)(1)(A) For purposes of determinations of substantial equivalence under subsection (f) and \\nsection 520(l), the term \"substantially equivalent\" or \"substantial equivalence\" means, with \\nrespect to a device being compared to a predicate device, that the device has the same'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 8, 'page_label': '9'}, page_content='section 520(l), the term \"substantially equivalent\" or \"substantial equivalence\" means, with \\nrespect to a device being compared to a predicate device, that the device has the same \\nintended use as the predicate device and that the Secretary by order has found that the device'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10'}, page_content='Contains Nonbinding Recommendations \\n \\n 7 \\n(i) has the same technological characteristics as the predicate device, or \\n(ii)(I) has different technological characteristics and the information submitted that the device \\nis substantially equivalent to the predicate device contains information, including appropriate \\nclinical or scientific data if deemed necessary by the Secretary or a person accredited under \\nsection 523, that demonstrates that the device is as safe and effective as a legally marketed \\ndevice, and (II) does not raise different questions of safety and effectiveness than the \\npredicate device. \\n(B) For purposes of subparagraph (A), the term “different technological characteristics” \\nmeans, with respect to a device being compared to a predicate device, that there is a \\nsignificant change in the materials, design, energy source, or other features of the device from \\nthose of the predicate device.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10'}, page_content='significant change in the materials, design, energy source, or other features of the device from \\nthose of the predicate device. \\nSafety and effectiveness factor into both parts of the FDA’s review.  First, FDA must find that the \\nintended use of the device and its predicate are “the same.”  As discussed in the Intended Use Section \\nof this guidance, differences in the indications for use, such as the population for which a device is \\nintended or the disease a device is intended to treat do not necessarily result in a new intended use.  \\nSuch differences result in a new intended use when they affect (or may affect) the safety and/or \\neffectiveness of the new device as compared to the predicate device and the differences cannot be \\nadequately evaluated under the comparative standard of substantial equivalence. (See Section IV.D.)  \\n \\nSecond, when comparing a new device to a predicate device, FDA must find that the two devices'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10'}, page_content='adequately evaluated under the comparative standard of substantial equivalence. (See Section IV.D.)  \\n \\nSecond, when comparing a new device to a predicate device, FDA must find that the two devices \\nhave “the same technological characteristics,” or that a “significant change in the materials, design, \\nenergy source or other features of the device” does not raise different questions of safety and \\neffectiveness and that the device is as safe and effective as a legally marketed device.   \\n \\nAlthough the 510(k) process involves a comparison of a new device to a predicate device rather than \\nan independent demonstration of the new device’s safety and effectiveness, as is required for \\napproval of a PMA, in both cases FDA’s review decision reflects a determination of the level of \\ncontrol necessary to provide a “reasonable assurance of safety and effectiveness.”\\n10  The evidentiary \\nstandard, however, is different.  In the 510(k) context, FDA generally relies, in part, on FDA’s prior'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10'}, page_content='10  The evidentiary \\nstandard, however, is different.  In the 510(k) context, FDA generally relies, in part, on FDA’s prior \\ndetermination that a reasonable assurance of safety and effectiveness exists for the predicate device.  \\nDemonstrating basic similarities between a new device and a predicate device typically requires \\nmanufacturers to provide descriptive information such as a comparison of specifications, materials, \\nand technology.  In contrast, FDA generally evaluates differences between the new device and the \\npredicate device to determine their effect on safety and effectiveness.  It follows that the evidence \\nnecessary to show substantial equivalence will increase as differences between the new device and \\nthe predicate device increase if those differences significantly affect, or may significantly affect, \\nsafety or effectiveness (21 CFR 807.81).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10'}, page_content='the predicate device increase if those differences significantly affect, or may significantly affect, \\nsafety or effectiveness (21 CFR 807.81). \\n                                                 \\n10 Under section 513(a)(2) of the FD&C Act, the safety and effectiveness of a device are to be determined: \\n(A) with respect to the persons for whose use the device is represented or intended, \\n(B) with respect to the conditions of use prescribed, recommended, or suggested in the labeling of the device, and \\n(C) weighing any probable benefit to health from the use of the device against any probable risk of injury or illness from \\nsuch use.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 10, 'page_label': '11'}, page_content='Contains Nonbinding Recommendations \\n \\n 8 \\n2. The Least Burdensome Principle \\nThe FDA Modernization Act of 1997 (FDAMA) added two provisions, commonly known as “the \\nleast burdensome provisions,” to the FD&C Act; these were amended by the FDA Safety and \\nInnovation Act of 2012 (FDASIA) (Pub. L. 112-144; 126 Stat. 1051).  The provision relating to \\nsubstantial equivalence, section 513(i)(1)(D), states: \\n \\n(i) Whenever the Secretary requests information to demonstrate that devices with \\ndiffering technological characteristics are substantially equivalent, the Secretary shall \\nonly request information that is necessary to making substantial equivalence \\ndeterminations. In making such request, the Secretary shall consider the least \\nburdensome means of demonstrating substantial equivalence and request information \\naccordingly. \\n(ii) For purposes of clause (i), the term “necessary” means the minimum required'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 10, 'page_label': '11'}, page_content='burdensome means of demonstrating substantial equivalence and request information \\naccordingly. \\n(ii) For purposes of clause (i), the term “necessary” means the minimum required \\ninformation that would support a determination of substantial equivalence between a \\nnew device and a predicate device. \\n(iii) Nothing in this subparagraph shall alter the standard for determining substantial \\nequivalence between a new device and a predicate device. \\n \\nAlthough the statutory provision refers only to information requests related to determining the \\nsubstantial equivalence of technological characteristics of a device and its predicate, the underlying \\nprinciple that information requests should relate to the review standard is a basic principle of good \\nregulatory practice with broad applicability to the 510(k) decision-making process. \\n \\nFDA’s guidances, “The Least Burdensome Provisions of the FDA Modernization Act of 1997: \\nConcept and Principles”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 10, 'page_label': '11'}, page_content='FDA’s guidances, “The Least Burdensome Provisions of the FDA Modernization Act of 1997: \\nConcept and Principles” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0859\\n94.htm) and “Suggested Format for Developing and Responding to Deficiencies in Accordance with \\nthe Least Burdensome Provisions of FDAMA” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0736\\n79.htm) (“the Least Burdensome Guidances”), explain how FDA intends to apply the least \\nburdensome provisions.  “The Least Burdensome Provisions of the FDA Modernization Act of 1997: \\nConcept and Principles” interprets least burdensome as “a successful means of addressing a \\npremarket issue that involves the most appropriate investment of time, effort, and resources on the \\npart of industry and FDA,” and specifies that the least burdensome provisions do not affect the'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 10, 'page_label': '11'}, page_content='premarket issue that involves the most appropriate investment of time, effort, and resources on the \\npart of industry and FDA,” and specifies that the least burdensome provisions do not affect the \\nstatutory premarket review standards for devices.  The recommendations discussed in this guidance \\nfor evaluating substantial equivalence are consistent with the principles discussed in the Least \\nBurdensome Guidances, but applies them by discussing the considerations that may affect the type of \\ninformation necessary to demonstrate substantial equivalence at different decision points in the \\nreview of a 510(k). \\n3. Categories of NSE Determinations \\nThe K86-3 Guidance stated:  “If it is clear from an initial review that a new device has a[n] intended \\nuse or technological feature that makes it NSE, the Center will not review or require performance \\ninformation in the 510(k). Instead the applicant will be notified that the device is NSE, and any'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 10, 'page_label': '11'}, page_content='use or technological feature that makes it NSE, the Center will not review or require performance \\ninformation in the 510(k). Instead the applicant will be notified that the device is NSE, and any \\nperformance data will be reviewed in a PMA or reclassification petition.”  The same is not true for \\nNSE decisions based on a lack of performance data, which do not preclude submission of a new \\n510(k) containing different or additional data to support a finding of substantial equivalence.  Thus, it'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='Contains Nonbinding Recommendations \\n \\n 9 \\nhas been FDA’s longstanding policy to treat NSE determinations as falling into two categories: (1) \\nthose that reflect FDA’s affirmative determination that the device is a Class III device and cannot be \\nreviewed in a 510(k) submission, and (2) those that reflect inadequacies in the evidence that preclude \\na finding of substantial equivalence.  \\nThe first category of NSE determinations includes a variety of different decisions, such as a finding \\nof a lack of a predicate device, a new intended use, or different technological characteristics that raise \\ndifferent questions of safety or effectiveness when the new device is compared to the cited predicate \\ndevice, that as a matter of law results in an NSE determination.  In most cases, FDA will provide the \\nopportunity for the manufacturer to respond to initial concerns regarding the equivalency of the new'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='opportunity for the manufacturer to respond to initial concerns regarding the equivalency of the new \\ndevice’s intended use or technology to a predicate device via response to a request for additional \\ninformation.  When FDA issues an NSE letter for a reason in this first category, the letter will \\ntypically not identify performance-based deficiencies.  Consequently, the device is automatically \\nclassified into Class III and will require PMA approval,\\n11 or if eligible, granting of a De Novo before \\nmarketing.  If FDA believes that the device found NSE may be eligible for the De Novo program, the \\nNSE letter will typically indicate FDA’s recommendation.  More information regarding the De Novo \\nprogram can be found in FDA’s Guidance for Industry and CDRH Staff, “New Section 513(f)(2) - \\nEvaluation of Automatic Class III Designation” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/ucm080197.pdf).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='Evaluation of Automatic Class III Designation” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/ucm080197.pdf). \\n                                                 \\n11 Alternatives to PMAs include submission of a Product Development Protocol (PDP) (Section 515(f) of the FD&C Act) or a \\nHumanitarian Device Exemption (HDE) (Section 520(m)(2) of the FD&C Act and 21 CFR 814.104).  An HDE may be an appropriate \\noption if the device has been determined by the Office of Orphan Products Development to be eligible for an HDE through a \\nHumanitarian Use Device (HUD) designation (21 CFR 814.100 and 814.102).  Unlike other regulatory submissions, given the limited \\npatient population, an HDE only has to demonstrate a reasonable assurance of safety and probable benefit (Section 520(m)(2) of the \\nFD&C Act and 21 CFR 814.104).  For more information on HUD designations, please see FDA’s guidance “Humanitarian Use Device'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='FD&C Act and 21 CFR 814.104).  For more information on HUD designations, please see FDA’s guidance “Humanitarian Use Device \\n(HUD) Designations” (http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM336515.pdf). \\n \\n12 The passage of FDASIA (Pub. L. 112-144) on July 9, 2012, included the Medical Device User Fee Amendments of 2012 (MDUFA \\nIII), Title II of FDASIA (126 Stat. 1002), which reauthorized the device user fee program for another five years.  The MDUFA III \\nCommitment Letter (http://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM295454.pdf) outlines \\nchanges to the review timeframes and/or expected interactions for many premarket submissions.   \\n \\nThe second category of NSE determinations is for those devices for which FDA has not affirmed that \\nthe new device has a different intended use or that the different technological characteristics raise'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='the new device has a different intended use or that the different technological characteristics raise \\ndifferent questions of safety or effectiveness when compared to the cited predicate device, but rather \\nthat the information provided in the submission is insufficient to demonstrate substantial equivalence \\nto the predicate device.  In this situation, FDA generally first identifies the specific additional \\ninformation – typically related to performance testing – that needs to be provided so that FDA may \\ncomplete its evaluation of substantial equivalence.  Upon receipt of FDA’s request for additional \\ninformation (either through a formal letter, email, phone call or fax), the manufacturer has the \\nopportunity to respond to FDA’s request.  If the manufacturer in its response does not provide the \\nrequested information or a substantive justification for not providing the requested information, FDA'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 11, 'page_label': '12'}, page_content='requested information or a substantive justification for not providing the requested information, FDA \\nwill consider the response incomplete and place the submission immediately back on hold as an \\nincomplete response.  Once a complete response is received, FDA will work with the manufacturer to \\ntry to resolve identified deficiencies in an interactive capacity following the timeframes and \\ninteractions instituted with the passage of the Medical Device User Fee Amendments of 2012 \\n(MDUFA III).\\n12  For more information on communications during the review of a 510(k) submission, \\nsee FDA’s Guidance for Industry and FDA Staff, “Types of Communication During the Review of \\nMedical Device Submissions”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 12, 'page_label': '13'}, page_content='Contains Nonbinding Recommendations \\n \\n 10 \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm3419\\n18.htm).  If the manufacturer does not respond at all to FDA’s requests for additional information, the \\nsubmission will be subsequently withdrawn by FDA within the timeframe specified by FDA’s \\nGuidance for Industry and FDA Staff, “FDA and Industry Actions on Premarket Notification \\n(510(k)) Submissions: Effect on FDA Review Clock and Goals” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/UCM089738.pdf).  If a 510(k) is withdrawn due to a lack of response, the manufacturer may submit \\na new 510(k) with additional information that addresses the outstanding deficiencies communicated \\nby FDA based on the review of the prior 510(k).  If the manufacturer provides the requested \\ninformation after the withdrawal date, it will be considered and processed as a new 510(k) (21 CFR'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 12, 'page_label': '13'}, page_content='by FDA based on the review of the prior 510(k).  If the manufacturer provides the requested \\ninformation after the withdrawal date, it will be considered and processed as a new 510(k) (21 CFR \\n807.87(l)); therefore, all information previously submitted would have to be resubmitted so that the \\nnew 510(k) is complete.  If a new 510(k) is submitted to address deficiencies raised in this type of \\nNSE letter, as explained in FDA’s Guidance for Industry and FDA Staff, “Refuse to Accept Policy \\nfor 510(k)s” (http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-\\ngen/documents/document/ucm315014.pdf), the new 510(k) should clearly identify how the \\noutstanding issues have been addressed and cross-reference where the new information is provided \\nwithin the newly submitted 510(k).  Failure to cite the prior 510(k) number may result in a Refuse to \\nAccept decision.     \\nB. The Flowchart \\nThe 510(k) Substantial Equivalence Decision-Making Process Flowchart (K86-3 Flowchart) was'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 12, 'page_label': '13'}, page_content='Accept decision.     \\nB. The Flowchart \\nThe 510(k) Substantial Equivalence Decision-Making Process Flowchart (K86-3 Flowchart) was \\noriginally presented in the K86-3 Guidance and has served as the overarching “framework” for \\n510(k) decision-making for decades.  The K86-3 Flowchart has provided a concise summary of the \\n510(k) decision-making process and serves as a common frame of reference for scientific and \\nregulatory discussions related to the 510(k) process.  However, the K86-3 Flowchart has not been \\nupdated since 1986 and, consequently, does not incorporate certain terminology set out in subsequent \\namendments to the FD&C Act.  Furthermore, the K86-3 Flowchart’s visual structure may be more \\ncomplex than necessary.  To specifically address these issues, a modified Flowchart is provided that \\nboth more closely tracks the language of section 513(i) of the FD&C Act and relevant regulations, \\nand visually simplifies our presentation of the decision-making algorithm.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 12, 'page_label': '13'}, page_content='both more closely tracks the language of section 513(i) of the FD&C Act and relevant regulations, \\nand visually simplifies our presentation of the decision-making algorithm.   \\nIt should be noted that the 510(k) Decision-Making Flowchart (the Flowchart) (see Appendix A) is \\nmeant to be used in conjunction with this guidance document and not as a “stand-alone” document \\nwithout appropriate references to the context of each critical decision point.    \\nC. Predicate Device(s) \\nAs discussed in Section IV.A, the 510(k) review standard is substantial equivalence of a new device \\nto a legally marketed device.  Under 21 CFR 807.92(a)(3), a legally marketed device is a device that \\n(i) was legally marketed prior to May 28, 1976 (preamendments device13) and for which a PMA is \\nnot required; or (ii) has been reclassified from Class III to Class II or I; or (iii) has been found SE \\nthrough the 510(k) process.  For purposes of determining substantial equivalence, the legally'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 12, 'page_label': '13'}, page_content='not required; or (ii) has been reclassified from Class III to Class II or I; or (iii) has been found SE \\nthrough the 510(k) process.  For purposes of determining substantial equivalence, the legally \\nmarketed device is commonly referred to as the “predicate device” or “predicate.”  While \\nmanufacturers may identify more than one predicate device, only one is required.  FDA encourages \\n                                                 \\n13 See Preamendment Status \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ComplianceActivities/ucm072746.htm).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 13, 'page_label': '14'}, page_content='Contains Nonbinding Recommendations \\n \\n 11 \\nmanufacturers to identify a single predicate device to simplify and facilitate the decision-making \\nprocess.  When a manufacturer does identify multiple predicates, the primary predicate refers to \\nthe one with indications for use and technological characteristics most similar to the device under \\nreview.  Although using a single predicate is optimal, when multiple predicates are appropriate (as \\ndescribed in the examples below), FDA recommends identifying a primary predicate in the \\nsubmission to facilitate a timely, well-supported decision.   \\nSection 513(i) of the FD&C Act and 21 CFR 807.100(b) state that, for a new device to be considered \\nsubstantially equivalent to a predicate device, the new device must have the same intended use as the \\npredicate device and the same technological characteristics or different technological characteristics'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 13, 'page_label': '14'}, page_content='predicate device and the same technological characteristics or different technological characteristics \\nthat do not raise different questions of safety and effectiveness than the predicate device.  Therefore, \\nthe use of a “split predicate” is inconsistent with the 510(k) regulatory standard.  “Split predicate” \\nrefers to a situation in which a manufacturer is attempting to “split” the 510(k) decision making \\nprocess by demonstrating that a new device has the same intended use as one marketed device while \\ncomparing the new device’s technological characteristics with a second marketed device that has a \\ndifferent intended use.  As a general matter, to find a device substantially equivalent, FDA must be \\nable to address Decision Points 1 through 4 in the Flowchart using one predicate device identified by \\nthe manufacturer.  FDA may use one or more additional devices proposed by the manufacturer in \\ncertain instances to help support substantial equivalence, as described below.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 13, 'page_label': '14'}, page_content='the manufacturer.  FDA may use one or more additional devices proposed by the manufacturer in \\ncertain instances to help support substantial equivalence, as described below.     \\n1. Multiple Predicates \\nA manufacturer may use multiple predicate devices\\n14 to help demonstrate substantial equivalence in \\ncertain circumstances.  Manufacturers sometimes choose to do this when combining features from \\ntwo or more predicate devices with the same intended use into a single new device, when seeking to \\nmarket a device with more than one intended use, or when seeking more than one indication for use \\nunder the same intended use, as described in the examples below.  \\n                                                 \\n14 See 510(k) and Science Report Recommendations: Summary and Overview of Comments and Next Steps.  \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pdf).     \\n \\n \\nMultiple Predicates Example 1:'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 13, 'page_label': '14'}, page_content='(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pdf).     \\n \\n \\nMultiple Predicates Example 1:   \\nA manufacturer submits a 510(k) for a new hemodialysis catheter.  This new catheter has an \\nextension (the portion of the device outside the body) design that is similar to predicate A and a \\ntip (the portion of the device inside the body) design similar to predicate B.  Both predicates A \\nand B have the same intended use as the new device. In this example, the manufacturer is relying \\non both predicate A and predicate B, which have the same intended use as the new device, to \\nsupport substantial equivalence with respect to technological characteristics.  The manufacturer \\nmay choose either predicate as the primary predicate in this example.   \\n \\nMultiple Predicates Example 2:   \\nA manufacturer submits a 510(k) for a plate indicated for fixation of both diaphyseal (the shaft of'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 13, 'page_label': '14'}, page_content='Multiple Predicates Example 2:   \\nA manufacturer submits a 510(k) for a plate indicated for fixation of both diaphyseal (the shaft of \\na long bone) and epiphyseal (the ends of a long bone) fractures, i.e., the plate can be used to set a \\nlong bone, such as the femur or thigh bone, that is broken in the middle or at the ends.  The \\nmanufacturer cites a predicate device that is a plate indicated for middle bone fractures only and \\nanother predicate device that is indicated specifically for bone tip fractures.  While the indications \\nfor use of each predicate device are different, both devices have the same intended use, namely,'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 14, 'page_label': '15'}, page_content='Contains Nonbinding Recommendations \\n \\n 12 \\nfracture fixation of the long bone.15  Thus, although the manufacturer could have used a single \\npredicate device, in cases where a manufacturer intends to market a device for more than one \\nindication and a different predicate exists to support each specific indication, the manufacturer \\nmay cite more than one relevant predicate device to support an SE determination.  In this case, \\nusing two appropriate predicates clearly identified by the manufacturer helped to facilitate \\nclearance of the new device, which was indicated to treat both types of fractures treated by the \\npredicates.   \\n                                                 \\n15 It is important to note that if multiple predicates are used to support the same intended use, any different technological characteristics \\nbetween the new device and the cited predicate devices must not raise different questions of safety and effectiveness.  Section 513(i) of'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 14, 'page_label': '15'}, page_content='between the new device and the cited predicate devices must not raise different questions of safety and effectiveness.  Section 513(i) of \\nthe FD&C Act (21 U.S.C. § 360c(i)). \\n \\nMultiple Predicates Example 3:   \\nA manufacturer submits a 510(k) for a laser platform that consists of two hand pieces:  an \\nEr:YAG laser hand piece and a Q-Switch Nd:YAG laser hand piece.  The manufacturer cites two \\npredicates to support substantial equivalence for both of their requested proposed indications for \\nuse.  In this case, each predicate cited does not share the same indications for use as the other \\npredicate because each predicate consists of only one hand piece in which the indications \\ncorrespond to the indications for one of the hand pieces included in the new device.  However, the \\nindications for both hand pieces fall within the scope of the general intended use of lasers, \\n“incision, excision, ablation, vaporization of soft tissue.”  The Er:YAG laser hand piece is'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 14, 'page_label': '15'}, page_content='indications for both hand pieces fall within the scope of the general intended use of lasers, \\n“incision, excision, ablation, vaporization of soft tissue.”  The Er:YAG laser hand piece is \\nindicated for the incision, excision, ablation, vaporization of soft tissue; and the Q-Switch \\nNd:YAG laser hand piece is indicated for tattoo removal.  The new device is found substantially \\nequivalent to the predicate devices because it has the same intended use and the new device’s \\ntechnological characteristics are similar to the cited predicates. \\n \\nIn each example above, a single predicate could have been used to establish substantial equivalence \\nof the new device, but the manufacturer used multiple predicates to show that FDA had found similar \\ntechnology or indications to be substantially equivalent.     \\n \\nMultiple Predicates Example 4:   \\nA manufacturer submits a 510(k) for a multi-parameter monitor.  The monitor includes different'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 14, 'page_label': '15'}, page_content='technology or indications to be substantially equivalent.     \\n \\nMultiple Predicates Example 4:   \\nA manufacturer submits a 510(k) for a multi-parameter monitor.  The monitor includes different \\ntechnologies that can stand alone independently, but can also be used together for the general \\nintended use of measuring patient vital information.  If there is a predicate device for each of the \\nparameters, then the combination of these parameters, assuming that monitoring of each \\nindividual parameter does not interfere with the others, can be found substantially equivalent.   \\n \\nIt should be noted that in Examples 2, 3, and 4 above, the specific indications of the new device may \\nnecessitate new performance testing, but they do not change the overall intended use of the device \\nrelative to the predicates.  These types of situations will need to be assessed on a case-by-case basis; \\nin some situations, a specific indication may actually alter the overall intended use of the device in'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 14, 'page_label': '15'}, page_content='in some situations, a specific indication may actually alter the overall intended use of the device in \\nwhich case the multiple predicates concept may not be applicable.  More information regarding when \\na specific indication is reasonably included within a general indication can be found in FDA’s \\nGuidance for Industry, “General/Specific Intended Use” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0739\\n44.htm). \\n \\nFeatures can also be added to a new device to increase convenience of use and/or functionality, \\nwithout altering the intended use or risk profile (relative to a predicate) of the new device.  Under'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 15, 'page_label': '16'}, page_content='Contains Nonbinding Recommendations \\n \\n 13 \\nsuch circumstances, the device with the added feature can be reviewed in a 510(k), even if the added \\nfeature consists of a component that may fall under a different classification regulation.  A catheter-\\nthermometer construct is useful in illustrating this concept.   \\n \\nMultiple Predicates Example 5:   \\nA manufacturer submits a 510(k) for a urinary catheter with a thermometer.  The \\nthermometer/temperature-measuring feature is not affecting the intended use or risks of using the \\ncatheter (assuming it is integrated appropriately), nor is the catheter affecting the performance or \\nrisk profile of the thermometer.  The temperature-measuring feature is a convenience component \\nthat is added to the catheter, with the intended use of the device still being that of the catheter to \\npass fluids to or from the urinary tract, so it is appropriate to have a legally marketed catheter \\nserving as the primary predicate.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 15, 'page_label': '16'}, page_content='pass fluids to or from the urinary tract, so it is appropriate to have a legally marketed catheter \\nserving as the primary predicate. \\n \\nThere are obvious limitations to feature/component additions in the 510(k) program.  If a feature is \\nadded which alters the intended use of the new device and/or alters the safety profile (i.e., introduces \\nnew or additional risk factors) such that comparison to a predicate cannot be made, the new device is \\nineligible for the 510(k) program.  A new device with a new design feature or added component must \\nmeet the SE standard with at least a single predicate from the same classification regulation.   \\n2. Reference Devices \\nWhen demonstrating substantial equivalence in a 510(k) submission, manufacturers sometimes direct \\nattention to similar situations FDA has encountered in the past.  If a manufacturer successfully \\nnavigates through Decision Point 4 on the Flowchart using a single predicate device, other legally'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 15, 'page_label': '16'}, page_content='attention to similar situations FDA has encountered in the past.  If a manufacturer successfully \\nnavigates through Decision Point 4 on the Flowchart using a single predicate device, other legally \\nmarketed devices, which FDA calls “reference devices,” may be used to support scientific \\nmethodology or standard reference values at Decision Point 5a.   \\nIt is important to note that a reference device is not considered a predicate device and it cannot be \\nused to address Decision Points 1 – 4 on the Flowchart.  Additionally, the applicability of a reference \\ndevice will need to be reviewed by FDA for its appropriateness.  If a selected reference device is used \\nin an anatomical location or for a physiological purpose that is considerably different than that of the \\nnew device, its utility as a reference device may be limited. \\nIf a manufacturer intends to use a reference device, the manufacturer should provide a scientific'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 15, 'page_label': '16'}, page_content='new device, its utility as a reference device may be limited. \\nIf a manufacturer intends to use a reference device, the manufacturer should provide a scientific \\nrationale that justifies its use.  This concept is illustrated in the Reference Device Examples below. \\nWe recommend that you read these examples side-by-side with the Flowchart in Appendix A so that \\nyou can follow the decision-making process. \\nReference Device Example 1:  A manufacturer submits a 510(k) for a total knee implant with \\ncoating X (the new device).  Other coated knee implants with the same intended use with coatings \\nA, B, and C are legally marketed.  In addition, a total hip implant with coating X is legally \\nmarketed.  The manufacturer cites the legally marketed knee implant with coating A as the \\npredicate device.  FDA determines that the new device has an appropriate predicate device (thus, \\nanswering “yes” at Decision Point 1) and the new device has the same intended use as the'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 15, 'page_label': '16'}, page_content='predicate device.  FDA determines that the new device has an appropriate predicate device (thus, \\nanswering “yes” at Decision Point 1) and the new device has the same intended use as the \\npredicate device (thus, answering “yes” at Decision Point 2 in the Flowchart).\\n16  However, FDA \\n                                                 \\n16 The answer at Decision Point 2 may possibly be “no” if the predicate device is uncoated.  Introducing a coated arthroplasty device \\ninto an anatomical location which previously only had non-coated devices would likely create a new intended use due to the different \\nfixation methods.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='Contains Nonbinding Recommendations \\n \\n 14 \\ndetermines that the new device does not have the same technological characteristics as the \\npredicate device (thus, answering “no” at Decision Point 3 in the Flowchart), because the new \\ndevice (knee implant with coating X) has a chemical profile different from the chemical profile of \\nthe cited predicate device (knee implant with coating A).  There are no other technological \\ndifferences between the new device and the cited predicate device (knee implant with coating A).  \\nFDA determines that the new device does not raise different questions of safety and effectiveness.  \\nIn this case, FDA determines that the safety and effectiveness questions regarding the coating \\nmaterial are whether it is biocompatible and whether it affects the fixation of the implant and \\nthese questions apply to both the new device and predicate device (thus, answering “no” at \\nDecision Point 4 in the Flowchart).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='these questions apply to both the new device and predicate device (thus, answering “no” at \\nDecision Point 4 in the Flowchart).   \\n \\nAfter Decision Point 4 in the Flowchart, if appropriate, the manufacturer may refer to the \\nreference device (the hip implant with coating X in this situation) to support the appropriate \\nscientific methods for the characterization of coating X on the new knee implant device.  In this \\nparticular example, the manufacturer provided an adequate scientific rationale to support that the \\nmethods used to characterize the biocompatibility and characteristics of the coating (e.g., \\nstrength, abrasion, etc.) on the hip implant are applicable to the knee implant.\\n17  The reference \\ndevice (hip implant with coating X) is used in this case solely to assist with the characterization of \\nthe coating on the new device (knee implant with coating X).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='the coating on the new device (knee implant with coating X).    \\n                                                 \\n17 The applicability of the scientific methodology used to characterize certain aspects of a legally marketed device will depend upon the \\nspecific scenario.  In this example, it is determined that the duration of contact, which affects the biocompatibility testing, and the \\nmechanical testing conducted to fully characterize the coating on the hip implant are directly relevant and informative for the same \\ncoating applied to the knee implant.  However, if the manufacturer wanted to rely on the scientific methodology for a coating used in a \\ndifferent type of implant (e.g., cardiovascular), it may not be appropriate to exercise this approach.    \\n \\n \\nReference Device Example 2:  A manufacturer submits a 510(k) for an over-the-counter blood \\nglucose test system (glucose meter).  Other glucose meters with the same intended use are legally'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='Reference Device Example 2:  A manufacturer submits a 510(k) for an over-the-counter blood \\nglucose test system (glucose meter).  Other glucose meters with the same intended use are legally \\nmarketed.  The manufacturer cites a legally marketed glucose meter as the predicate device.  FDA \\ndetermines that the new device has an appropriate predicate device (thus, answering “yes” at \\nDecision Point 1) and the new device has the same intended use as the predicate device (thus, \\nanswering “yes” at Decision Point 2 in the Flowchart).  The manufacturer has not demonstrated \\nthat the new device has the same technological characteristics as the predicate device (thus, \\nanswering “no” at Decision Point 3 in the Flowchart), but the new device does not raise different \\nquestions of safety and effectiveness (thus, answering “no” at Decision Point 4 in the Flowchart).   \\n \\nBecause glucose meters of this type typically have relatively high inherent total error due to'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='questions of safety and effectiveness (thus, answering “no” at Decision Point 4 in the Flowchart).   \\n \\nBecause glucose meters of this type typically have relatively high inherent total error due to \\nlimitations in their technology and other factors, in order to sufficiently characterize the analytical \\nperformance of the new device (and answer “yes” at Decision Point 5a in the Flowchart), the new \\ndevice uses the same approach to characterize analytical performance as the predicate device.  \\nSpecifically, the accuracy of the new device is evaluated by comparing its blood glucose results \\nto reference values generated on a laboratory-based glucose measurement device that has been \\nwell-validated for precision and accuracy, and that is traceable to a higher order, e.g., \\ninternationally recognized standard.  If the performance of the new device (including accuracy \\ncompared to the reference values from a reference device) is equivalent to the performance of the'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 16, 'page_label': '17'}, page_content='internationally recognized standard.  If the performance of the new device (including accuracy \\ncompared to the reference values from a reference device) is equivalent to the performance of the \\npredicate device (including accuracy of the predicate compared to the reference values from a \\nreference device), the FDA would determine that the data demonstrate equivalence (thus \\nanswering “yes” at Decision Point 5b in the Flowchart).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='Contains Nonbinding Recommendations \\n \\n 15 \\n3. Lack of Predicate Device \\nIf a predicate device with the same intended use cannot be identified, or if the new device’s different \\ntechnological characteristics raise different questions of safety or effectiveness, a manufacturer may \\nsubmit a De Novo request, either after receipt of an NSE letter or directly requesting classification \\nthrough the De Novo process.18  For high risk devices, a PMA (or alternative submission type) may \\nbe required.  \\n                                                 \\n18 Section 607 of FDASIA (Pub. L. 112-144; 126 Stat. 1054), which was enacted on July 9, 2012, amended section 513(f)(2) of the \\nFD&C Act by providing the option of directly submitting a request for De Novo classification without the need for an NSE \\ndetermination.  A manufacturer who intends to submit a direct De Novo request is encouraged to engage in dialogue with FDA through'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='determination.  A manufacturer who intends to submit a direct De Novo request is encouraged to engage in dialogue with FDA through \\nthe pre-submission process to obtain additional feedback related to whether a valid predicate exists for the new device and appropriate \\nperformance data that will be necessary to support a reasonable assurance of safety and effectiveness.  For more information on the pre-\\nsubmission process, see FDA’s Guidance for Industry and FDA Staff, “Requests for Feedback on Medical Device Submissions: The \\nPre-Submission Program and Meetings with Food and Drug Administration Staff” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM311176.pdf). \\n \\n19 Although devices recently cleared under the 510(k) program are often selected as the predicate device to which substantial \\nequivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2)'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='equivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2) \\nof the FD&C Act provides that a predicate device may not have been removed from the market at the initiative of the Commissioner of \\nFood and Drugs or been determined to be misbranded or adulterated by a judicial order.  See also 21 CFR 807.100. \\n \\n20 This guidance is not intended to supplant either of the following guidance documents:  “Determination of Intended Use for 510(k) \\nDevices; Guidance for CDRH Staff (Update to K98-1)” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082162.htm) or “General/Specific \\nIntended Use” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm). \\n \\n21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations” \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm259173.htm). \\n \\n4. Identification and Documentation of the Predicate(s) \\nAlthough manufacturers may cite more than one predicate device in a 510(k), FDA recommends that \\nthe manufacturer clearly identify the primary predicate device to which substantial equivalence is \\nbeing claimed.\\n19  Further, as part of the decision-making process, FDA should clearly cite the \\npredicate device relied upon in determining substantial equivalence for the new device in its review \\ndocumentation.  If multiple predicates or reference devices are used in accordance with this guidance, \\nthe manufacturer should identify each device and explain why more than one predicate or a reference \\ndevice is necessary and appropriate to support substantial equivalence.  Manufacturers should choose'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='device is necessary and appropriate to support substantial equivalence.  Manufacturers should choose \\nthe most appropriate single or primary predicate for their new device, and should limit the multiple \\npredicates to those most helpful in facilitating review of the new device and to the minimum number \\nnecessary to support substantial equivalence.  Predicate device(s) relied upon for SE must be \\naccurately cited in the 510(k) Summary (see Appendix B) according to 21 CFR 807.92 (a)(3).  \\nReference devices also may be cited in the 510(k) Summary.   \\nD. Intended Use \\nUnder section 513(i) of the FD&C Act, FDA may only determine that a device is substantially \\nequivalent to a predicate device if it has the same intended use.20  (Refer to the 510(k) Decision-\\nMaking Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18'}, page_content='Making Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE \\ndetermination generally reflects a finding that a change in the indications for use of a device creates a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19'}, page_content='Contains Nonbinding Recommendations \\n \\n 16 \\nnew intended use.  This section of the guidance provides further clarification about the terms \\n“intended use” and “indications for use,” describes how FDA determines what the intended use of a \\ndevice is, and provides examples of changes in indications for use that may constitute a new intended \\nuse making the device ineligible for review under the 510(k) program.     \\n1. Explanation of Intended Use and Indications for Use \\nFor purposes of substantial equivalence, the term intended use means the general purpose of the \\ndevice or its function, and encompasses the indications for use.  The term indications for use, as \\ndefined in 21 CFR 814.20(b)(3)(i), describes the disease or condition the device will diagnose, treat, \\nprevent, cure or mitigate, including a description of the patient population for which the device is \\nintended.\\n22  The intended use of a device is one criterion that determines whether a device can be'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19'}, page_content='intended.\\n22  The intended use of a device is one criterion that determines whether a device can be \\ncleared for marketing through the 510(k) process or must be evaluated in a PMA (or alternative \\nsubmission type), or if appropriate, a De Novo request.  The proposed labeling in a 510(k) is used to \\ndetermine a device’s intended use (Section 513(i)(1)(E) of the FD&C Act).  The indications for use \\nstatement in a 510(k) is also a factor in determining a device’s intended use.  Consistency between \\nthe indications for use statement and the proposed labeling will facilitate the review of the 510(k). \\n \\n                                                 \\n22 We have a long-standing policy of applying the definition of indications for use in the PMA regulation at 21 CFR 814.20(b)(3)(i) in \\nthe same way in the 510(k) context. \\n \\n23 For purposes of Section IV.D, the term “new” in describing indications for use refers to an indication that is new or differs from that \\nof the predicate device.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19'}, page_content='23 For purposes of Section IV.D, the term “new” in describing indications for use refers to an indication that is new or differs from that \\nof the predicate device. \\nA finding of substantial equivalence means that the indications for use of the new device fall within \\nthe intended use of the predicate device and, therefore, the two devices have the same intended use.  \\nFor devices with general indications for use that do not specify a disease, condition, or population (or \\nan anatomical site from which a disease state or population may be inferred), the indications for use \\nand intended use are the same.  Such indications for use are referred to as “tool type” indications for \\nuse.  Examples of devices with “tool type” indications for use include devices such as scalpels, which \\nare often indicated for cutting tissue, or imaging devices, which are often indicated for taking images \\nof the body.  A scalpel indicated for removing a particular type of cancerous cell, however, has'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19'}, page_content='of the body.  A scalpel indicated for removing a particular type of cancerous cell, however, has \\nindications for use specific to the identified disease, condition, or population, and therefore, does not \\nhave “tool type” indications for use. \\n2. Determining Intended Use \\nSection 513(i)(1)(E)(i) of the FD&C Act provides that the FDA’s determination of intended use of a \\ndevice “shall be based upon the proposed labeling” submitted in a 510(k).  When a review of the \\nindications for use and all other information in the proposed labeling submitted with a 510(k) \\nsupports an intended use that is the same as that of the predicate device, FDA will determine that the \\nnew device and predicate device have the same intended use.  This guidance does not address FDA’s \\nauthority to consider information outside the labeling in reviewing a 510(k) and issue an “SE with \\nlimitations” under section 513(i)(l)(E) of the FD&C Act because “there is a reasonable likelihood that'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19'}, page_content='limitations” under section 513(i)(l)(E) of the FD&C Act because “there is a reasonable likelihood that \\nthe device will be used for an intended use not identified in the proposed labeling” and such use \\n“could cause harm.”  For information on “SE with limitations,” please see the guidance document, \\n“Determination of Intended Use for 510(k) Devices; Guidance for CDRH Staff (Update to K98-1 )” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0821\\n62.htm).  When a review of the labeling submitted with a 510(k) shows that the indications for use of \\na new device and predicate device differ, FDA must evaluate whether the new23 indications for use'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='Contains Nonbinding Recommendations \\n \\n                                                                                                                                                                     \\n \\n24 See 21 CFR 807.92(a)(5); see also FDA guidance “General/Specific Intended Use” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm) which implements section \\n513(i)(1)(F) of the FD&C Act.   \\n 17 \\nfall within the same intended use as that of the predicate device.  As described in Section IV.A, \\nbecause the substantial equivalence determination is grounded in safety and effectiveness, this \\ndetermination depends upon the safety and effectiveness of the new device for the new indications \\nrelative to the safety and effectiveness of the predicate device. \\nOnce FDA has determined the indications for use of the new device upon review of the proposed'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='relative to the safety and effectiveness of the predicate device. \\nOnce FDA has determined the indications for use of the new device upon review of the proposed \\nlabeling, FDA may rely upon relevant clinical and/or scientific information, that does not appear in \\nthe proposed labeling submitted with the 510(k), regarding the safety and effectiveness of the new \\nindications for use.  For example, FDA may rely upon publicly-available scientific information or \\nAgency knowledge about how a disease progresses to determine whether indications for use to treat a \\ncertain disease or anatomical site constitute a new intended use.   \\n3. Determining When Indications for Use Result in a New Intended Use \\nNot every change in indications for use that may affect safety or effectiveness will result in a finding \\nof a new intended use.  Only a change in the indications for use that raises different questions of'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='of a new intended use.  Only a change in the indications for use that raises different questions of \\nsafety and effectiveness and therefore, precludes a meaningful comparison with the predicate device \\nconstitutes a new intended use.  FDA may find changes in indications for use of a device to constitute \\na new intended use when the changes raise a safety or effectiveness issue that was not raised by the \\npredicate device, or the changes have the potential to significantly increase a safety or effectiveness \\nconcern raised by the predicate device.\\n24  In the first case, reliance on a predicate device is inadequate \\nbecause the safety or effectiveness issue was not considered in reviewing the 510(k) for the predicate \\ndevice.  In the second case, although the safety or effectiveness issue may have been considered in \\nthe 510(k) for the predicate device, the finding of substantial equivalence for the predicate device'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='the 510(k) for the predicate device, the finding of substantial equivalence for the predicate device \\ncannot be generalized to the new indications for use because of a probable, significant change in the \\nincidence or severity of the issue.  In both cases, the predicate device is not an adequate “proxy” for \\nan independent determination of safety and effectiveness.   \\nIllustrative Example 1:  A new device’s instructions for use describe using a general surgery \\ndevice in a body cavity, but the predicate device is used only to treat external injuries.  A \\ncomparison to the predicate device may not be adequate to address the risk of infection posed by \\ninternal use of the device.  Because of the need for an independent assessment of an issue that \\nwas not evaluated or was of significantly less concern during FDA’s review of the 510(k) for the \\npredicate device, FDA may determine that the indication for use of the new device constitutes a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='was not evaluated or was of significantly less concern during FDA’s review of the 510(k) for the \\npredicate device, FDA may determine that the indication for use of the new device constitutes a \\nnew intended use and a PMA (or alternative submission type), or if appropriate, a De Novo \\nrequest, is required.   \\n \\nIllustrative Example 2:  A 510(k) for an existing surgical ablation device cleared for ablation of \\ncardiac tissue has now been submitted for the treatment of atrial fibrillation. While the devices are \\nsimilar in technology, additional clinical testing has been conducted to demonstrate that not only \\ncan the device ablate cardiac tissue, but also that doing so can treat atrial fibrillation safely and \\neffectively.  While the question of whether or not cardiac tissue can be safely and effectively \\nablated was raised by the predicate device, FDA has determined that the specific indication for'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20'}, page_content='effectively.  While the question of whether or not cardiac tissue can be safely and effectively \\nablated was raised by the predicate device, FDA has determined that the specific indication for \\nthe treatment of atrial fibrillation constitutes a new intended use because it raises questions of \\nboth safety and effectiveness not raised by the predicate device.  Specifically, treatment of atrial'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21'}, page_content='Contains Nonbinding Recommendations \\n \\n 18 \\nfibrillation requires extensive ablation to create linear lines of conduction block in a maze-like \\npattern that eliminates fibrillatory conduction in the atria.  The effectiveness assessment for the \\ntreatment of atrial fibrillation warrants a clinical outcome study.  Furthermore, the risks of \\niatrogenic heart block and collateral cardiac or extra-cardiac damage are either raised or increased \\nwhen such a complex and extensive lesion set is created.  As a result, a PMA (or alternative \\nsubmission type) is required. \\n4. Changes in Indications for Use that May Result in a New Intended Use \\nAll new indications for use should be evaluated to determine whether they reflect a new intended use.  \\nCertain types of changes, however, warrant particular attention in evaluating whether the new \\nindications for use result in a new intended use because they are more likely to significantly affect \\nsafety or effectiveness:'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21'}, page_content='indications for use result in a new intended use because they are more likely to significantly affect \\nsafety or effectiveness: \\n \\n\\uf0b7 a change from a functional/performance indication to a treatment or aesthetic indication; \\n \\n\\uf0b7 a change from a diagnostic indication to a screening indication, or vice versa; \\n \\n\\uf0b7 a change in the anatomical structure of use; \\n \\n\\uf0b7 a change in the patient population (e.g., adult versus pediatric; different disease populations);  \\n \\n\\uf0b7 a change in the clinical context or setting (e.g., periodic monitoring versus continuous \\nmonitoring; hospital versus home use). \\nE. Technological Characteristics \\nAfter FDA has determined that a valid predicate device exists for a new device and that both devices \\nhave the same intended use, FDA will move to Decision Points 3 and 4 of the Flowchart (see \\nAppendix A).  In these steps of the 510(k) review process, FDA compares the technological'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21'}, page_content='have the same intended use, FDA will move to Decision Points 3 and 4 of the Flowchart (see \\nAppendix A).  In these steps of the 510(k) review process, FDA compares the technological \\ncharacteristics of the new device and the predicate device to determine whether the new device has \\nthe same technological characteristics as the predicate, and if not, whether the different technological \\ncharacteristics raise different questions of safety and effectiveness.\\n25  Devices reviewed under the \\n510(k) program commonly have different technological characteristics from their predicate device(s); \\nhowever, FDA rarely makes a finding of NSE at Decision Point 4.\\n26   \\n                                                 \\n25 Section 513(i)(1)(A) of the FD&C Act and 21 CFR 807.100(b)(2).  “Different technological characteristics” are defined as \\n“significant change in the materials, design, energy source, or other features of the device from those of the predicate device.”  Section'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21'}, page_content='“significant change in the materials, design, energy source, or other features of the device from those of the predicate device.”  Section \\n513(i)(1)(B) of the FD&C Act and 21 CFR 807.100(b)(2)(ii)(A). \\n \\n26 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”  \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm259173.htm).  \\n \\n1. Step 1 – Identification of Technological Characteristics of the New and Predicate \\nDevice \\nFor FDA to evaluate whether differences exist between the technological characteristics of the new \\ndevice and the predicate device(s), the manufacturer should clearly identify the technological \\ncharacteristics of each device individually.  Technological characteristics include materials, design,'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content='Contains Nonbinding Recommendations \\n \\n 19 \\nenergy source, and other device features, as defined in section 513(i)(1)(B) of the FD&C Act and 21 \\nCFR 807.100(b)(2)(ii)(A). \\n  \\nTo facilitate FDA’s review of a device’s technological characteristics, the device description in a \\n510(k)\\n27 should include the information necessary to explain the new device’s technological \\ncharacteristics, including similarities in materials, design, energy source, and other device features.  \\nThis information will be evaluated by FDA to determine whether the technological characteristics of \\nthe new device are different and, if so, whether they raise different questions of safety and \\neffectiveness as compared to the predicate(s).  Examples of key characteristics that should be \\nprovided as part of a 510(k) submission include, but are not limited to, the following features:'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content='provided as part of a 510(k) submission include, but are not limited to, the following features: \\n                                                 \\n27 FDA’s regulations require manufacturers to include in their 510(k)s “[a] description of the device that is the subject of the premarket \\nnotification submission, such as might be found in the labeling or promotional material for the device, including an explanation of how \\nthe device functions, the scientific concepts that form the basis for the device, and the significant physical and performance \\ncharacteristics of the device, such as device design, material used, and physical properties.” 21 CFR 807.92(a)(4); see also 21 CFR \\n807.87(f). \\n \\n28 The original Flowchart from the K86-3 Guidance included a decision point related to whether or not “descriptive characteristics” \\nwere precise enough to ensure equivalence.  However, the term “descriptive characteristics” does not appear in the statute or'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content=\"were precise enough to ensure equivalence.  However, the term “descriptive characteristics” does not appear in the statute or \\nregulations.  The 510(k) Decision-Making Flowchart described in Appendix A specifically addresses this to reflect the statute more \\nclosely and minimize confusion. \\n \\n29 For additional considerations, refer to the FDA guidance, “Use of International Standard ISO-10993, 'Biological Evaluation of \\nMedical Devices Part 1: Evaluation and Testing' (Replaces #G87-1 #8294) (blue book memo)” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080735.htm).  See also Draft Guidance \\nfor Industry and FDA Staff, “Use of International Standard ISO-10993, ‘Biological Evaluation of Medical Devices Part 1: Evaluation \\nand Testing’” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM348890.pdf). FDA’s draft \\nguidance represents the Agency’s proposed approach on this topic.\"),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content='(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM348890.pdf). FDA’s draft \\nguidance represents the Agency’s proposed approach on this topic.      \\n \\n \\n\\uf0b7 An overall description of the device design.  A complete description of the device may be \\nfacilitated by the submission of engineering drawings or other figures.  If the device consists \\nof multiple components, a diagram identifying how the different components of the device \\nsystem work together may be beneficial.  The device description should also include a \\ndiscussion of the physical specifications, dimensions and design tolerances that are critical to \\nthe new device.\\n28  Significant features of the new device should have a clear purpose within \\nthe context of the overall design and intended use.  In cases where this is not apparent, it is \\nimportant for the 510(k) submission to provide a discussion of how a particular device design'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content='the context of the overall design and intended use.  In cases where this is not apparent, it is \\nimportant for the 510(k) submission to provide a discussion of how a particular device design \\nor component contributes to the overall use and function of the new device.  \\n \\n\\uf0b7 Materials.  For many devices, a complete identification of the detailed chemical formulation \\nused in the materials of construction, especially for those materials that come into contact \\nwith the patient, should be provided.  Note that the FDA does not clear/approve materials.\\n29  \\nAny additives, including color additives, coatings, or other surface modifications should also \\nbe identified.  For some devices, the processing of the material (e.g., forged vs. cast) or the \\nstate of the material (e.g., amorphous vs. crystalline) may also significantly contribute to or \\naffect the overall safety or function of the device, and so should be included as part of the \\ndevice description, as applicable.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 21, 'page_label': '22'}, page_content='affect the overall safety or function of the device, and so should be included as part of the \\ndevice description, as applicable.   \\n \\n\\uf0b7 Energy sources.  This not only includes energy delivery to the device, including the use of \\nbatteries, but also energy delivery that is part of the functional aspect of the device (e.g., laser, \\nradiofrequency, ultrasound, etc.) and that affects the patient and/or the health care'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 22, 'page_label': '23'}, page_content='Contains Nonbinding Recommendations \\n \\n 20 \\nprofessional using the device.  Where applicable, a discussion of this characteristic should be \\nprovided.    \\n \\n\\uf0b7 Other key technological features.  These include, but are not limited to, software/hardware \\nfeatures, density, porosity, degradation characteristics, nature of reagents (recombinant, \\nplasma derived, etc.), principle of the assay method, etc., that are not explicitly included as \\npart of the materials, design or energy source characteristics.  These technological features \\nshould be included as part of the device description in the 510(k) submission, as appropriate \\nfor the specific device technology.\\n30   \\n                                                 \\n30 We encourage manufacturers to determine whether there is an applicable device-specific guidance or special controls for the device \\ntype as provided in a special controls document or classification regulation.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 22, 'page_label': '23'}, page_content='type as provided in a special controls document or classification regulation.   \\n \\nA 510(k) submission must also contain information about the technological characteristics of the \\npredicate device (21 CFR 807.87(f), 807.92(a)(3) and (a)(6)).  The manufacturer of the new device \\nshould provide information necessary and sufficient to fully and clearly identify and describe the \\ntechnological characteristics of the predicate device so that FDA can conduct a comparative \\nassessment of the technological characteristics, as further described in Step 2. \\n2. Step 2 – Identification of Differences in Technological Characteristics Between the \\nNew and Predicate Device \\nOnce the technological characteristics of the new and predicate device(s) have been clearly identified, \\nthe next step involves a comparison of these characteristics to identify any differences.  This may \\ninvolve a comparison of detailed specifications as well as a comparison of the system-level'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 22, 'page_label': '23'}, page_content='the next step involves a comparison of these characteristics to identify any differences.  This may \\ninvolve a comparison of detailed specifications as well as a comparison of the system-level \\ntechnological characteristics of the devices.  FDA relies upon information provided about the \\npredicate device, in addition to the information in our files as appropriate, and the new device to \\ndetermine whether the new device has different technological characteristics (Decision Point 3) in \\ncomparison to the predicate(s). \\n \\nAt this point, FDA will assess whether the similarities/differences in technological characteristics \\nbetween the new and predicate device(s) have been appropriately identified.  FDA highly \\nrecommends that the manufacturer summarize this information in tabular format to facilitate this step \\nof review.   \\n3. Step 3 – Determination of Whether the Differences in Technological Characteristics \\nRaise Different Questions of Safety and Effectiveness'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 22, 'page_label': '23'}, page_content='of review.   \\n3. Step 3 – Determination of Whether the Differences in Technological Characteristics \\nRaise Different Questions of Safety and Effectiveness \\nIf FDA determines that there are differences in the technological characteristics of the new device \\nand the predicate device, FDA will review and evaluate all relevant information bearing on any such \\ndifferences in technological characteristics to determine whether they raise different questions of \\nsafety and effectiveness for the new device as compared to the predicate device (Decision Point 4 on \\nthe Flowchart).  A “different question of safety or effectiveness” is a question raised by the \\ntechnological characteristics of the new device that was not applicable to the predicate device, and \\nposes a significant safety or effectiveness concern for the new device.   \\n \\nSome examples are provided below to illustrate cases where the response to this general question was'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 22, 'page_label': '23'}, page_content='poses a significant safety or effectiveness concern for the new device.   \\n \\nSome examples are provided below to illustrate cases where the response to this general question was \\n“yes,” i.e., the new device was determined to raise different safety and effectiveness questions in \\ncomparison to the predicate device, and the new device was found NSE.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 23, 'page_label': '24'}, page_content='Contains Nonbinding Recommendations \\n \\n 21 \\n \\nIllustrative Example 1   \\nPredicate:  A biological indicator utilizing natural bacterial spores with recognized resistance \\ncharacteristics as organisms for the biological indicator, where the presence of a color change or \\nfluorescent signal is indicative of bacterial viability. \\nNew Device: A biological indicator based on recombinant technology/genetic engineering, where \\nthe fluorescent signal is not indicative of bacterial viability; it is indicative of plasmid enzyme \\nexpression. \\nIntended Use:  Same   \\nDifferent questions of safety and effectiveness?  Yes \\nWhy:  Due to the engineering of a plasmid into the biological indicator, it is possible to have \\nviable bacteria that do not contain the plasmid in sufficient amounts to generate a signal.  In this \\ncase, the biological indicator could falsely indicate that the monitored load was sterilized properly'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 23, 'page_label': '24'}, page_content='case, the biological indicator could falsely indicate that the monitored load was sterilized properly \\ndue to the absence of fluorescent signal, while there are viable non-expressing bacteria in the \\nindicator (development of false negatives).  This technological difference raises different types of \\nsafety and effectiveness concerns for using a recombinant-DNA plasmid that codes for antibiotic \\nresistance and a signaling enzyme in the spores of a biological indicator.  Appropriate test \\nmethodologies and risk assessments need to be determined to address the properties of the \\nintroduced plasmid and host bacterial spore that could affect indicator performance.  Because \\nthese types of questions were not necessary to take into account for the predicate device, the new \\ndevice would be found NSE.   \\n \\nIllustrative Example 2   \\nPredicate:  A mechanical device used for embryo dissection \\nNew Device:  An electrical device used for embryo dissection \\nIntended Use:  Same'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 23, 'page_label': '24'}, page_content='Illustrative Example 2   \\nPredicate:  A mechanical device used for embryo dissection \\nNew Device:  An electrical device used for embryo dissection \\nIntended Use:  Same  \\nDifferent questions of safety and effectiveness?  Yes \\nWhy:  In this example, changing the process from a mechanical process to an electrical energy \\nsource (e.g., laser) changes the way the device operates and raises different safety concerns \\nregarding how the heating aspect of the electrical mechanism affects the embryo.  Because these \\ntypes of questions were not necessary to take into account for the predicate device, the new \\ndevice would be found NSE.   \\n \\nIllustrative Example 3 \\nPredicate:  A device inserted into the patient’s pharynx through the mouth to provide a patent \\nairway by mechanically moving the soft tissue. \\nNew Device:  A device placed externally on the mandible and neck to apply a vacuum to move \\nthe soft tissue forward and thus “open” the airway.  \\nIntended Use:  Same'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 23, 'page_label': '24'}, page_content='New Device:  A device placed externally on the mandible and neck to apply a vacuum to move \\nthe soft tissue forward and thus “open” the airway.  \\nIntended Use:  Same   \\nDifferent questions of safety and effectiveness?  Yes \\nWhy:  The predicate device is invasive and placed midline in the oropharynx and does not exert \\npressure on the vascular, respiratory, or nerve structures in the neck, whereas the new device \\nexerts continuous external negative pressure on these areas, raising different types of safety \\nquestions, such as the risks and potential adverse events associated with the stimulation of the \\nnerve structures in the neck.  Because these types of questions were not necessary to take into \\naccount for the predicate device, the new device would be found NSE.\\n      \\n  \\nIn the event the answer to Decision Point 4 is “No” and the differences between the new device and \\nthe predicate device do not raise different questions of safety and effectiveness, then the scientific'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 24, 'page_label': '25'}, page_content='Contains Nonbinding Recommendations \\n \\n 22 \\nreview of the performance data will proceed.  However, if the answer to Decision Point 4 is “Yes” \\nand the differences between the new device and predicate device raise different questions of safety \\nand effectiveness, then the new device will be found NSE.  Upon receipt of this type of NSE letter, \\nthe manufacturer may submit a PMA (or alternative submission type), or if appropriate, a De Novo \\nrequest.  \\nF. Requests for Performance Data \\nAlthough FDA may rely upon descriptive information alone to address the critical questions in the \\nFlowchart (Decision Points 1 through 4), performance data are typically needed in a Traditional \\n510(k) to demonstrate the substantial equivalence of a new device to a predicate device.  In addition, \\ninformation on device performance described in labeling or other sections of the 510(k) should be \\nsupported with appropriate performance data.  The type and quantity of performance data necessary'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 24, 'page_label': '25'}, page_content='information on device performance described in labeling or other sections of the 510(k) should be \\nsupported with appropriate performance data.  The type and quantity of performance data necessary \\nto support a determination of substantial equivalence depend upon the device and/or device type.\\n31  \\nPerformance data may be needed to address a variety of safety and effectiveness issues and may be \\ngenerated from different types of tests and studies.   \\n                                                 \\n31 Manufacturers should also determine whether there is an applicable device-specific guidance or special controls for the device type \\nas provided in a special controls document or classification regulation.   \\n \\n32 FDA follows the “least burdensome” provisions.  See Final Guidance for FDA and Industry, “The Least Burdensome Provisions of \\nthe FDA Modernization Act of 1997: Concept and Principles”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 24, 'page_label': '25'}, page_content='32 FDA follows the “least burdensome” provisions.  See Final Guidance for FDA and Industry, “The Least Burdensome Provisions of \\nthe FDA Modernization Act of 1997: Concept and Principles” \\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085994.htm). \\n \\n \\nFDA’s data requests typically follow a stepwise analytical process to ensure the information \\nrequested reflects the least burdensome approach to establishing substantial equivalence.\\n32  First, \\nFDA considers whether descriptive information about the technological characteristics, such as the \\nmaterials, design, and specifications, of the new device is sufficient.  Very few 510(k) submissions \\nrely solely on descriptive information about materials, design, specifications, and other technological \\ncharacteristics (see 21 CFR 807.87(f) and (g)).  When this information is not sufficient to support a \\nsubstantial equivalence determination, FDA then considers whether non-clinical bench performance'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 24, 'page_label': '25'}, page_content='substantial equivalence determination, FDA then considers whether non-clinical bench performance \\ntesting or analytical studies using clinical samples would be sufficient.  For in vitro diagnostic \\ndevices (IVDs), analytical studies include, but are not limited to, evaluations of accuracy, precision, \\nspecificity, and sensitivity.  Non-clinical bench performance testing includes a wide variety of test \\nmodalities that will be dependent upon the specifics of the actual device, including, but not limited to: \\n \\n\\uf0b7 mechanical, electrical, and biological engineering performance, such as fatigue, wear, tensile \\nstrength, compression, flowrate, burst pressure;  \\n\\uf0b7 electromagnetic compatibility (EMC); \\n\\uf0b7 sterility; \\n\\uf0b7 stability/shelf life; \\n\\uf0b7 software validation; \\n\\uf0b7 other forms of non-clinical, including device-specific. \\nNon-clinical animal and/or biocompatibility studies are typically requested when other forms of non-'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 24, 'page_label': '25'}, page_content='\\uf0b7 software validation; \\n\\uf0b7 other forms of non-clinical, including device-specific. \\nNon-clinical animal and/or biocompatibility studies are typically requested when other forms of non-\\nclinical bench performance testing are not sufficient to demonstrate substantial equivalence.  Non-\\nclinical laboratory studies that support the safety of medical devices must be conducted in \\ncompliance with 21 CFR Part 58, Good Laboratory Practice (GLP) for Nonclinical Laboratory'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='Contains Nonbinding Recommendations \\n \\n 23 \\nStudies, as applicable, to ensure the quality, reliability, and integrity of study data.33 For more \\ninformation on this topic, see FDA’s Draft Guidance for Industry and Food and Drug Administration \\nStaff, “The Applicability of Good Laboratory Practice in Premarket Device Submissions: Questions \\n& Answers” \\n(http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm366338.h\\ntm).  FDA’s draft guidance represents FDA’s proposed approach on this topic.   \\n                                                 \\n33 The applicability of GLPs to non-clinical studies in a 510(k) submission is also mentioned in FDA’s Guidance “Refuse to Accept \\nPolicy for 510(k)s” in the Performance Data – General section of the checklist \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm315014.pdf).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='Policy for 510(k)s” in the Performance Data – General section of the checklist \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm315014.pdf). \\n \\n34 21 CFR 860.7(c)(2): Valid scientific evidence is evidence from well-controlled investigations, partially controlled studies, studies \\nand objective trials without matched controls, well-documented case histories conducted by qualified experts, and reports of significant \\nhuman experience with a marketed device, from which it can fairly and responsibly be concluded by qualified experts that there is \\nreasonable assurance of the safety and effectiveness of a device under its conditions of use. The evidence required may vary according \\nto the characteristics of the device, its conditions of use, the existence and adequacy of warnings and other restrictions, and the extent'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='to the characteristics of the device, its conditions of use, the existence and adequacy of warnings and other restrictions, and the extent \\nof experience with its use. Isolated case reports, random experience, reports lacking sufficient details to permit scientific evaluation, \\nand unsubstantiated opinions are not regarded as valid scientific evidence to show safety or effectiveness. Such information may be \\nconsidered, however, in identifying a device the safety and effectiveness of which is questionable. \\n \\n35 In the U.S., clinical studies/investigations (see 21 CFR 812.3(h)) involving one or more human subjects to determine the safety or \\neffectiveness of a device must be conducted in accordance with the Investigational Device Exemptions (IDE) regulations, 21 CFR Part \\n812, as applicable.  In addition, such studies/investigations must comply with the regulations governing institutional review boards (21'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='812, as applicable.  In addition, such studies/investigations must comply with the regulations governing institutional review boards (21 \\nCFR Part 56), informed consent (21 CFR Part 50), and financial disclosure (21 CFR Part 54).  See also Guidance for Clinical \\nInvestigators, Industry, and FDA Staff, “Financial Disclosure by Clinical Investigators” \\n(http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM341008.pdf). Studies conducted outside the U.S. generally do \\nnot have to comply with the IDE regulations, but FDA recommends that such studies be conducted in accordance with good clinical \\npractice.  For information on good clinical practice, see 78 FR 12664 (Feb. 25, 2013). \\n \\n36 The acceptability or level of data necessary to support an SE determination is product specific and therefore, not discussed in this \\nguidance.  Manufacturers should determine whether there is an applicable device-specific guidance or special controls for the device'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='guidance.  Manufacturers should determine whether there is an applicable device-specific guidance or special controls for the device \\ntype as provided in a special controls document or classification regulation as these sources may provide further information about \\nperformance data that may be necessary in a 510(k) submission.       \\n \\nWhen analytical or non-clinical bench performance testing data, or non-clinical animal and/or \\nbiocompatibility studies are insufficient, or available scientific methods are not acceptable, e.g., the \\nscientific methods are deemed unacceptable because they are not clinically validated or are not \\nsupported by a valid scientific rationale, FDA may request clinical performance data to support a \\nsubstantial equivalence determination.  For 510(k)s reviewed in the Office of Device Evaluation, \\nFDA currently requests clinical data for less than 10 percent of the 510(k) submissions.  In some'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='substantial equivalence determination.  For 510(k)s reviewed in the Office of Device Evaluation, \\nFDA currently requests clinical data for less than 10 percent of the 510(k) submissions.  In some \\ninstances, clinical data may be a less burdensome means of demonstrating substantial equivalence \\nthan other means of performance testing, and 510(k)s reviewed in CBER for products intended to \\nensure the safety and effectiveness of blood and blood products typically include clinical data.  \\nClinical data provided in support of any marketing application, including a 510(k) when those data \\nare relevant to a substantial equivalence determination, should constitute valid scientific evidence as \\ndefined in 21 CFR 860.7(c)(2)\\n34 and must comply with the Investigational Device Exemptions (IDE) \\nregulations as applicable.35   \\n \\nAlthough not an exhaustive list of instances in which FDA may request clinical data to demonstrate \\nsubstantial equivalence,'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 25, 'page_label': '26'}, page_content='regulations as applicable.35   \\n \\nAlthough not an exhaustive list of instances in which FDA may request clinical data to demonstrate \\nsubstantial equivalence,\\n36 the following scenarios illustrate the most common situations in which \\nclinical data may be requested.  As explained in the Scope Section (see Section III), the information \\nin this guidance and the examples below do not take the place of any device-specific guidance.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 26, 'page_label': '27'}, page_content='Contains Nonbinding Recommendations \\n \\n 24 \\nNote:  The examples provided below distinguish between examples that are only applicable to \\ndiagnostic devices, including IVDs, and therapeutic devices.  This is because there are significant \\ndifferences in the clinical data requirements for these two categories of devices.  \\n1. New or Modified Indications for Use – Same Intended Use \\nIn rare instances, FDA may rely upon clinical data to determine that new or modified indications for \\nuse fall within the same intended use as a predicate device.   \\nIllustrative Examples:  \\n\\uf0b7 The new device is an IVD that is indicated for over-the-counter use, whereas the predicate \\ndevice is indicated for prescription use in the home or prescription use in a clinical setting.  \\nThe newly indicated test population might fall within the intended use of the predicate device.  \\nClinical data (demonstrating that the user can collect the sample, generate an accurate result,'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 26, 'page_label': '27'}, page_content='The newly indicated test population might fall within the intended use of the predicate device.  \\nClinical data (demonstrating that the user can collect the sample, generate an accurate result, \\nand adequately interpret the result) might establish that the indication for use for the new \\ndevice falls within the intended use of the predicate device. \\n\\uf0b7 The new IVD is indicated for use with patients who have symptoms and signs of illness from \\nany member of a specified set of closely related diseases.  The indications for use for the \\npredicate IVD do not include one of the diseases addressed by the new IVD.  Clinical data \\n(concerning all diseases in the newly specified set) might establish that the indications for use \\nfor the new device fall within the intended use of the predicate device. \\n\\uf0b7 The manufacturer modifies the indications for use, explicitly or implicitly, by proposing a \\ndifferent surgical implantation method which also affects the indications for use, e.g., a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 26, 'page_label': '27'}, page_content='\\uf0b7 The manufacturer modifies the indications for use, explicitly or implicitly, by proposing a \\ndifferent surgical implantation method which also affects the indications for use, e.g., a \\nminimally invasive procedure in place of an open procedure, and the safety and effectiveness \\nof the new device cannot be adequately replicated or otherwise characterized in a non-clinical \\nperformance (including animal) test environment to adequately support substantial \\nequivalence to the predicate.  Although on its face a minimally invasive procedure would \\nappear to involve less serious risks than an open procedure, the minimally invasive procedure \\nmay be less effective or may present different but still serious risks. \\n2. Technological Differences \\nFDA may request clinical data for a 510(k) when the technological differences between the new \\ndevice and predicate device are significant but do not support an immediate NSE determination due'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 26, 'page_label': '27'}, page_content='FDA may request clinical data for a 510(k) when the technological differences between the new \\ndevice and predicate device are significant but do not support an immediate NSE determination due \\nto different questions of safety and effectiveness.  In these limited situations, clinical data may be \\nneeded to evaluate the safety and effectiveness of the new device as compared to the predicate \\ndevice. \\n \\nIllustrative Examples: \\n \\n\\uf0b7 A new IVD uses the same analyte-specific chemistry as the predicate, but with a different \\nread-out technology (e.g., chemiluminescence instead of colorimetry).  Clinical data may be \\nnecessary to demonstrate that the new device performs equivalent to the predicate. \\n \\n\\uf0b7 Performance characteristics of the new device in comparison to the predicate are significantly \\ndifferent in non-clinical performance testing, e.g., the predicate is rigid whereas the new'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 27, 'page_label': '28'}, page_content='Contains Nonbinding Recommendations \\n \\n 25 \\ndevice is designed to be more flexible.  Clinical data may be necessary to demonstrate that the \\nnew device performs equivalent to the predicate.   \\n \\n\\uf0b7 Some devices that display data about the patient’s anatomy or physiology, e.g., glucose \\nmeters, pulse oximeters, blood pressure cuffs, are supported by software.  If there is a change \\nin the software that relates to how the software analyzes the patient’s anatomy or physiology, \\nthe device may need to be tested on actual patients to assure that the software performs in a \\nmanner that is equivalent to the previous version.  In this case, non-clinical data may not \\nsuffice.   \\n \\n\\uf0b7 The technological characteristics of the new device raise a question concerning whether its \\nclinical performance can be expected to be equivalent to the clinical performance of the \\npredicate.  Clinical data may be necessary to demonstrate that the new device performs'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 27, 'page_label': '28'}, page_content='clinical performance can be expected to be equivalent to the clinical performance of the \\npredicate.  Clinical data may be necessary to demonstrate that the new device performs \\nequivalent to the predicate.  For IVDs, an example is a new prothrombin time (clotting) test \\nusing thromboplastin that is a recombinant product instead of a naturally occurring material.     \\n3. Non-clinical Testing Methods are Limited or Inappropriate Because of the \\nIndications for Use or Device Technology  \\nFDA requests clinical data for a 510(k) submission to address issues that cannot be adequately \\naddressed using non-clinical test methods because of the indications for use or device technology.  \\nFor instance, for certain indications or technologies, FDA may request clinical data when non-clinical \\ntesting methods are not validated, are limited or are inappropriate, because of either their scope or \\ntheir applicability, to demonstrate substantial equivalence.   \\n \\nIllustrative Examples:'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 27, 'page_label': '28'}, page_content='testing methods are not validated, are limited or are inappropriate, because of either their scope or \\ntheir applicability, to demonstrate substantial equivalence.   \\n \\nIllustrative Examples:  \\n \\n\\uf0b7 For some devices, the way they are used and the environment in which they are used affect \\nthe way they perform.  For example, the non-clinical performance testing on the new device \\nmay be insufficient to support a substantial equivalence determination if the testing cannot \\nreplicate the way the device will be used or the way similar devices have been demonstrated \\nto fail in a clinical setting. Although the non-clinical testing for these devices might be \\ninformative for many other aspects of the device, it may be necessary to supplement the non-\\nclinical data with clinical simulation performance data or clinical performance data.   \\n \\n\\uf0b7 If the non-clinical testing of a device raises safety concerns that cannot be mitigated or'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 27, 'page_label': '28'}, page_content='clinical data with clinical simulation performance data or clinical performance data.   \\n \\n\\uf0b7 If the non-clinical testing of a device raises safety concerns that cannot be mitigated or \\nanswered through non-clinical testing, such a device may require clinical testing to assure that \\nthe safety questions are not greater than those raised by the predicate device.  \\n \\nNew scientific information may affect FDA’s expectations concerning the type and level of \\nperformance data included in a 510(k) submission.  For device types with long histories of safe use \\nand well understood mechanisms of action, more limited performance testing data may be sufficient.  \\nOn the other hand, a pattern of adverse events or published literature documenting poor clinical \\noutcomes with a particular technology may lead FDA to reconsider its regulatory approach to \\npremarket submissions for such technology.\\n 37  Should FDA change its scientific decision making'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 27, 'page_label': '28'}, page_content='premarket submissions for such technology.\\n 37  Should FDA change its scientific decision making \\n                                                 \\n37 See SOP: Decision Authority for Additional or Changed Data Needs for Premarket Submissions  \\n(http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm279288.htm).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 28, 'page_label': '29'}, page_content='Contains Nonbinding Recommendations \\n \\n 26 \\nwith regard to a particular device, FDA will consider its options (e.g., guidance, advisory panel \\nmeeting, etc.), for explaining such change and the basis for the decision to ensure transparency in the \\nchange in policy.  FDA also intends to consider any pending 510(k) submissions that may be affected \\nby the change or allow for an appropriate transition period, in certain situations that may affect the \\nindustry at large. \\nG. The 510(k) Summary \\nThe 510(k) Summary38 is a document that provides a high-level discussion of the content of a 510(k) \\nand must include all the elements identified in 21 CFR 807.92.  A 510(k) Summary must be in \\nsufficient detail to provide an understanding of the basis for a determination of substantial \\nequivalence (21 CFR 807.92(a)). \\n                                                 \\n38 As specified in 21 CFR 807.87(h), a 510(k) Statement as described in 21 CFR 807.93 may be provided in lieu of a 510(k) Summary.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 28, 'page_label': '29'}, page_content='38 As specified in 21 CFR 807.87(h), a 510(k) Statement as described in 21 CFR 807.93 may be provided in lieu of a 510(k) Summary.  \\nHowever, in order to facilitate transparency, FDA encourages all submitters to utilize the 510(k) Summary option. \\n \\nIn an effort to improve the transparency and predictability of the 510(k) program and to ensure that \\nthe 510(k) Summary reflects the information provided in a 510(k) submission to support a substantial \\nequivalence determination, FDA intends to verify the accuracy and completeness of the information \\nincluded in a 510(k) Summary.   \\nAlthough the 510(k) Summary is a document created by the manufacturer and is included in the \\n510(k), revisions to the 510(k) Summary may be necessary to accurately reflect the FDA’s decision-\\nmaking process.  For example, manufacturers may have identified several devices as potential'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 28, 'page_label': '29'}, page_content='510(k), revisions to the 510(k) Summary may be necessary to accurately reflect the FDA’s decision-\\nmaking process.  For example, manufacturers may have identified several devices as potential \\npredicate devices, whereas, in the course of FDA’s substantial equivalence evaluation, FDA may \\nhave determined that only one of these devices is an appropriate predicate device.  In addition, it is \\npossible during the course of FDA’s review of the 510(k), that additional information or testing may \\nbe requested and submitted.  Consequently, the manufacturer may be requested to update the 510(k) \\nSummary to accurately include and convey the information identified in 21 CFR 807.92 and which \\nwas used to support the final decision-making process.   \\nIn Appendix B, FDA describes the requirements of the content to be included in a 510(k) Summary, \\nin accordance with 21 CFR 807.92, and provides guidance on the information to be included in a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 28, 'page_label': '29'}, page_content='In Appendix B, FDA describes the requirements of the content to be included in a 510(k) Summary, \\nin accordance with 21 CFR 807.92, and provides guidance on the information to be included in a \\n510(k) Summary to ensure compliance with 21 CFR 807.92 and consistency in the level of \\ninformation conveyed and captured in the 510(k) Summaries which are available to the public on \\nFDA’s website.  In Appendix C, FDA has provided a hypothetical 510(k) Summary in order to \\ndemonstrate the recommended level of detail for each section.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 29, 'page_label': '30'}, page_content='Contains Nonbinding Recommendations \\n \\nIdentify the new device and the \\npredicate device.\\nDecision 1\\nIs the \\npredicate device legally \\nmarketed?\\nNSENO\\nReview all labeling and assure \\nthat it is consistent with IFU \\nstatements.\\nYES\\nDecision 2\\nDo the devices\\nhave the same\\nintended use?\\nNSENO\\nReview design, materials, energy \\nsource and other features of the \\ndevices.\\nYES\\nDecision 3\\nDo the devices\\nhave the same\\ntechnological \\ncharacteristics?\\nSE\\nYES\\nDetermine what questions of \\nsafety and effectiveness the \\ndifferent technological \\ncharacteristics raise.\\nNO\\nDecision 4\\nDo the different \\ntechnological characteristics \\nof the devices raise different \\nquestions \\nof safety and \\neffectiveness?\\nNSE YES\\nNO\\nReview the proposed scientific \\nmethods for evaluating new/\\ndifferent characteristics’ effects \\non safety and effectiveness.\\nDecision 5a\\nAre the methods \\nacceptable?\\nNSE NO\\nYES\\nEvaluate performance data.\\nDecision 5b\\nDo the data \\ndemonstrate substantial \\nequivalence?\\nNSE\\nSE\\nYES'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 29, 'page_label': '30'}, page_content='on safety and effectiveness.\\nDecision 5a\\nAre the methods \\nacceptable?\\nNSE NO\\nYES\\nEvaluate performance data.\\nDecision 5b\\nDo the data \\ndemonstrate substantial \\nequivalence?\\nNSE\\nSE\\nYES\\nSE = “Substantially Equivalent”\\nNSE = “Not Substantially Equivalent”\\nIFU = “Indications For Use”\\nThis Flowchart is not intended to be used as a ‘stand-alone’ document and should only be considered in conjunction with the accompanying text in \\nthis guidance.\\n Refer to Section IV.D. \\n(Intended Use) and\\n21 CFR 807.100(b)(1).  \\nRefer to Section IV.C. \\n(Predicate Devices) and \\n21 CFR 807.100(b)(3).\\nRefer to Section IV.E. \\n(Technological \\nCharacteristics) and 21 \\nCFR 807.100(b)(2)(i) and \\n(ii)(A). \\nNO\\nRefer to Section IV. \\nF (Requests for \\nPerformance Data) \\nand\\n21 CFR \\n807.100(b)(2)(ii)(B).\\nRefer to Section IV. \\nF (Requests for \\nPerformance Data) \\nand 21 CFR\\n807.100(b)(2)(ii)(B). \\nRefer to Sections \\nIV.E. (Technological \\nCharacteristics) and \\nIV.F. (Requests for \\nPerformance Data) \\nand\\n21 CFR'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 29, 'page_label': '30'}, page_content='F (Requests for \\nPerformance Data) \\nand 21 CFR\\n807.100(b)(2)(ii)(B). \\nRefer to Sections \\nIV.E. (Technological \\nCharacteristics) and \\nIV.F. (Requests for \\nPerformance Data) \\nand\\n21 CFR \\n807.100(b)(2)(ii)(C). \\n 27 \\nAppendix A.  510(k) Decision-Making Flowchart'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 30, 'page_label': '31'}, page_content=\"Contains Nonbinding Recommendations \\n \\n 28 \\nAppendix B.  The 510(k) Summary Document Requirements \\nIn Appendix B, FDA provides further clarification and guidance to facilitate compliance with the \\nrequirements set forth in 21 CFR 807.92 and consistency in the information conveyed in the 510(k) \\nSummaries which are available to the public on FDA’s website.  As noted earlier in this guidance \\ndocument, if during the course of review, additional testing or information are requested, the \\nmanufacturer should submit a revised 510(k) Summary to reflect the additional information.  The \\nfollowing identifies the information that must be included in the 510(k) Summary under 21 CFR \\n807.92, information that we recommend be included in the 510(k) Summary, and other \\nconsiderations.   \\n   \\n\\uf0b7 807.92(a)(1): “The submitter's name, address, telephone number, a contact person, and the \\ndate the summary was prepared.”\"),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 30, 'page_label': '31'}, page_content=\"considerations.   \\n   \\n\\uf0b7 807.92(a)(1): “The submitter's name, address, telephone number, a contact person, and the \\ndate the summary was prepared.”   \\no The “submitter” or manufacturer should be the holder of the 510(k), not a consultant \\nor law firm. \\n \\n\\uf0b7 807.92(a)(2): “The name of the device, including the trade or proprietary name if applicable, \\nthe common or usual name, and the classification name, if known.”   \\no FDA recommends that the manufacturer list all applicable names and model numbers, \\nif known. \\no If the submission is bundled\\n39, the 510(k) Summary should list all applicable \\nclassification regulations and product codes.   \\n                                                 \\n39 See Guidance for Industry and FDA Staff, “Bundling Multiple Devices or Multiple Indications in a Single Submission”  \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089732.pdf).\"),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 30, 'page_label': '31'}, page_content='(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089732.pdf).  \\n \\n\\uf0b7 807.92(a)(3): “An identification of the legally marketed device to which the submitter claims \\nequivalence.  A legally marketed device to which a new device may be compared for a \\ndetermination regarding substantial equivalence is a device that was legally marketed prior to \\nMay 28, 1976, or a device which has been reclassified from class III to class II or I (the \\npredicate), or a device which has been found to be substantially equivalent through the 510(k) \\npremarket notification process.”\\n \\no FDA recommends that the manufacturer provide the 510(k) number of the device used \\nas the predicate device in support of the current 510(k) submission.   \\no If using an exempt device as a predicate, the manufacturer should list the classification \\nregulation and the product code.   \\no If using a device that has been reclassified from Class III to II as a predicate, where a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 30, 'page_label': '31'}, page_content='regulation and the product code.   \\no If using a device that has been reclassified from Class III to II as a predicate, where a \\n510(k) has not been submitted, please list the PMA number. \\no If the manufacturer lists an inappropriate predicate device, FDA will request that such \\ninformation be removed and the 510(k) Summary updated accordingly by the \\nmanufacturer.   \\n \\n\\uf0b7 807.92(a)(4): “A description of the device that is the subject of the premarket notification \\nsubmission, such as might be found in the labeling or promotional material for the device, \\nincluding an explanation of how the device functions, the scientific concepts that form the \\nbasis for the device, and the significant physical and performance characteristics of the \\ndevice, such as device design, material used, and physical properties.”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 31, 'page_label': '32'}, page_content='Contains Nonbinding Recommendations \\n \\n 29 \\nThe description of the device attributes should include the following details: \\no Device Identification: \\n\\uf0a7 List all key device components included in the submission (e.g., catheter, cable \\nwire, leads) \\n\\uf0a7 List all model numbers (if known) and briefly explain the differences among \\nmodels \\n \\no Device Characteristics (address all that apply): \\n\\uf0a7 software \\n\\uf0a7 biologics \\n\\uf0a7 drugs \\n\\uf0a7 any patient-contacting materials  \\n\\uf0a7 coatings \\n\\uf0a7 additives \\n\\uf0a7 single-use \\n\\uf0a7 sterile \\n\\uf0a7 sterilization method [specify] \\n \\no Environment of Use (address all that apply): \\n\\uf0a7 healthcare facility/hospital \\n\\uf0a7 home \\n\\uf0a7 other [specify] \\n \\no Brief Written Description of the Device: \\n\\uf0a7 Explanation of how the device works/principle of operation \\n\\uf0a7 Mechanism of action \\n\\uf0a7 Any necessary feature to determine SE or device performance \\n\\uf0a7 Energy source (if applicable) \\n \\no Materials of Use  \\n\\uf0a7 General type of material used (e.g., polysulfone, stainless steel)'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 31, 'page_label': '32'}, page_content='\\uf0a7 Any necessary feature to determine SE or device performance \\n\\uf0a7 Energy source (if applicable) \\n \\no Materials of Use  \\n\\uf0a7 General type of material used (e.g., polysulfone, stainless steel) \\n\\uf0a7 If material conforms to an FDA recognized consensus standard for medical \\nuse, include the applicable number (e.g., ASTM FXXXX-last 2 numbers of the \\nyear) \\n\\uf0a7 Duration and type of contact \\n \\no Key Performance Specifications/Characteristics of the Device \\n \\n\\uf0b7 807.92(a)(5): “A statement of the intended use of the device that is the subject of the \\npremarket notification submission, including a general description of the diseases or \\nconditions that the device will diagnose, treat, prevent, cure, or mitigate, including a \\ndescription, where appropriate, of the patient population for which the device is intended. If \\nthe indication statements are different from those of the legally marketed device identified in'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 31, 'page_label': '32'}, page_content='description, where appropriate, of the patient population for which the device is intended. If \\nthe indication statements are different from those of the legally marketed device identified in \\nparagraph (a)(3) of this section, the 510(k) summary shall contain an explanation as to why \\nthe differences are not critical to the intended therapeutic, diagnostic, prosthetic, or surgical \\nuse of the device, and why the differences do not affect the safety and effectiveness of the \\ndevice when used as labeled.”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 32, 'page_label': '33'}, page_content='Contains Nonbinding Recommendations \\n \\n 30 \\no The 510(k) Summary should include the Indications for Use, which should be \\nidentical to that proposed on the Indications for Use Sheet and the labeling. \\no If the Indications for Use are different from those of the predicate device, a brief \\nexplanation is required to address why the differences in the Indications do not affect \\nthe safety and effectiveness of the device and do not alter the intended therapeutic, \\ndiagnostic, prosthetic, or surgical use of the device.   \\n \\n\\uf0b7 807.92(a)(6): “If the device has the same technological characteristics (i.e., design, material, \\nchemical composition, energy source) as the predicate device identified in paragraph (a)(3) of \\nthis section, a summary of the technological characteristics of the new device in comparison \\nto those of the predicate device.  If the device has different technological characteristics from'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 32, 'page_label': '33'}, page_content='this section, a summary of the technological characteristics of the new device in comparison \\nto those of the predicate device.  If the device has different technological characteristics from \\nthe predicate device, a summary of how the technological characteristics of the device \\ncompare to a legally marketed device identified in paragraph (a)(3) of this section.”  \\n \\n\\uf0b7 807.92(b): “510(k) summaries for those premarket submissions in which a determination of \\nsubstantial equivalence is also based on an assessment of performance data shall contain the \\nfollowing information:”  \\n“(1) A brief discussion of the nonclinical tests submitted, referenced, or relied on in the \\npremarket notification submission for a determination of substantial equivalence,” \\no A high level summary of the tests that were used to demonstrate substantial \\nequivalence should be included (e.g., fatigue testing, biocompatibility, etc.).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 32, 'page_label': '33'}, page_content='o A high level summary of the tests that were used to demonstrate substantial \\nequivalence should be included (e.g., fatigue testing, biocompatibility, etc.). \\no If a guidance document was referenced/used for the testing, the guidance document \\nshould be referenced in this section. \\no If an FDA recognized consensus standard (e.g., test method or guide) was used/relied \\nupon for testing, please list the standard connotation (e.g., ASTM FXXXX-last 2 \\nnumbers of the year). \\n \\n“(2) A brief discussion of the clinical tests submitted, referenced, or relied on in the premarket \\nnotification submission for a determination of substantial equivalence. This discussion shall \\ninclude, where applicable, a description of the subjects upon whom the device was tested, a \\ndiscussion of the safety or effectiveness data obtained from the testing, with specific reference \\nto adverse effects and complications, and any other information from the clinical testing'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 32, 'page_label': '33'}, page_content='discussion of the safety or effectiveness data obtained from the testing, with specific reference \\nto adverse effects and complications, and any other information from the clinical testing \\nrelevant to a determination of substantial equivalence,”  \\no FDA is interested in collecting an appropriate degree of detail within this section to be \\ninformative regarding the level of evidence that was necessary to support an SE \\ndetermination. \\no As applicable, FDA recommends the following details be included regarding the \\nclinical evidence provided to support an SE determination: \\n \\n\\uf0b7 Level of Evidence (identify one) \\n\\uf0a7 Randomized, multi-arm, “blinded” study with concurrent sham (placebo) \\ncontrol \\n\\uf0a7 Randomized, multi-arm, “blinded” study with concurrent (“active”) control \\n\\uf0a7 Randomized, multi-arm, un“blinded” study with a control (control that is either \\nactive or consists of no treatment) \\n\\uf0a7 Non-randomized study with concurrent (“active”) control'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 32, 'page_label': '33'}, page_content='\\uf0a7 Randomized, multi-arm, un“blinded” study with a control (control that is either \\nactive or consists of no treatment) \\n\\uf0a7 Non-randomized study with concurrent (“active”) control \\n\\uf0a7 Single-arm study with patient serving as own control (include designed single-\\narm crossover) \\n\\uf0a7 Single-arm study with Historical Control (using patient-level data)'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 33, 'page_label': '34'}, page_content='Contains Nonbinding Recommendations \\n \\n 31 \\n\\uf0a7 Single-arm study with Literature Control (historical control) \\n\\uf0a7 Single-arm study with Objective Performance Criteria \\n\\uf0a7 Single-arm study with Performance Goals  \\n\\uf0a7 Registry  \\n\\uf0a7 Observational study \\n\\uf0a7 Systematic review (meta-analysis with patient-level data) \\n\\uf0a7 Meta-analysis based on summary information only  \\n\\uf0a7 Literature Summary \\n\\uf0a7 Uncertain \\n \\n\\uf0b7 Location of Study (specify one of the following) \\no United States only \\no outside of United States only \\no both in United States and outside of United States \\no Identify applicable IDE number [Gxxxxxx]   \\n \\n\\uf0b7 Primary Safety Endpoint Identified?  \\n\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Primary Effectiveness Endpoint Identified?   \\n\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Primary Composite Safety/Effectiveness Endpoint Identified, if applicable?   \\n\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Patient Accountability (Enter number of patients reported at each stage): \\n \\nStage Investigational \\nDevice Arm Total \\nControl Arm \\nTotal \\nTotal \\nEnrollment'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 33, 'page_label': '34'}, page_content='\\uf0a7 If Yes, describe \\n \\n\\uf0b7 Patient Accountability (Enter number of patients reported at each stage): \\n \\nStage Investigational \\nDevice Arm Total \\nControl Arm \\nTotal \\nTotal \\nEnrollment    \\nTreatment    \\nPrimary Safety Endpoint \\nAnalysis \\n   \\nPrimary Effectiveness \\nEndpoint Analysis \\n   \\nPrimary Composite \\nSafety/Effectiveness (if app) \\n   \\nThe content of the table may need to be modified depending upon the specifics of the clinical data provided and the \\nendpoints studied.   \\n \\n\\uf0b7 Identify whether the study met the primary endpoint  \\n\\uf0a7 Whether Yes or No, describe \\n \\n\\uf0b7 Describe the study results in appropriate parameters \\n \\n\\uf0b7 Identify the adverse events and complications observed in the study, including \\nthose associated with the device.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 34, 'page_label': '35'}, page_content='Contains Nonbinding Recommendations \\n \\n 32 \\n“(3) The conclusions drawn from the nonclinical and clinical tests that demonstrate that the \\ndevice is as safe, as effective, and performs as well as or better than the legally marketed \\ndevice identified in paragraph (a)(3) of this section.” \\no A brief summary of why the device is substantially equivalent to the predicate. \\n \\n\\uf0b7 807.92(c): “The summary should be in a separate section of the submission, beginning on a \\nnew page and ending on a page not shared with any other section of the premarket notification \\nsubmission, and should be clearly identified as a ‘510(k) summary’.” \\n \\n\\uf0b7 807.92(d): “Any other information reasonably deemed necessary by the agency.”  \\no If the FDA determines that other information needs to be included within the 510(k) \\nSummary, such information must be included within this document.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 35, 'page_label': '36'}, page_content='Contains Nonbinding Recommendations \\n \\n 33 \\nAppendix C. Sample of 510(k) Summary Complying with 21 CFR \\n807.92 \\n \\n510(k) Summary \\n \\nI. SUBMITTER \\n \\nDevice Submitter, Inc. \\n123 Main Street \\nAnywhere, MD 01234 \\n \\nPhone: 555-555-1234 \\nFax: 555-555-0123 \\n \\nContact Person: John Contact \\nDate Prepared: May 16, 2013 \\n \\nII. DEVICE \\n \\nName of Device: Brand X Endoscopic Stapling System, Model x123, Model y456 \\nCommon or Usual Name: Endoscopic Stapling System \\nClassification Name: Endoscope and Accessories (21 CFR 876.1500) \\nRegulatory Class: II \\nProduct Code: ODE \\n \\nIII. PREDICATE DEVICE \\n \\nBrand Z Endoscopic Plication System, KXXXXXX \\nThis predicate has not been subject to a design-related recall.\\n40 \\n                                                 \\n40 On July 9, 2012, section 605 of FDASIA (Pub. L. 112-144) added section 518A to the FD&C Act, which directs FDA to establish a'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 35, 'page_label': '36'}, page_content='40 \\n                                                 \\n40 On July 9, 2012, section 605 of FDASIA (Pub. L. 112-144) added section 518A to the FD&C Act, which directs FDA to establish a \\nprogram to routinely and systematically assess information regarding device recalls, and to use that information to proactively identify \\nstrategies for mitigating health risks presented by defective or unsafe devices.  FDA believes that one way to carry out this directive is \\nto provide greater transparency on recalled devices.  Identifying whether a predicate was recalled is optional, but doing so would help \\nthe Agency achieve this FDASIA directive. \\n \\nNo reference devices were used in this submission. \\n \\nIV. DEVICE DESCRIPTION \\n \\nThe Brand X Endoscopic Stapling System consists of a flexible endoscope, an endoscopy suite, and a \\nnumber of associated accessories. The endoscope and staples are provided sterile (EtO).'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 35, 'page_label': '36'}, page_content='The Brand X Endoscopic Stapling System consists of a flexible endoscope, an endoscopy suite, and a \\nnumber of associated accessories. The endoscope and staples are provided sterile (EtO). \\n \\nBrand X uses an implant (surgical staple) that is delivered by a flexible endoscope by a surgeon or \\ngastroenterologist for approximating adjoining portions of the esophageal and gastric tissues at the \\ngastroesophageal junction, thereby creating a permanent surgical fundoplication. The system includes \\nan ultrasonic transducer that operates as a range finder for measuring the relative alignment and the \\ndistance between the transducer at the tip of the endoscope (the anvil) and the ultrasonic mirror in the'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 36, 'page_label': '37'}, page_content='Contains Nonbinding Recommendations \\n \\n 34 \\ncartridge (that includes the staples). The device deploys sets of implantable staples for performing the \\nfundoplication procedure. \\n \\nThe system combines a video camera, an ultrasonic range finder and a surgical stapler in a single \\nunit. The flexible endoscope includes light guides, irrigation, air insufflation and suction channels \\nthat terminate at the endoscope tip.  The stapler portion includes a cartridge that contains sterile 4.8 \\nmm standard \"B\" shaped titanium surgical staples. Model x123 includes five (5) staples per cartridge, \\nwhile Model y456 contains only four (4). The tip of the endoscope contains an anvil for the staples, \\nas well as two small stainless steel screws that are extracted from the tip of the endoscope and engage \\ninto nuts positioned in the cartridge. The ultrasonic range finder measures the distance between an'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 36, 'page_label': '37'}, page_content='into nuts positioned in the cartridge. The ultrasonic range finder measures the distance between an \\nultrasonic mirror in the cartridge and the tip of the endoscope. It also verifies alignment between the \\ncartridge and the anvil, before insertion of the screws. \\n \\nThe endoscopy suite includes the ISL (Insufflation, Suction and Light) console, the CCU (Camera \\nControl Unit) console and a monitor. The ISL console provides suction, insufflation and a white light \\n(Xenon) source for illumination. The CCU console contains a controller for the camera, ultrasonic \\nrange finder and sensors that indicate status of the bending angle, screws and fire. The monitor \\ndisplays patient information, the video image, and the processed data from the controllers such as \\nultrasonic data, fire status, degree of bending and screw position.  A keyboard for entering data \\nduring the procedure is also included.  The System includes three software applications: the video'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 36, 'page_label': '37'}, page_content='ultrasonic data, fire status, degree of bending and screw position.  A keyboard for entering data \\nduring the procedure is also included.  The System includes three software applications: the video \\ncontroller software, the ultrasound controller software, and the ISL controller software.  The software \\nsystems work in conjunction with the hardware consoles listed above in order to visualize the \\nprocedure and deliver the staples.  The endoscope is designed for single-patient use, and it is \\nconnected to the CCU and ISL consoles via a multi-connector.  The endoscope handle contains the \\ncontrols used by the operator to manipulate the endoscope. \\n \\nThe associated accessories include: \\n\\uf0b7 Irrigation bottle with liquids for irrigation of the camera lens \\n\\uf0b7 Suction canister for extracting liquids during the procedure \\n\\uf0b7 Silicon tubes for connecting the ISL and other accessories to the endoscope \\n\\uf0b7 Disposable air filter of the suction ISL input channel'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 36, 'page_label': '37'}, page_content=\"\\uf0b7 Silicon tubes for connecting the ISL and other accessories to the endoscope \\n\\uf0b7 Disposable air filter of the suction ISL input channel \\n\\uf0b7 Overtube for protecting patient's pharynx \\n \\nV. INDICATIONS FOR USE \\n \\nThe Brand X Stapling System is indicated for the endoscopic placement of surgical staples in the soft \\ntissue of the esophagus and stomach in order to create anterior partial fundoplication for treatment of \\nsymptomatic chronic Gastro Esophageal Reflux Disease (GERD) in patients who require and respond \\nto pharmacological therapy. \\n \\nThe Indications for Use statement for the Brand X device is not identical to the predicate device; \\nhowever, the differences do not alter the intended therapeutic use of the device nor do they affect the \\nsafety and effectiveness of the device relative to the predicate.  Both the subject and predicate devices \\nhave the same intended use for the treatment of GERD, by approximating tissue in the esophagus and \\nstomach.\"),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 37, 'page_label': '38'}, page_content='Contains Nonbinding Recommendations \\n \\n 35 \\nVI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE \\nDEVICE \\n \\nTransoral endoscopic fundoplication is the technological principle for both the subject and predicate \\ndevices. It is based on the use of endoscopic instrumentation for approximating and permanently \\nadjoining gastric and esophageal tissues, creating plications at the level of the gastroesophageal valve \\nand thereby restoring valvular functionality and reducing gastric reflux into the esophagus.  \\nAt a high level, the subject and predicate devices are based on the following same technological \\nelements: \\n\\uf0b7 Endoscope – used to reach the target tissue \\n\\uf0b7 Device inserted through an overtube – to protect the esophagus \\n\\uf0b7 Creation of a gastric (or gastroesophageal) plication in close proximity to the \\ngastroesophageal junction by the retroflexed device  \\n\\uf0b7 Use of a permanent implant to secure tissue'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 37, 'page_label': '38'}, page_content='\\uf0b7 Creation of a gastric (or gastroesophageal) plication in close proximity to the \\ngastroesophageal junction by the retroflexed device  \\n\\uf0b7 Use of a permanent implant to secure tissue  \\n\\uf0b7 Use of a mechanical component for positioning and launching the implant \\n\\uf0b7 User-controlled mechanical trigger (or knob) to launch the fastener (implant) \\n\\uf0b7 Mechanically securing the plication by a permanent implant fastener \\n \\nThe following technological differences exist between the subject and predicate devices: \\n\\uf0b7 Use of an ultrasound range finder  \\n\\uf0b7 Use of a staple as a fastener  \\n\\uf0b7 Use of different tissue capture and fixation mechanisms  \\n\\uf0b7 The predicate device must be used in conjunction with a flexible endoscope whereas the \\nsubject device has a flexible endoscope incorporated into the system. \\n \\nVII. PERFORMANCE DATA \\n \\nThe following performance data were provided in support of the substantial equivalence \\ndetermination. \\n \\nBiocompatibility testing'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 37, 'page_label': '38'}, page_content='VII. PERFORMANCE DATA \\n \\nThe following performance data were provided in support of the substantial equivalence \\ndetermination. \\n \\nBiocompatibility testing \\nThe biocompatibility evaluation for the Brand X device was conducted in accordance with the FDA \\nBlue Book Memorandum #G95-1 “Use of International Standard ISO-10993, ‘Biological Evaluation \\nof Medical Devices Part 1: Evaluation and Testing,’” May 1, 1995, and International Standard ISO \\n10993-1 “Biological Evaluation of Medical Devices − Part 1: Evaluation and Testing Within a Risk \\nManagement Process,” as recognized by FDA.  The battery of testing included the following tests: \\n \\n\\uf0b7 Cytotoxicity \\n\\uf0b7 Sensitization \\n\\uf0b7 Irritation \\n\\uf0b7 Systemic toxicity \\n\\uf0b7 Pyrogen Testing \\n \\nThe endoscopic delivery system is considered tissue contacting for a duration of less than 24 hours, \\nwhile the staples are considered permanent implants.  The titanium staple material conforms to \\nASTM F-67-06 for chemical composition.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 38, 'page_label': '39'}, page_content='Contains Nonbinding Recommendations \\n \\n 36 \\nElectrical safety and electromagnetic compatibility (EMC) \\nElectrical safety and EMC testing were conducted on the Brand X device, consisting of the ISL \\nconsole, CCU console and endoscope.  The system complies with the IEC 60601-1, IEC 60601-2-18 \\nand IEC 60601-2-37 standards for safety and the IEC 60601-1-2 standard for EMC. \\n \\nSoftware Verification and Validation Testing  \\nSoftware verification and validation testing were conducted and documentation was provided as \\nrecommended by FDA’s Guidance for Industry and FDA Staff, “Guidance for the Content of \\nPremarket Submissions for Software Contained in Medical Devices.”  The software for this device \\nwas considered as a “major” level of concern, since a failure or latent flaw in the software could \\ndirectly result in serious injury or death to the patient or operator. \\n \\nMechanical and acoustic testing \\n\\uf0b7 Acoustic Testing \\n\\uf0b7 Elongation of the bending cable'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 38, 'page_label': '39'}, page_content='directly result in serious injury or death to the patient or operator. \\n \\nMechanical and acoustic testing \\n\\uf0b7 Acoustic Testing \\n\\uf0b7 Elongation of the bending cable \\n\\uf0b7 Torque on the handle wheel and force on cable \\n\\uf0b7 Crimp assembly, cable tensile strength, cable flexibility, minimum bending radius of the \\ncables \\n\\uf0b7 Staple verification \\n\\uf0b7 Simulated use testing \\n \\nAnimal Study \\nIn the animal study conducted, 16 pigs underwent endoscopy with the Brand X System. Twelve pigs \\nunderwent fundoplication, and 4 pigs served as a sham (control) group. There were no procedure \\nrelated complications or premature deaths in this study, at the 2, 4 and 6 week follow-up (4 pigs in \\neach group). \\n \\nThe safety and feasibility of the Brand X device were evaluated by macroscopic and histological \\nevaluation of the tissue in the treatment stapled areas. These studies demonstrated that the Brand X \\ndevice can safely create an anterior partial fundoplication, similar to that which is constructed using'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 38, 'page_label': '39'}, page_content='device can safely create an anterior partial fundoplication, similar to that which is constructed using \\nother endoscopic suturing devices.  \\n \\nClinical Studies \\nClinical testing of the Brand X device included an initial feasibility study of 6 patients, a pilot study \\nconsisting of 13 patients and a pivotal study of 72 patients. Substantial equivalence was based in part \\non the pivotal study. \\n \\nPivotal Study \\nThe pivotal study was a prospective, multi-center, open label, non-randomized, single arm study of \\n72 patients, of which 66 were available for primary endpoint analysis; 3 subjects did not complete the \\nprocedure, and 3 were excluded from the effectiveness analysis.  The device was used to staple the \\nfundus of the stomach to the esophagus, using standard B shaped surgical staples. Stapling was \\nperformed in two or three locations at least 1.5 cm above the GE junction, separated by at least 90'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 38, 'page_label': '39'}, page_content='fundus of the stomach to the esophagus, using standard B shaped surgical staples. Stapling was \\nperformed in two or three locations at least 1.5 cm above the GE junction, separated by at least 90 \\ndegrees. The procedure was intended to create a partial anterior fundoplication as a reflux barrier. \\nPatients were followed for a period of six months at 6 sites both in the United States and outside of \\nthe United States under IDE G070136.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 39, 'page_label': '40'}, page_content='Contains Nonbinding Recommendations \\n \\n 37 \\nPrimary effectiveness endpoint: \\nGERD health related quality of life score (GERD-HRQL) off proton pump inhibitor (PPI) was \\nimproved from baseline by > 50%, at six months post procedure in at least 53% of the patients (53% \\nis the lower boundary of the 95% confidence interval). \\n \\nPrimary safety endpoint: \\nThe primary safety endpoint consisted of all treatment-related adverse events, during and after the \\nprocedure. “Treatment-related” events were conventionally defined as those which occurred in the \\nfirst 30 days post-procedure. \\n \\nEffectiveness \\nThe primary endpoint for the Brand X study focused on the GERD-HRQL score. The study results \\ndemonstrated that 75% of the patients had a >50% improvement in their GERD-HRQL score off PPI \\nat six months compared to baseline. Hence the study met its primary endpoint with the required 95% \\nconfidence level.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 39, 'page_label': '40'}, page_content='at six months compared to baseline. Hence the study met its primary endpoint with the required 95% \\nconfidence level. \\n \\nThe reduction in the median score for the Brand X device of 23.0 units (from 29.0 to 6.0) represents a \\n79.3% improvement. This value is almost identical to the published result for the pivotal trial of the \\npredicate device (79.2%). Therefore, the effectiveness of the Brand X system in successfully treating \\nchronic symptoms of GERD is similar to the effectiveness reported for the predicate device. \\n \\nThe median value of the percent of time pH < 4.0 decreased from an initial value of 8.3% at baseline \\nto 6.75%. Therefore, the study met its secondary endpoint related to the acid exposure test. A \\ncomparison to results reported in the literature revealed that the change in the median values of the \\nBrand X device showed a decrease of 19%, while the predicate showed a decrease of 18%.  Hence,'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 39, 'page_label': '40'}, page_content='comparison to results reported in the literature revealed that the change in the median values of the \\nBrand X device showed a decrease of 19%, while the predicate showed a decrease of 18%.  Hence, \\nthe Brand X results in reducing the exposure to gastric acids are similar to those reported for the \\npredicate system. \\n \\nSafety \\nThe study reported nine patients with a total of nine serious adverse events (SAEs). Four events were \\nconsidered mild in intensity, involving pain and fever. Three events were classified as moderate in \\nintensity, involving pneumothorax, pneumomediastinum, and pneumoperitoneum (all resolved \\nspontaneously). Two events were considered severe in intensity: one involved esophageal perforation \\n(required drainage) and another had suicidal thoughts (non-device/procedure related). \\n \\nSix of the SAEs were considered related to the device: one definitely (esophageal perforation) and the'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 39, 'page_label': '40'}, page_content='(required drainage) and another had suicidal thoughts (non-device/procedure related). \\n \\nSix of the SAEs were considered related to the device: one definitely (esophageal perforation) and the \\nothers possibly. Three events were considered not related to the device. The median time from \\nprocedure to SAE was 1.5 days for events related to the device. None of the patients with SAEs \\nrequired any operation or re-operation. Adverse events reported that occurred in greater than the 5% \\nlevel were postoperative pain or discomfort in 33% of patients, postoperative nausea in \\napproximately 10%, and sore throat in 21%. The adverse events were mild or insignificant in most \\ncases.  \\n \\nThe SAEs and overall safety profile were similar to the predicate device for which two perforations \\nand one bleeding event were reported. The number of AEs was similar to those reported for the \\npredicate device. Three cases of fever were reported in the current study (for 72 patients), similar to'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 39, 'page_label': '40'}, page_content='and one bleeding event were reported. The number of AEs was similar to those reported for the \\npredicate device. Three cases of fever were reported in the current study (for 72 patients), similar to \\nthe 3 cases of fever reported for the predicate. There were 23 cases of chest pain (23/72 = 32%) vs. \\n17% reported for the predicate; abdominal pain was recorded for 5% of the patients in the current'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 40, 'page_label': '41'}, page_content='Contains Nonbinding Recommendations \\n \\n 38 \\nstudy vs. 44% of the patients for the predicate. Sore throat was reported for 15 patients (15/72 = 21%) \\nvs. 15% for the predicate. \\n \\nSummary \\nBased on the clinical performance as documented in the pivotal clinical study, the Brand X system \\nwas found to have a safety and effectiveness profile that is similar to the predicate device. \\n \\nVIII. CONCLUSIONS \\n \\nSince the predicate device was cleared based in part on the results of clinical studies, and since the \\ncomparison of bench testing to clinical outcomes is still not well understood for this type of device, \\nclinical testing was required to support substantial equivalence.  The non-clinical data support the \\nsafety of the device and the hardware and software verification and validation demonstrate that the \\nBrand X device should perform as intended in the specified use conditions.  The clinical data'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 40, 'page_label': '41'}, page_content='safety of the device and the hardware and software verification and validation demonstrate that the \\nBrand X device should perform as intended in the specified use conditions.  The clinical data \\ndemonstrate that the Brand X device performs comparably to the predicate device that is currently \\nmarketed for the same intended use.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 41, 'page_label': '42'}, page_content='Contains Nonbinding Recommendations \\n \\n 39 \\nAppendix D.  Glossary of Significant Terminology  \\n \\nThe following terms are defined for purposes of this guidance: \\n \\nClassification regulation – The classification regulations are Agency-defined categories of medical \\ndevices based on intended use and technology. Each device classification regulation defines the class \\n(i.e., Class I, II, or III) for the device category which in turn determines the regulatory requirements.  \\nDevice classification regulations are codified by rule or order in 21 CFR Parts 862-892.   \\n \\nIndications for use – The disease or condition the device will diagnose, treat, prevent, cure or \\nmitigate, including a description of the patient population for which the device is intended. \\n \\nIntended use – The general purpose of the device or its function.  The intended use of a device \\nencompasses the indications for use.   \\n \\nMultiple Predicate Devices – Two or more predicate devices that have been provided to support an'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 41, 'page_label': '42'}, page_content='encompasses the indications for use.   \\n \\nMultiple Predicate Devices – Two or more predicate devices that have been provided to support an \\nSE determination.  If using multiple predicate devices to demonstrate substantial equivalence, each \\npredicate device must have the same intended use as the new device, and any different technological \\ncharacteristics between the new device and the predicate devices must not raise different questions of \\nsafety and effectiveness.   \\n \\nPerformance Data – Performance data can be any data, including non-clinical (e.g., data from \\nengineering testing, such as fatigue, wear, corrosion, etc., biocompatibility, functional animal studies, \\ncadaver, etc.) and/or clinical, that are provided to support the substantial equivalence of a device that \\nis intended to be marketed.   \\n \\nPredicate Device – A legally marketed device (as defined in 21 CFR 807.92(a)(3)) to which a new'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 41, 'page_label': '42'}, page_content='is intended to be marketed.   \\n \\nPredicate Device – A legally marketed device (as defined in 21 CFR 807.92(a)(3)) to which a new \\ndevice may be compared for a determination regarding substantial equivalence because the devices \\nhave the same intended use and the same technological characteristics or different technological \\ncharacteristics that do not raise different questions of safety and effectiveness.   \\n \\nPrimary Predicate Device – A predicate device with indications for use and technological \\ncharacteristics that are most similar to the new device.  The primary predicate should be identified \\nwithin a 510(k) submission.   \\n \\nReference Device – A legally marketed device that is intended to provide scientific and/or technical \\ninformation (e.g., test methodology) to help address the safety and effectiveness of a new \\ntechnological characteristic.  Reference devices are not predicate devices and may only be used after \\nDecision Point 4 on the 510(k) Decision-Making Flowchart.'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 41, 'page_label': '42'}, page_content='technological characteristic.  Reference devices are not predicate devices and may only be used after \\nDecision Point 4 on the 510(k) Decision-Making Flowchart. \\n \\nSplit Predicate – Using one legally marketed device for intended use and a different legally \\nmarketed device for technological characteristics to demonstrate substantial equivalence.  The use of \\na “split predicate” is inconsistent with the 510(k) regulatory standard.')]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "                    chunk_size=1000,\n",
    "                    chunk_overlap=200\n",
    "                )\n",
    "\n",
    "fda_guidelines_chunks = text_splitter.split_documents(fda_guidelines_doc)\n",
    "fda_guidelines_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "6bbae8c3",
   "metadata": {},
   "outputs": [],
   "source": [
    "_ = guidelines_vector_store.add_documents(documents=fda_guidelines_chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "d0c4a896",
   "metadata": {},
   "outputs": [],
   "source": [
    "guidelines_retriever = guidelines_vector_store.as_retriever(search_kwargs={\"k\": 5})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "f1948a03",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7', '_id': '8fb234c9cbd7439bb7e7e2b2f5869051', '_collection_name': 'guidelines'}, page_content='4  \\nnew device through the 510(k) process requires FDA to determine the issues of safety and \\neffectiveness presented by the new device, and the regulatory controls necessary to address those \\nissues.7 \\nC. Evolution of the 510(k) Program \\nSince its inception, the 510(k) program has undergone a number of statutory changes.  Notably, the \\nSafe Medical Devices Act of 1990 (Pub. L. 101-629) added section 513(i), which codified FDA \\nreview practice in applying the “substantial equivalence” review standard.  In addition, FDA has \\nmodified its implementation of the program to adapt to changing circumstances and to accommodate \\nthe evolving medical device landscape.  For example, the alternative options of a Special 510(k) or an \\nAbbreviated 510(k) still exist today.  Additional information regarding these alternative options can \\nbe found in FDA’s guidance, “The New 510(k) Paradigm – Alternative Approaches to Demonstrating \\nSubstantial Equivalence in Premarket Notifications”'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7', '_id': '656dde6eb4ca4b6498e5a1647176a4c4', '_collection_name': 'guidelines'}, page_content='be found in FDA’s guidance, “The New 510(k) Paradigm – Alternative Approaches to Demonstrating \\nSubstantial Equivalence in Premarket Notifications” \\n(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument\\ns/ucm080189.pdf).  The current 510(k) program reflects the current statutory framework and FDA’s \\nimplementation of that framework through regulation, guidance, and administrative practice.  A \\nhistory of the 510(k) program has been summarized in other documents that FDA has published.\\n8 \\nThis guidance document provides updated information to the existing guidance document entitled \\n“Guidance on the CDRH Premarket Notification Review Program, 510(k) Memorandum K86-3” \\n(K86-3 Guidance), issued on June 30, 1986.  The K86-3 Guidance was written and issued as final \\nguidance prior to the February 27, 1997 implementation of FDA’s Good Guidance Practices (GGPs),'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 3, 'page_label': '4', '_id': '75a55bb2503d4b51b00b9afc1888a38f', '_collection_name': 'guidelines'}, page_content='FDA staff, call the appropriate number listed on the title page of this guidance.  \\n \\nI. Introduction \\nFDA developed this document to provide guidance to industry and FDA staff about current review \\npractices for premarket notification (510(k)) submissions.  The intent of this guidance is to identify, \\nexplain, and clarify each of the critical decision points in the decision-making process FDA uses to \\ndetermine substantial equivalence.  This guidance is not intended to implement significant policy \\nchanges to the current 510(k) review process.  Rather, the intent of this guidance is to enhance the \\npredictability, consistency, and transparency of the 510(k) program by describing in greater detail the \\nregulatory framework, policies, and practices underlying FDA’s 510(k) review.   \\n \\nThe draft of this guidance document contained sections addressing FDA’s Special and Abbreviated \\n510(k) programs.  FDA intends to finalize those sections separately.  Until FDA issues new final'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 6, 'page_label': '7', '_id': '4d098b972a70489da1066a4ff4a91cd0', '_collection_name': 'guidelines'}, page_content='by the special controls for the device to be classified into Class II.  See Section 513(a)(1)(B) of the FD&C Act (21 U.S.C. \\n§ 360c(a)(1)(B)).   \\n \\n8 See CDRH Preliminary Internal Evaluations – Volume I: 510(k) Working Group Preliminary Report and Recommendations \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf).  See also CDRH Preliminary \\nInternal Evaluations – Volume II: Task Force on the Utilization of Science in Regulatory Decision Making Preliminary Report and \\nRecommendations (http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220783.pdf).  See also \\n510(k) and Science Report Recommendations: Summary and Overview of Comments and Next Steps \\n(http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pdf). \\n \\n 4  \\nnew device through the 510(k) process requires FDA to determine the issues of safety and \\neffectiveness presented by the new device, and the regulatory controls necessary to address those'),\n",
       " Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 28, 'page_label': '29', '_id': '65ac1f73b85d407599be19ad097bceb6', '_collection_name': 'guidelines'}, page_content='Contains Nonbinding Recommendations \\n \\n 26 \\nwith regard to a particular device, FDA will consider its options (e.g., guidance, advisory panel \\nmeeting, etc.), for explaining such change and the basis for the decision to ensure transparency in the \\nchange in policy.  FDA also intends to consider any pending 510(k) submissions that may be affected \\nby the change or allow for an appropriate transition period, in certain situations that may affect the \\nindustry at large. \\nG. The 510(k) Summary \\nThe 510(k) Summary38 is a document that provides a high-level discussion of the content of a 510(k) \\nand must include all the elements identified in 21 CFR 807.92.  A 510(k) Summary must be in \\nsufficient detail to provide an understanding of the basis for a determination of substantial \\nequivalence (21 CFR 807.92(a)). \\n                                                 \\n38 As specified in 21 CFR 807.87(h), a 510(k) Statement as described in 21 CFR 807.93 may be provided in lieu of a 510(k) Summary.')]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "guidelines_retriever.invoke(\"What is the purpose of the FDA's 510(k) program?\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7101e4b7",
   "metadata": {},
   "source": [
    "#### Uploaded 501K"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "84aa305a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'producer': '', 'creator': '', 'creationdate': '', 'source': './data/510K_1.pdf', 'total_pages': 4}, page_content='5 1 0(k) Pre-Market Notification APR 1 3 2005 lti\\nReliant Stent Graft Balloon Catheter\\nMedtronic, Inc.\\n5 10(k) Summary\\nSubmitter: Mcdtronic Vascular\\n3576 Unocal Place\\nSanta Rosa, CA 95403\\nUSA\\nContact Person: Willie Mitchell\\nAssociate Regulatory Affairs Specialist\\n(707) 591-2091\\n(707) 566-1432 - FAX\\nwillie.mitchell~medtronic.com\\nDate Prepared: January 6, 2005\\nTrade Name: Reliant Stent Graft Balloon Catheter\\nCommon Name: Balloon Catheter\\nClassification Percutaneous Catheter\\nName:\\nPredicate Devices: The CODA Balloon Catheter (K032869) manufactured by\\nCook Incorporated (vessel occlusion and expansion of\\nvascular prosthesis, product code DQY), and was cleared by\\nFDA on November 19, 2003.\\nThe Iliac Balloon Catheter (K003495) manufactured by\\nGuidant Corporation (prosthesis expansion, product code\\nDQY), and was cleared by FDA on February 7, 200 1.\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\nmanufactured by Cook Incorporated (vessel occlusion,\\nproduct code MJN), and was cleared by FDA on March 22,\\n2001.\\nSubstantial The Reliant Stent Graft Balloon Catheter is substantially\\nEquivalence: equivalent to the predicate devices listed above, as it is\\ncomparable with respect to their intended use, overall catheter\\nconfiguration, and performance characteristics.\\n\\x0cDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service\\nFood and Drug Administration\\n9200 Corporate Boulevard\\nA.PR 1 3 Z005 Rockville MD 20850\\nMedtronic Vascular\\nc/o Mr. Willie Mitchell\\nAssociate Regulatory Affairs Specialist\\n3576 Unocal Place\\nSanta Rosa, CA 95403\\nRe: K050038\\nReliant Stent Graft Balloon Catheter\\nRegulation Number: 21 CFR 870.1250\\nRegulation Name: Percutaneous Catheter\\nRegulatory Class: Class 1L (Two)\\nProduct Code: DQY\\nDated: January 6, 2005\\nReceived: January 7, 2005\\nDear Mr. Mitchell:\\nWe have reviewed your Section 510(k) premarket notification of intent to market the device\\nreferenced above and have determined the device is substantially equivalent (for the indications\\nfor use stated in the enclosure) to legally marketed predicate devices marketed in interstate\\ncommerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to\\ndevices that have been reclassified in accordance with the provisions of the Federal Food, Drug,\\nand Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).\\nYou may, therefore, market the device, subject to the general controls provisions of the Act. The\\ngeneral controls provisions of the Act include requirements for annual registration, listing of\\ndevices, good manufacturing practice, labeling, and prohibitions against misbranding and\\nadulteration.\\nIf your device is classified (see above) into either class 1I (Special Controls) or class III (PMA), it\\nmay be subject to such additional controls. Existing major regulations affecting your device can\\nbe found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may\\npublish further announcements concerning your device in the F\\'ederal Register.\\n\\x0cPage 2 - Mr. Willie Mitchell\\nPlease be advised that FDA\\'s issuance of a substantial equivalence determination does not mean\\nthat FDA has made a determination that your device complies with other requirements of the Act\\nor any Federal statutes and regulations administered by other Federal agencies. You must\\ncomply with all the Act\\'s requirements, including, but not limited to: registration and listing (21\\nCFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set\\nforth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic\\nproduct radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.\\nThis letter will allow you to begin marketing your device as described in your Section 510(k)\\npremarket notification. The FDA finding of substantial equivalence of your device to a legally\\nmarketed predicate device results in a classification for your device and thus, permits your device\\nto proceed to the market.\\nIf you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please\\ncontact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled,\\n\"Misbranding by reference to premarket notification\" (21CFR Part 807.97). You may obtain\\nother general information on your responsibilities under the Act from the Division of Small\\nManufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 cr\\n(301) 443-6597 or at its Internet address http://www.fda wv/cdrh/ds ma/dsnmain.html\\nSincerely yours,\\nBrain D. Zuckerman, M.D.\\nDirector\\nDivision of Cardiovascular Devices\\nOffice of Device Evaluation\\nCenter for Devices and\\nRadiological Health\\nEnclosure\\n\\x0cIndications for Use\\n510(k) Number (if known): not yet assigned ( & )5 CC I 3\\nDevice Name: Reliant Stent Graft Balloon Catheter\\nIndications For Use:\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\nvessels, or to expand vascular prostheses.\\nPrescription Use _X_--- AND/OR Over-The-Counter Use\\n(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)\\n(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE\\nIF NEEDED)\\nConcurrence of CDRH, Office of Device Evaluation (ODE)\\nPage I oft_\\n(Division Sign-Off)\\nOlvislon of C~rdiovascuIar Devices\\n5 IOk) Numlber _ 603_')]\n"
     ]
    }
   ],
   "source": [
    "loader = PyPDFLoader(\"./data/510K_1.pdf\", mode=\"single\")\n",
    "predicate_device_doc = loader.load()\n",
    "\n",
    "print(predicate_device_doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "89c21859",
   "metadata": {},
   "outputs": [],
   "source": [
    "predicate_device_chunks = text_splitter.split_documents(predicate_device_doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "298bce86",
   "metadata": {},
   "outputs": [],
   "source": [
    "guidelines_client.create_collection(\n",
    "    collection_name=\"predicate_device_501K\",\n",
    "    vectors_config=VectorParams(size=embedding_dim, distance=Distance.COSINE),\n",
    ")\n",
    "\n",
    "predicate_vector_store = QdrantVectorStore(\n",
    "    client=guidelines_client,\n",
    "    collection_name=\"predicate_device_501K\",\n",
    "    embedding=embedding_model,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "93bae7ca",
   "metadata": {},
   "outputs": [],
   "source": [
    "_ = predicate_vector_store.add_documents(documents=predicate_device_chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "0a39ed6d",
   "metadata": {},
   "outputs": [],
   "source": [
    "predicate_retriever = predicate_vector_store.as_retriever(search_kwargs={\"k\": 5})"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9d6b4bcd",
   "metadata": {},
   "source": [
    "### Build RAG Tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "a3ea204f",
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Annotated, List, Tuple, Union\n",
    "from langchain_core.tools import tool\n",
    "\n",
    "# TODO: turn it into a graph\n",
    "@tool\n",
    "def retrieve_fda_guidelines(\n",
    "    query: Annotated[str, \"query to ask the retrieve fda guidelines tool\"]\n",
    "    ):\n",
    "  \"\"\"Use Retrieval Augmented Generation to retrieve information fda guidelines for determining substantial equivalence between a target device and a predicate device\"\"\"\n",
    "  return guidelines_retriever.invoke(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "2ef7c1a0",
   "metadata": {},
   "outputs": [],
   "source": [
    "@tool\n",
    "def retrieve_predicate_device_details(\n",
    "    query: Annotated[str, \"query to ask the retrieve predicate device details tool\"]\n",
    "    ):\n",
    "  \"\"\"Use Retrieval Augmented Generation to retrieve details about a predicate device\"\"\"\n",
    "  return predicate_retriever.invoke(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "b29cc5df",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.agents import AgentExecutor, create_openai_functions_agent\n",
    "from langchain.output_parsers.openai_functions import JsonOutputFunctionsParser\n",
    "from langchain_core.prompts import ChatPromptTemplate, MessagesPlaceholder\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "def create_agent(\n",
    "    llm: ChatOpenAI,\n",
    "    tools: list,\n",
    "    system_prompt: str,\n",
    ") -> str:\n",
    "    \"\"\"Create a function-calling agent and add it to the graph.\"\"\"\n",
    "    system_prompt += (\"\\nWork autonomously according to your specialty, using the tools available to you.\"\n",
    "    \" Do not ask for clarification.\"\n",
    "    \" Your other team members (and other teams) will collaborate with you with their own specialties.\"\n",
    "    \" You are chosen for a reason!\")\n",
    "    prompt = ChatPromptTemplate.from_messages(\n",
    "        [\n",
    "            (\n",
    "                \"system\",\n",
    "                system_prompt,\n",
    "            ),\n",
    "            MessagesPlaceholder(variable_name=\"messages\"),\n",
    "            MessagesPlaceholder(variable_name=\"agent_scratchpad\"),\n",
    "        ]\n",
    "    )\n",
    "    agent = create_openai_functions_agent(llm, tools, prompt)\n",
    "    executor = AgentExecutor(agent=agent, tools=tools)\n",
    "    return executor"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "64bebe2b",
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = ChatOpenAI(model=\"gpt-4o-mini\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "523a4562",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/r5/wsbp5_jj7lsfh6rxrw7p7lv00000gn/T/ipykernel_66077/4251892148.py:3: LangChainDeprecationWarning: The class `TavilySearchResults` was deprecated in LangChain 0.3.25 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-tavily package and should be used instead. To use it run `pip install -U :class:`~langchain-tavily` and import as `from :class:`~langchain_tavily import TavilySearch``.\n",
      "  tavily_tool = TavilySearchResults(max_results=5)\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.tools.tavily_search import TavilySearchResults\n",
    "\n",
    "tavily_tool = TavilySearchResults(max_results=5)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "7e5b616e",
   "metadata": {},
   "outputs": [],
   "source": [
    "tool_belt = [retrieve_fda_guidelines, retrieve_predicate_device_details, tavily_tool]\n",
    "model = llm.bind_tools(tool_belt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "2fe02b11",
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import TypedDict, Annotated\n",
    "from langgraph.graph.message import add_messages\n",
    "from langchain_core.messages import BaseMessage\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "  messages: Annotated[list, add_messages]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "1a3f2568",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langgraph.prebuilt import ToolNode\n",
    "\n",
    "def call_model(state):\n",
    "  messages = state[\"messages\"]\n",
    "  response = model.invoke(messages)\n",
    "  return {\"messages\" : [response]}\n",
    "\n",
    "tool_node = ToolNode(tool_belt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "679b4305",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langgraph.graph import StateGraph, END\n",
    "\n",
    "uncompiled_graph = StateGraph(AgentState)\n",
    "\n",
    "uncompiled_graph.add_node(\"agent\", call_model)\n",
    "uncompiled_graph.add_node(\"action\", tool_node)\n",
    "uncompiled_graph.set_entry_point(\"agent\")\n",
    "\n",
    "def should_continue(state):\n",
    "  last_message = state[\"messages\"][-1]\n",
    "\n",
    "  if last_message.tool_calls:\n",
    "    return \"action\"\n",
    "\n",
    "  return END\n",
    "\n",
    "uncompiled_graph.add_conditional_edges(\n",
    "    \"agent\",\n",
    "    should_continue\n",
    ")\n",
    "\n",
    "uncompiled_graph.add_edge(\"action\", \"agent\")\n",
    "\n",
    "\n",
    "device_regulatory_agent = uncompiled_graph.compile()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "88d9bf2d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<langgraph.graph.state.CompiledStateGraph object at 0x116584bf0>"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "device_regulatory_agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d4bdaf3c",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are an intelligent regulatory agent whose task is to evaluate whether a new medical device is *substantially equivalent* to a predicate device under the FDA’s 510(k) program, focusing specifically on **whether the intended use (as captured in the Indications for Use statement)** matches.\n",
    "\n",
    "You have access to two tools:\n",
    "- `retrieve_fda_guidelines(query)` — to retrieve relevant snippets from the FDA’s *“The 510(k) Program: Evaluating Substantial Equivalence…”* guidance, especially definitions and examples of “intended use”.\n",
    "- `retrieve_predicate_device_details(query)` — to fetch the predicate device’s documented “Indications for Use” statement and related context from its 510(k) filing.\n",
    "\n",
    "Do not ask follow-up questions.\n",
    "\n",
    "**Your task flow:**\n",
    "1. Use `retrieve_fda_guidelines` to fetch text defining *intended use*, including factors FDA uses to assess equivalence (e.g., disease target, clinical purpose, patient population). Always use this tool first.\n",
    "2. Use `retrieve_predicate_device_details` to fetch the predicate device’s “Indications for Use”.\n",
    "3. Compare the new device’s Indications for Use (provided by user) with the predicate’s, applying FDA's logic:\n",
    "   - Are they targeted to the **same disease or condition**?\n",
    "   - Do they serve the **same clinical purpose or function** (diagnosis, treatment, monitoring, etc.)?\n",
    "   - Are they intended for the **same patient population**?\n",
    "   - Does the new device include any **new modalities or indications** not in the predicate?\n",
    "4. Determine if the intended use is **the same**. If yes → `substantially_equivalent = true`. If no → `false`.\n",
    "5. Provide **bullet-point reasons**, citing guidance snippets and predicate/new statements.\n",
    "6. If not equivalent, provide **suggestions** to revise indications (e.g. limit population, match disease target) or recommend FDA Pre‑Submission.\n",
    "\n",
    "**Output format (JSON):**\n",
    "```json\n",
    "{\n",
    "  \"substantially_equivalent\": <true|false>,\n",
    "  \"reasons\": [\"...\"],\n",
    "  \"citations\": [\n",
    "     {\"tool\": \"fda_guidelines\", \"text\": \"…\"},\n",
    "     {\"tool\": \"predicate_device\", \"text\": \"…\"}\n",
    "  ],\n",
    "  \"suggestions\": [\"...\"]\n",
    "}\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "db726942",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are an intelligent regulatory agent whose task is to evaluate whether a new medical device is *substantially equivalent* to a predicate device under the FDA’s 510(k) program, focusing specifically on **whether the intended use (as captured in the Indications for Use statement)** matches.\n",
    "\n",
    "You have access to two tools:\n",
    "- `retrieve_fda_guidelines(query)` — to retrieve relevant snippets from the FDA’s *“The 510(k) Program: Evaluating Substantial Equivalence…”* guidance, especially definitions and examples of “intended use”.\n",
    "- `retrieve_predicate_device_details(query)` — to fetch the predicate device’s documented “Indications for Use” statement and related context from its 510(k) filing.\n",
    "\n",
    "Do not ask follow-up questions.\n",
    "\n",
    "**Your task flow:**\n",
    "1. Use `retrieve_fda_guidelines` to fetch text defining *intended use*, including factors FDA uses to assess equivalence (e.g., disease target, clinical purpose, patient population). Always use this tool first. Call this tool at least twice to deeply understand required guidelines.\n",
    "2. Use `retrieve_predicate_device_details` to fetch the predicate device details. Call this tool at least twice. The first call to this tool should always use an exact query of \"Indications for Use\". Subsequent calls should be to fetch other details as needed. \n",
    "3. Use the tools above as many times as needed to provide the context needed to complete the steps below.\n",
    "4. Compare the new device’s Indications for Use (provided by user) with the predicate’s, applying FDA's logic from the guidance:\n",
    "5. Determine if the intended use is **the same**. If yes → `substantially_equivalent = true`. If no → `false`.\n",
    "6. Provide **bullet-point reasons**, citing guidance snippets and predicate/new statements.\n",
    "7. If not equivalent, provide **suggestions** to revise indications (e.g. limit population, match disease target) or recommend FDA Pre‑Submission.\n",
    "\n",
    "**Output format (JSON):**\n",
    "```json\n",
    "{\n",
    "  \"substantially_equivalent\": <true|false>,\n",
    "  \"reasons\": [\"...\"],\n",
    "  \"citations\": [\n",
    "     {\"tool\": \"fda_guidelines\", \"text\": \"…\"},\n",
    "     {\"tool\": \"predicate_device\", \"text\": \"…\"}\n",
    "  ],\n",
    "  \"suggestions\": [\"...\"]\n",
    "}\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "5c46bb4e",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.messages import HumanMessage, SystemMessage\n",
    "def create_initial_state(query: str):\n",
    "    return {\"messages\": [\n",
    "        SystemMessage(content=system_prompt),\n",
    "        HumanMessage(content=query),\n",
    "    ]}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3b38e81b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_MrdXKGgpwxGc9O9tUHlIs4RM', 'function': {'arguments': '{\"query\": \"intended use definition and factors for substantial equivalence\"}', 'name': 'retrieve_fda_guidelines'}, 'type': 'function'}, {'id': 'call_uLAtUwYguEQP2DmaBcYQHxFR', 'function': {'arguments': '{\"query\": \"intended use evaluation factors\"}', 'name': 'retrieve_fda_guidelines'}, 'type': 'function'}], 'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 63, 'prompt_tokens': 689, 'total_tokens': 752, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzehZNdjqYsOQsPD0UmXqLHJkaSqq', 'service_tier': 'default', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run--559eca13-a6bc-4fe2-8c4a-76723818d6fb-0', tool_calls=[{'name': 'retrieve_fda_guidelines', 'args': {'query': 'intended use definition and factors for substantial equivalence'}, 'id': 'call_MrdXKGgpwxGc9O9tUHlIs4RM', 'type': 'tool_call'}, {'name': 'retrieve_fda_guidelines', 'args': {'query': 'intended use evaluation factors'}, 'id': 'call_uLAtUwYguEQP2DmaBcYQHxFR', 'type': 'tool_call'}], usage_metadata={'input_tokens': 689, 'output_tokens': 63, 'total_tokens': 752, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'action'\n",
      "[ToolMessage(content='[Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 8, \\'page_label\\': \\'9\\', \\'_id\\': \\'2a4a910e794c4610b687b8af89a3f4d1\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'section 520(l), the term \"substantially equivalent\" or \"substantial equivalence\" means, with \\\\nrespect to a device being compared to a predicate device, that the device has the same \\\\nintended use as the predicate device and that the Secretary by order has found that the device\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 17, \\'page_label\\': \\'18\\', \\'_id\\': \\'2f9999c4bb764bb2a229e13c01f48acf\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'device is necessary and appropriate to support substantial equivalence.  Manufacturers should choose \\\\nthe most appropriate single or primary predicate for their new device, and should limit the multiple \\\\npredicates to those most helpful in facilitating review of the new device and to the minimum number \\\\nnecessary to support substantial equivalence.  Predicate device(s) relied upon for SE must be \\\\naccurately cited in the 510(k) Summary (see Appendix B) according to 21 CFR 807.92 (a)(3).  \\\\nReference devices also may be cited in the 510(k) Summary.   \\\\nD. Intended Use \\\\nUnder section 513(i) of the FD&C Act, FDA may only determine that a device is substantially \\\\nequivalent to a predicate device if it has the same intended use.20  (Refer to the 510(k) Decision-\\\\nMaking Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\\\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 9, \\'page_label\\': \\'10\\', \\'_id\\': \\'b87fc760c2874fcaa2b4b99e72d92f59\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'significant change in the materials, design, energy source, or other features of the device from \\\\nthose of the predicate device. \\\\nSafety and effectiveness factor into both parts of the FDA’s review.  First, FDA must find that the \\\\nintended use of the device and its predicate are “the same.”  As discussed in the Intended Use Section \\\\nof this guidance, differences in the indications for use, such as the population for which a device is \\\\nintended or the disease a device is intended to treat do not necessarily result in a new intended use.  \\\\nSuch differences result in a new intended use when they affect (or may affect) the safety and/or \\\\neffectiveness of the new device as compared to the predicate device and the differences cannot be \\\\nadequately evaluated under the comparative standard of substantial equivalence. (See Section IV.D.)  \\\\n \\\\nSecond, when comparing a new device to a predicate device, FDA must find that the two devices\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 19, \\'page_label\\': \\'20\\', \\'_id\\': \\'e9752ea42e9d4c13adfd13aeb7637a80\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'of a new intended use.  Only a change in the indications for use that raises different questions of \\\\nsafety and effectiveness and therefore, precludes a meaningful comparison with the predicate device \\\\nconstitutes a new intended use.  FDA may find changes in indications for use of a device to constitute \\\\na new intended use when the changes raise a safety or effectiveness issue that was not raised by the \\\\npredicate device, or the changes have the potential to significantly increase a safety or effectiveness \\\\nconcern raised by the predicate device.\\\\n24  In the first case, reliance on a predicate device is inadequate \\\\nbecause the safety or effectiveness issue was not considered in reviewing the 510(k) for the predicate \\\\ndevice.  In the second case, although the safety or effectiveness issue may have been considered in \\\\nthe 510(k) for the predicate device, the finding of substantial equivalence for the predicate device\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 17, \\'page_label\\': \\'18\\', \\'_id\\': \\'02cb04efe196455bb6b323a51d4ff95e\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'equivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2) \\\\nof the FD&C Act provides that a predicate device may not have been removed from the market at the initiative of the Commissioner of \\\\nFood and Drugs or been determined to be misbranded or adulterated by a judicial order.  See also 21 CFR 807.100. \\\\n \\\\n20 This guidance is not intended to supplant either of the following guidance documents:  “Determination of Intended Use for 510(k) \\\\nDevices; Guidance for CDRH Staff (Update to K98-1)” \\\\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082162.htm) or “General/Specific \\\\nIntended Use” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm). \\\\n \\\\n21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”\\')]', name='retrieve_fda_guidelines', id='dafd89d0-f5ac-457a-b1af-bdd8914b9e02', tool_call_id='call_MrdXKGgpwxGc9O9tUHlIs4RM'), ToolMessage(content=\"[Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21', '_id': 'bc27bbf289254d768803b99b62dd391d', '_collection_name': 'guidelines'}, page_content='indications for use result in a new intended use because they are more likely to significantly affect \\\\nsafety or effectiveness: \\\\n \\\\n\\\\uf0b7 a change from a functional/performance indication to a treatment or aesthetic indication; \\\\n \\\\n\\\\uf0b7 a change from a diagnostic indication to a screening indication, or vice versa; \\\\n \\\\n\\\\uf0b7 a change in the anatomical structure of use; \\\\n \\\\n\\\\uf0b7 a change in the patient population (e.g., adult versus pediatric; different disease populations);  \\\\n \\\\n\\\\uf0b7 a change in the clinical context or setting (e.g., periodic monitoring versus continuous \\\\nmonitoring; hospital versus home use). \\\\nE. Technological Characteristics \\\\nAfter FDA has determined that a valid predicate device exists for a new device and that both devices \\\\nhave the same intended use, FDA will move to Decision Points 3 and 4 of the Flowchart (see \\\\nAppendix A).  In these steps of the 510(k) review process, FDA compares the technological'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19', '_id': 'b6778182e86e4ad0aa63061d54970a82', '_collection_name': 'guidelines'}, page_content='Contains Nonbinding Recommendations \\\\n \\\\n 16 \\\\nnew intended use.  This section of the guidance provides further clarification about the terms \\\\n“intended use” and “indications for use,” describes how FDA determines what the intended use of a \\\\ndevice is, and provides examples of changes in indications for use that may constitute a new intended \\\\nuse making the device ineligible for review under the 510(k) program.     \\\\n1. Explanation of Intended Use and Indications for Use \\\\nFor purposes of substantial equivalence, the term intended use means the general purpose of the \\\\ndevice or its function, and encompasses the indications for use.  The term indications for use, as \\\\ndefined in 21 CFR 814.20(b)(3)(i), describes the disease or condition the device will diagnose, treat, \\\\nprevent, cure or mitigate, including a description of the patient population for which the device is \\\\nintended.\\\\n22  The intended use of a device is one criterion that determines whether a device can be'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19', '_id': 'bdc43359228a4dfdb01376fb5e1aacaa', '_collection_name': 'guidelines'}, page_content='intended.\\\\n22  The intended use of a device is one criterion that determines whether a device can be \\\\ncleared for marketing through the 510(k) process or must be evaluated in a PMA (or alternative \\\\nsubmission type), or if appropriate, a De Novo request.  The proposed labeling in a 510(k) is used to \\\\ndetermine a device’s intended use (Section 513(i)(1)(E) of the FD&C Act).  The indications for use \\\\nstatement in a 510(k) is also a factor in determining a device’s intended use.  Consistency between \\\\nthe indications for use statement and the proposed labeling will facilitate the review of the 510(k). \\\\n \\\\n                                                 \\\\n22 We have a long-standing policy of applying the definition of indications for use in the PMA regulation at 21 CFR 814.20(b)(3)(i) in \\\\nthe same way in the 510(k) context. \\\\n \\\\n23 For purposes of Section IV.D, the term “new” in describing indications for use refers to an indication that is new or differs from that \\\\nof the predicate device.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19', '_id': '86cb5e6d428f4d009aed2a10b4c798e9', '_collection_name': 'guidelines'}, page_content='of the body.  A scalpel indicated for removing a particular type of cancerous cell, however, has \\\\nindications for use specific to the identified disease, condition, or population, and therefore, does not \\\\nhave “tool type” indications for use. \\\\n2. Determining Intended Use \\\\nSection 513(i)(1)(E)(i) of the FD&C Act provides that the FDA’s determination of intended use of a \\\\ndevice “shall be based upon the proposed labeling” submitted in a 510(k).  When a review of the \\\\nindications for use and all other information in the proposed labeling submitted with a 510(k) \\\\nsupports an intended use that is the same as that of the predicate device, FDA will determine that the \\\\nnew device and predicate device have the same intended use.  This guidance does not address FDA’s \\\\nauthority to consider information outside the labeling in reviewing a 510(k) and issue an “SE with \\\\nlimitations” under section 513(i)(l)(E) of the FD&C Act because “there is a reasonable likelihood that'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20', '_id': '51c67b5906524dbf8182efbcd574a987', '_collection_name': 'guidelines'}, page_content='relative to the safety and effectiveness of the predicate device. \\\\nOnce FDA has determined the indications for use of the new device upon review of the proposed \\\\nlabeling, FDA may rely upon relevant clinical and/or scientific information, that does not appear in \\\\nthe proposed labeling submitted with the 510(k), regarding the safety and effectiveness of the new \\\\nindications for use.  For example, FDA may rely upon publicly-available scientific information or \\\\nAgency knowledge about how a disease progresses to determine whether indications for use to treat a \\\\ncertain disease or anatomical site constitute a new intended use.   \\\\n3. Determining When Indications for Use Result in a New Intended Use \\\\nNot every change in indications for use that may affect safety or effectiveness will result in a finding \\\\nof a new intended use.  Only a change in the indications for use that raises different questions of')]\", name='retrieve_fda_guidelines', id='cfebb861-762d-43b0-8899-53db5d736abe', tool_call_id='call_uLAtUwYguEQP2DmaBcYQHxFR')]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_xym10oi5YpkvXxHmJM1Elbd6', 'function': {'arguments': '{\"query\":\"Indications for Use\"}', 'name': 'retrieve_predicate_device_details'}, 'type': 'function'}], 'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 20, 'prompt_tokens': 14260, 'total_tokens': 14280, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzehbUFffkw3rdxJkyjL8a8mLWu9q', 'service_tier': 'default', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run--5c07363b-72d3-493b-afb8-b77f1b0e05af-0', tool_calls=[{'name': 'retrieve_predicate_device_details', 'args': {'query': 'Indications for Use'}, 'id': 'call_xym10oi5YpkvXxHmJM1Elbd6', 'type': 'tool_call'}], usage_metadata={'input_tokens': 14260, 'output_tokens': 20, 'total_tokens': 14280, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'action'\n",
      "[ToolMessage(content='[Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'f864264c22b54c0197ad2b4f98d58535\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'Device Name: Reliant Stent Graft Balloon Catheter\\\\nIndications For Use:\\\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\\\nvessels, or to expand vascular prostheses.\\\\nPrescription Use _X_--- AND/OR Over-The-Counter Use\\\\n(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)\\\\n(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE\\\\nIF NEEDED)\\\\nConcurrence of CDRH, Office of Device Evaluation (ODE)\\\\nPage I oft_\\\\n(Division Sign-Off)\\\\nOlvislon of C~rdiovascuIar Devices\\\\n5 IOk) Numlber _ 603_\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'909bc42f183c4ff78454d00b9f815622\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'to proceed to the market.\\\\nIf you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please\\\\ncontact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled,\\\\n\"Misbranding by reference to premarket notification\" (21CFR Part 807.97). You may obtain\\\\nother general information on your responsibilities under the Act from the Division of Small\\\\nManufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 cr\\\\n(301) 443-6597 or at its Internet address http://www.fda wv/cdrh/ds ma/dsnmain.html\\\\nSincerely yours,\\\\nBrain D. Zuckerman, M.D.\\\\nDirector\\\\nDivision of Cardiovascular Devices\\\\nOffice of Device Evaluation\\\\nCenter for Devices and\\\\nRadiological Health\\\\nEnclosure\\\\n\\\\x0cIndications for Use\\\\n510(k) Number (if known): not yet assigned ( & )5 CC I 3\\\\nDevice Name: Reliant Stent Graft Balloon Catheter\\\\nIndications For Use:\\\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'9df95e0bf60944e9ab9bbf20e1476a5d\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'Regulation Number: 21 CFR 870.1250\\\\nRegulation Name: Percutaneous Catheter\\\\nRegulatory Class: Class 1L (Two)\\\\nProduct Code: DQY\\\\nDated: January 6, 2005\\\\nReceived: January 7, 2005\\\\nDear Mr. Mitchell:\\\\nWe have reviewed your Section 510(k) premarket notification of intent to market the device\\\\nreferenced above and have determined the device is substantially equivalent (for the indications\\\\nfor use stated in the enclosure) to legally marketed predicate devices marketed in interstate\\\\ncommerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to\\\\ndevices that have been reclassified in accordance with the provisions of the Federal Food, Drug,\\\\nand Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).\\\\nYou may, therefore, market the device, subject to the general controls provisions of the Act. The\\\\ngeneral controls provisions of the Act include requirements for annual registration, listing of\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'ea116e42f3ef47158e1c08bf2e5ff5dc\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'5 1 0(k) Pre-Market Notification APR 1 3 2005 lti\\\\nReliant Stent Graft Balloon Catheter\\\\nMedtronic, Inc.\\\\n5 10(k) Summary\\\\nSubmitter: Mcdtronic Vascular\\\\n3576 Unocal Place\\\\nSanta Rosa, CA 95403\\\\nUSA\\\\nContact Person: Willie Mitchell\\\\nAssociate Regulatory Affairs Specialist\\\\n(707) 591-2091\\\\n(707) 566-1432 - FAX\\\\nwillie.mitchell~medtronic.com\\\\nDate Prepared: January 6, 2005\\\\nTrade Name: Reliant Stent Graft Balloon Catheter\\\\nCommon Name: Balloon Catheter\\\\nClassification Percutaneous Catheter\\\\nName:\\\\nPredicate Devices: The CODA Balloon Catheter (K032869) manufactured by\\\\nCook Incorporated (vessel occlusion and expansion of\\\\nvascular prosthesis, product code DQY), and was cleared by\\\\nFDA on November 19, 2003.\\\\nThe Iliac Balloon Catheter (K003495) manufactured by\\\\nGuidant Corporation (prosthesis expansion, product code\\\\nDQY), and was cleared by FDA on February 7, 200 1.\\\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\\\nmanufactured by Cook Incorporated (vessel occlusion,\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'258d633b02474f99b65cf30feb5e51b7\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'DQY), and was cleared by FDA on February 7, 200 1.\\\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\\\nmanufactured by Cook Incorporated (vessel occlusion,\\\\nproduct code MJN), and was cleared by FDA on March 22,\\\\n2001.\\\\nSubstantial The Reliant Stent Graft Balloon Catheter is substantially\\\\nEquivalence: equivalent to the predicate devices listed above, as it is\\\\ncomparable with respect to their intended use, overall catheter\\\\nconfiguration, and performance characteristics.\\\\n\\\\x0cDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service\\\\nFood and Drug Administration\\\\n9200 Corporate Boulevard\\\\nA.PR 1 3 Z005 Rockville MD 20850\\\\nMedtronic Vascular\\\\nc/o Mr. Willie Mitchell\\\\nAssociate Regulatory Affairs Specialist\\\\n3576 Unocal Place\\\\nSanta Rosa, CA 95403\\\\nRe: K050038\\\\nReliant Stent Graft Balloon Catheter\\\\nRegulation Number: 21 CFR 870.1250\\\\nRegulation Name: Percutaneous Catheter\\\\nRegulatory Class: Class 1L (Two)\\\\nProduct Code: DQY\\\\nDated: January 6, 2005\\\\nReceived: January 7, 2005\\\\nDear Mr. Mitchell:\\')]', name='retrieve_predicate_device_details', id='f13a3ff2-3b47-4d32-acbd-1566ef6dfab7', tool_call_id='call_xym10oi5YpkvXxHmJM1Elbd6')]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='```json\\n{\\n  \"substantially_equivalent\": false,\\n  \"reasons\": [\\n    \"The new device is intended for non-invasive diagnosis of coronary artery disease in adult patients, specifically measuring fractional flow reserve.\",\\n    \"In contrast, the predicate device, the Reliant Stent Graft Balloon Catheter, is intended for temporary occlusion of large vessels or to expand vascular prostheses, which represents a different functional use.\",\\n    \"The intended uses are fundamentally different as they target separate diseases: coronary artery disease diagnostics versus vascular occlusion.\"\\n  ],\\n  \"citations\": [\\n    {\"tool\": \"fda_guidelines\", \"text\": \"Under section 513(i) of the FD&C Act, FDA may only determine that a device is substantially equivalent to a predicate device if it has the same intended use.\"},\\n    {\"tool\": \"fda_guidelines\", \"text\": \"Only a change in the indications for use that raises different questions of safety and effectiveness and therefore precludes a meaningful comparison with the predicate device constitutes a new intended use.\"},\\n    {\"tool\": \"predicate_device\", \"text\": \"The Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large vessels, or to expand vascular prostheses.\"}\\n  ],\\n  \"suggestions\": [\\n    \"Consider narrowing the indications for use to a specific population or sub-group within coronary artery disease.\",\\n    \"Seek FDA Pre-Submission to discuss the intended use and gather feedback on how to align it closer to the predicate device’s indications.\"\\n  ]\\n}\\n```', additional_kwargs={'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 317, 'prompt_tokens': 15839, 'total_tokens': 16156, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 14208}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzehdxBJQ5LED28FjEutMU32ngkn2', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': None}, id='run--08c8d047-a743-4ba3-9bb7-6c0d321aaf16-0', usage_metadata={'input_tokens': 15839, 'output_tokens': 317, 'total_tokens': 16156, 'input_token_details': {'audio': 0, 'cache_read': 14208}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "query = \"\"\"\n",
    "New Device — Indications for Use:\n",
    "\"For use in the non‑invasive diagnosis of coronary artery disease in adult patients through measurement of fractional flow reserve.\"\n",
    "\"\"\"\n",
    "\n",
    "input = create_initial_state(query)\n",
    "async for chunk in device_regulatory_agent.astream(input, stream_mode=\"updates\"):\n",
    "    for node, values in chunk.items():\n",
    "        print(f\"Receiving update from node: '{node}'\")\n",
    "        print(values[\"messages\"])\n",
    "        print(\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "64cd54d5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_5haoL2GDVfNDGywNncbNpNxt', 'function': {'arguments': '{\"query\": \"intended use definition and substantial equivalence factors\"}', 'name': 'retrieve_fda_guidelines'}, 'type': 'function'}, {'id': 'call_LbS0bBioqAIkBaVomU08PSmR', 'function': {'arguments': '{\"query\": \"criteria for evaluating intended use in 510(k) applications\"}', 'name': 'retrieve_fda_guidelines'}, 'type': 'function'}], 'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 68, 'prompt_tokens': 685, 'total_tokens': 753, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzeoYD9eMFEJjFmHAbYEAbDW8AnnL', 'service_tier': 'default', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run--12d301bf-490e-4e75-9a04-4672ce39b6b3-0', tool_calls=[{'name': 'retrieve_fda_guidelines', 'args': {'query': 'intended use definition and substantial equivalence factors'}, 'id': 'call_5haoL2GDVfNDGywNncbNpNxt', 'type': 'tool_call'}, {'name': 'retrieve_fda_guidelines', 'args': {'query': 'criteria for evaluating intended use in 510(k) applications'}, 'id': 'call_LbS0bBioqAIkBaVomU08PSmR', 'type': 'tool_call'}], usage_metadata={'input_tokens': 685, 'output_tokens': 68, 'total_tokens': 753, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'action'\n",
      "[ToolMessage(content='[Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 8, \\'page_label\\': \\'9\\', \\'_id\\': \\'2a4a910e794c4610b687b8af89a3f4d1\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'section 520(l), the term \"substantially equivalent\" or \"substantial equivalence\" means, with \\\\nrespect to a device being compared to a predicate device, that the device has the same \\\\nintended use as the predicate device and that the Secretary by order has found that the device\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 17, \\'page_label\\': \\'18\\', \\'_id\\': \\'2f9999c4bb764bb2a229e13c01f48acf\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'device is necessary and appropriate to support substantial equivalence.  Manufacturers should choose \\\\nthe most appropriate single or primary predicate for their new device, and should limit the multiple \\\\npredicates to those most helpful in facilitating review of the new device and to the minimum number \\\\nnecessary to support substantial equivalence.  Predicate device(s) relied upon for SE must be \\\\naccurately cited in the 510(k) Summary (see Appendix B) according to 21 CFR 807.92 (a)(3).  \\\\nReference devices also may be cited in the 510(k) Summary.   \\\\nD. Intended Use \\\\nUnder section 513(i) of the FD&C Act, FDA may only determine that a device is substantially \\\\nequivalent to a predicate device if it has the same intended use.20  (Refer to the 510(k) Decision-\\\\nMaking Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\\\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 9, \\'page_label\\': \\'10\\', \\'_id\\': \\'b87fc760c2874fcaa2b4b99e72d92f59\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'significant change in the materials, design, energy source, or other features of the device from \\\\nthose of the predicate device. \\\\nSafety and effectiveness factor into both parts of the FDA’s review.  First, FDA must find that the \\\\nintended use of the device and its predicate are “the same.”  As discussed in the Intended Use Section \\\\nof this guidance, differences in the indications for use, such as the population for which a device is \\\\nintended or the disease a device is intended to treat do not necessarily result in a new intended use.  \\\\nSuch differences result in a new intended use when they affect (or may affect) the safety and/or \\\\neffectiveness of the new device as compared to the predicate device and the differences cannot be \\\\nadequately evaluated under the comparative standard of substantial equivalence. (See Section IV.D.)  \\\\n \\\\nSecond, when comparing a new device to a predicate device, FDA must find that the two devices\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 19, \\'page_label\\': \\'20\\', \\'_id\\': \\'e9752ea42e9d4c13adfd13aeb7637a80\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'of a new intended use.  Only a change in the indications for use that raises different questions of \\\\nsafety and effectiveness and therefore, precludes a meaningful comparison with the predicate device \\\\nconstitutes a new intended use.  FDA may find changes in indications for use of a device to constitute \\\\na new intended use when the changes raise a safety or effectiveness issue that was not raised by the \\\\npredicate device, or the changes have the potential to significantly increase a safety or effectiveness \\\\nconcern raised by the predicate device.\\\\n24  In the first case, reliance on a predicate device is inadequate \\\\nbecause the safety or effectiveness issue was not considered in reviewing the 510(k) for the predicate \\\\ndevice.  In the second case, although the safety or effectiveness issue may have been considered in \\\\nthe 510(k) for the predicate device, the finding of substantial equivalence for the predicate device\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 17, \\'page_label\\': \\'18\\', \\'_id\\': \\'02cb04efe196455bb6b323a51d4ff95e\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'equivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2) \\\\nof the FD&C Act provides that a predicate device may not have been removed from the market at the initiative of the Commissioner of \\\\nFood and Drugs or been determined to be misbranded or adulterated by a judicial order.  See also 21 CFR 807.100. \\\\n \\\\n20 This guidance is not intended to supplant either of the following guidance documents:  “Determination of Intended Use for 510(k) \\\\nDevices; Guidance for CDRH Staff (Update to K98-1)” \\\\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082162.htm) or “General/Specific \\\\nIntended Use” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm). \\\\n \\\\n21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”\\')]', name='retrieve_fda_guidelines', id='e1a53ad6-e4cd-4786-9bf9-8ff5148a9f66', tool_call_id='call_5haoL2GDVfNDGywNncbNpNxt'), ToolMessage(content=\"[Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19', '_id': 'bdc43359228a4dfdb01376fb5e1aacaa', '_collection_name': 'guidelines'}, page_content='intended.\\\\n22  The intended use of a device is one criterion that determines whether a device can be \\\\ncleared for marketing through the 510(k) process or must be evaluated in a PMA (or alternative \\\\nsubmission type), or if appropriate, a De Novo request.  The proposed labeling in a 510(k) is used to \\\\ndetermine a device’s intended use (Section 513(i)(1)(E) of the FD&C Act).  The indications for use \\\\nstatement in a 510(k) is also a factor in determining a device’s intended use.  Consistency between \\\\nthe indications for use statement and the proposed labeling will facilitate the review of the 510(k). \\\\n \\\\n                                                 \\\\n22 We have a long-standing policy of applying the definition of indications for use in the PMA regulation at 21 CFR 814.20(b)(3)(i) in \\\\nthe same way in the 510(k) context. \\\\n \\\\n23 For purposes of Section IV.D, the term “new” in describing indications for use refers to an indication that is new or differs from that \\\\nof the predicate device.'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 7, 'page_label': '8', '_id': 'd3ca7fb9184245228d17341c7b68a6fc', '_collection_name': 'guidelines'}, page_content='has a new intended use (See Section IV.D); \\\\n\\\\uf0b7 the process for determining whether different technological characteristics raise different \\\\nquestions of safety and effectiveness (See Section IV.E); \\\\n\\\\uf0b7 when performance data, with special emphasis on clinical performance data, may be \\\\nnecessary to support an SE determination (See Section IV.F); and  \\\\n\\\\uf0b7 how to develop 510(k) Summaries to promote greater transparency in the 510(k) decision-\\\\nmaking process (See Section IV.G).   \\\\n \\\\nThe overarching principles in this guidance are applicable to devices that are subject to 510(k) review \\\\nby CDRH, including the Office of Device Evaluation (ODE) and the Office of In Vitro Diagnostics \\\\nand Radiological Health (OIR), as well as devices that are subject to 510(k) review by the Center for \\\\nBiologics Evaluation and Research (CBER).  This guidance is not intended to supplant existing \\\\ndevice-specific guidance, but may cover broader areas not addressed in device-specific guidance'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 20, 'page_label': '21', '_id': 'bc27bbf289254d768803b99b62dd391d', '_collection_name': 'guidelines'}, page_content='indications for use result in a new intended use because they are more likely to significantly affect \\\\nsafety or effectiveness: \\\\n \\\\n\\\\uf0b7 a change from a functional/performance indication to a treatment or aesthetic indication; \\\\n \\\\n\\\\uf0b7 a change from a diagnostic indication to a screening indication, or vice versa; \\\\n \\\\n\\\\uf0b7 a change in the anatomical structure of use; \\\\n \\\\n\\\\uf0b7 a change in the patient population (e.g., adult versus pediatric; different disease populations);  \\\\n \\\\n\\\\uf0b7 a change in the clinical context or setting (e.g., periodic monitoring versus continuous \\\\nmonitoring; hospital versus home use). \\\\nE. Technological Characteristics \\\\nAfter FDA has determined that a valid predicate device exists for a new device and that both devices \\\\nhave the same intended use, FDA will move to Decision Points 3 and 4 of the Flowchart (see \\\\nAppendix A).  In these steps of the 510(k) review process, FDA compares the technological'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 18, 'page_label': '19', '_id': 'b6778182e86e4ad0aa63061d54970a82', '_collection_name': 'guidelines'}, page_content='Contains Nonbinding Recommendations \\\\n \\\\n 16 \\\\nnew intended use.  This section of the guidance provides further clarification about the terms \\\\n“intended use” and “indications for use,” describes how FDA determines what the intended use of a \\\\ndevice is, and provides examples of changes in indications for use that may constitute a new intended \\\\nuse making the device ineligible for review under the 510(k) program.     \\\\n1. Explanation of Intended Use and Indications for Use \\\\nFor purposes of substantial equivalence, the term intended use means the general purpose of the \\\\ndevice or its function, and encompasses the indications for use.  The term indications for use, as \\\\ndefined in 21 CFR 814.20(b)(3)(i), describes the disease or condition the device will diagnose, treat, \\\\nprevent, cure or mitigate, including a description of the patient population for which the device is \\\\nintended.\\\\n22  The intended use of a device is one criterion that determines whether a device can be'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 31, 'page_label': '32', '_id': 'ad0fde3117714e9298fff69673b0cd20', '_collection_name': 'guidelines'}, page_content='description, where appropriate, of the patient population for which the device is intended. If \\\\nthe indication statements are different from those of the legally marketed device identified in \\\\nparagraph (a)(3) of this section, the 510(k) summary shall contain an explanation as to why \\\\nthe differences are not critical to the intended therapeutic, diagnostic, prosthetic, or surgical \\\\nuse of the device, and why the differences do not affect the safety and effectiveness of the \\\\ndevice when used as labeled.”')]\", name='retrieve_fda_guidelines', id='efd26c44-d5c1-4897-b3af-42cfb261c9db', tool_call_id='call_LbS0bBioqAIkBaVomU08PSmR')]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_UBu1GPdMj0790GnA1if9mZMs', 'function': {'arguments': '{\"query\":\"Indications for Use\"}', 'name': 'retrieve_predicate_device_details'}, 'type': 'function'}], 'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 20, 'prompt_tokens': 14157, 'total_tokens': 14177, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzeobIfqjAD9yIH5z2VyyHs2VCLo5', 'service_tier': 'default', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run--8c5bb4aa-c3bb-4f72-9303-45ae998e8ab2-0', tool_calls=[{'name': 'retrieve_predicate_device_details', 'args': {'query': 'Indications for Use'}, 'id': 'call_UBu1GPdMj0790GnA1if9mZMs', 'type': 'tool_call'}], usage_metadata={'input_tokens': 14157, 'output_tokens': 20, 'total_tokens': 14177, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'action'\n",
      "[ToolMessage(content='[Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'f864264c22b54c0197ad2b4f98d58535\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'Device Name: Reliant Stent Graft Balloon Catheter\\\\nIndications For Use:\\\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\\\nvessels, or to expand vascular prostheses.\\\\nPrescription Use _X_--- AND/OR Over-The-Counter Use\\\\n(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)\\\\n(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE\\\\nIF NEEDED)\\\\nConcurrence of CDRH, Office of Device Evaluation (ODE)\\\\nPage I oft_\\\\n(Division Sign-Off)\\\\nOlvislon of C~rdiovascuIar Devices\\\\n5 IOk) Numlber _ 603_\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'909bc42f183c4ff78454d00b9f815622\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'to proceed to the market.\\\\nIf you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please\\\\ncontact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled,\\\\n\"Misbranding by reference to premarket notification\" (21CFR Part 807.97). You may obtain\\\\nother general information on your responsibilities under the Act from the Division of Small\\\\nManufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 cr\\\\n(301) 443-6597 or at its Internet address http://www.fda wv/cdrh/ds ma/dsnmain.html\\\\nSincerely yours,\\\\nBrain D. Zuckerman, M.D.\\\\nDirector\\\\nDivision of Cardiovascular Devices\\\\nOffice of Device Evaluation\\\\nCenter for Devices and\\\\nRadiological Health\\\\nEnclosure\\\\n\\\\x0cIndications for Use\\\\n510(k) Number (if known): not yet assigned ( & )5 CC I 3\\\\nDevice Name: Reliant Stent Graft Balloon Catheter\\\\nIndications For Use:\\\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'9df95e0bf60944e9ab9bbf20e1476a5d\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'Regulation Number: 21 CFR 870.1250\\\\nRegulation Name: Percutaneous Catheter\\\\nRegulatory Class: Class 1L (Two)\\\\nProduct Code: DQY\\\\nDated: January 6, 2005\\\\nReceived: January 7, 2005\\\\nDear Mr. Mitchell:\\\\nWe have reviewed your Section 510(k) premarket notification of intent to market the device\\\\nreferenced above and have determined the device is substantially equivalent (for the indications\\\\nfor use stated in the enclosure) to legally marketed predicate devices marketed in interstate\\\\ncommerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to\\\\ndevices that have been reclassified in accordance with the provisions of the Federal Food, Drug,\\\\nand Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).\\\\nYou may, therefore, market the device, subject to the general controls provisions of the Act. The\\\\ngeneral controls provisions of the Act include requirements for annual registration, listing of\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'ea116e42f3ef47158e1c08bf2e5ff5dc\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'5 1 0(k) Pre-Market Notification APR 1 3 2005 lti\\\\nReliant Stent Graft Balloon Catheter\\\\nMedtronic, Inc.\\\\n5 10(k) Summary\\\\nSubmitter: Mcdtronic Vascular\\\\n3576 Unocal Place\\\\nSanta Rosa, CA 95403\\\\nUSA\\\\nContact Person: Willie Mitchell\\\\nAssociate Regulatory Affairs Specialist\\\\n(707) 591-2091\\\\n(707) 566-1432 - FAX\\\\nwillie.mitchell~medtronic.com\\\\nDate Prepared: January 6, 2005\\\\nTrade Name: Reliant Stent Graft Balloon Catheter\\\\nCommon Name: Balloon Catheter\\\\nClassification Percutaneous Catheter\\\\nName:\\\\nPredicate Devices: The CODA Balloon Catheter (K032869) manufactured by\\\\nCook Incorporated (vessel occlusion and expansion of\\\\nvascular prosthesis, product code DQY), and was cleared by\\\\nFDA on November 19, 2003.\\\\nThe Iliac Balloon Catheter (K003495) manufactured by\\\\nGuidant Corporation (prosthesis expansion, product code\\\\nDQY), and was cleared by FDA on February 7, 200 1.\\\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\\\nmanufactured by Cook Incorporated (vessel occlusion,\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'258d633b02474f99b65cf30feb5e51b7\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'DQY), and was cleared by FDA on February 7, 200 1.\\\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\\\nmanufactured by Cook Incorporated (vessel occlusion,\\\\nproduct code MJN), and was cleared by FDA on March 22,\\\\n2001.\\\\nSubstantial The Reliant Stent Graft Balloon Catheter is substantially\\\\nEquivalence: equivalent to the predicate devices listed above, as it is\\\\ncomparable with respect to their intended use, overall catheter\\\\nconfiguration, and performance characteristics.\\\\n\\\\x0cDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service\\\\nFood and Drug Administration\\\\n9200 Corporate Boulevard\\\\nA.PR 1 3 Z005 Rockville MD 20850\\\\nMedtronic Vascular\\\\nc/o Mr. Willie Mitchell\\\\nAssociate Regulatory Affairs Specialist\\\\n3576 Unocal Place\\\\nSanta Rosa, CA 95403\\\\nRe: K050038\\\\nReliant Stent Graft Balloon Catheter\\\\nRegulation Number: 21 CFR 870.1250\\\\nRegulation Name: Percutaneous Catheter\\\\nRegulatory Class: Class 1L (Two)\\\\nProduct Code: DQY\\\\nDated: January 6, 2005\\\\nReceived: January 7, 2005\\\\nDear Mr. Mitchell:\\')]', name='retrieve_predicate_device_details', id='e4f933ad-46d3-4238-bac3-c4082d815681', tool_call_id='call_UBu1GPdMj0790GnA1if9mZMs')]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='```json\\n{\\n  \"substantially_equivalent\": true,\\n  \"reasons\": [\\n    \"Both the new device and the predicate device are indicated for temporary occlusion of large vessels.\",\\n    \"The function of both devices includes the expansion of vascular prostheses.\",\\n    \"The intended use aligns with the definitions outlined in FDA\\'s guidance that stipulate the same intended use is necessary for substantial equivalence.\"\\n  ],\\n  \"citations\": [\\n    {\"tool\": \"fda_guidelines\", \"text\": \"Under section 513(i) of the FD&C Act, FDA may only determine that a device is substantially equivalent to a predicate device if it has the same intended use.\"},\\n    {\"tool\": \"fda_guidelines\", \"text\": \"For purposes of substantial equivalence, the term intended use means the general purpose of the device or its function, and encompasses the indications for use.\"},\\n    {\"tool\": \"predicate_device\", \"text\": \"The Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large vessels, or to expand vascular prostheses.\"}\\n  ],\\n  \"suggestions\": []\\n}\\n```', additional_kwargs={'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 235, 'prompt_tokens': 15736, 'total_tokens': 15971, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 14080}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzeocDloUjGqjDjPCHC3yZDdEm5TY', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': None}, id='run--53a849c2-4d17-41bc-8db9-cebb262c1074-0', usage_metadata={'input_tokens': 15736, 'output_tokens': 235, 'total_tokens': 15971, 'input_token_details': {'audio': 0, 'cache_read': 14080}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "query = \"\"\"\n",
    "ndicated for temporary occlusion of the thoracic or abdominal aorta or iliac vessels and expansion of stent graft prostheses.\n",
    "\"\"\"\n",
    "\n",
    "input = create_initial_state(query)\n",
    "async for chunk in device_regulatory_agent.astream(input, stream_mode=\"updates\"):\n",
    "    for node, values in chunk.items():\n",
    "        print(f\"Receiving update from node: '{node}'\")\n",
    "        print(values[\"messages\"])\n",
    "        print(\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "a8adf550",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_qYBqzbdFgJHoodM3eKLlSFpk', 'function': {'arguments': '{\"query\": \"intended use definitions and criteria for evaluating substantial equivalence\"}', 'name': 'retrieve_fda_guidelines'}, 'type': 'function'}, {'id': 'call_MANISB7u7tm2DadEg8QNT9s0', 'function': {'arguments': '{\"query\": \"factors for assessing intended use equivalence\"}', 'name': 'retrieve_fda_guidelines'}, 'type': 'function'}], 'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 67, 'prompt_tokens': 672, 'total_tokens': 739, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzeqAT07MB6PjFN7zO0ZviayvgYHs', 'service_tier': 'default', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run--590a448b-df75-4da5-9a25-bb34e7ad055e-0', tool_calls=[{'name': 'retrieve_fda_guidelines', 'args': {'query': 'intended use definitions and criteria for evaluating substantial equivalence'}, 'id': 'call_qYBqzbdFgJHoodM3eKLlSFpk', 'type': 'tool_call'}, {'name': 'retrieve_fda_guidelines', 'args': {'query': 'factors for assessing intended use equivalence'}, 'id': 'call_MANISB7u7tm2DadEg8QNT9s0', 'type': 'tool_call'}], usage_metadata={'input_tokens': 672, 'output_tokens': 67, 'total_tokens': 739, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'action'\n",
      "[ToolMessage(content='[Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 8, \\'page_label\\': \\'9\\', \\'_id\\': \\'2a4a910e794c4610b687b8af89a3f4d1\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'section 520(l), the term \"substantially equivalent\" or \"substantial equivalence\" means, with \\\\nrespect to a device being compared to a predicate device, that the device has the same \\\\nintended use as the predicate device and that the Secretary by order has found that the device\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 17, \\'page_label\\': \\'18\\', \\'_id\\': \\'2f9999c4bb764bb2a229e13c01f48acf\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'device is necessary and appropriate to support substantial equivalence.  Manufacturers should choose \\\\nthe most appropriate single or primary predicate for their new device, and should limit the multiple \\\\npredicates to those most helpful in facilitating review of the new device and to the minimum number \\\\nnecessary to support substantial equivalence.  Predicate device(s) relied upon for SE must be \\\\naccurately cited in the 510(k) Summary (see Appendix B) according to 21 CFR 807.92 (a)(3).  \\\\nReference devices also may be cited in the 510(k) Summary.   \\\\nD. Intended Use \\\\nUnder section 513(i) of the FD&C Act, FDA may only determine that a device is substantially \\\\nequivalent to a predicate device if it has the same intended use.20  (Refer to the 510(k) Decision-\\\\nMaking Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\\\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 7, \\'page_label\\': \\'8\\', \\'_id\\': \\'0d6fbb081c754f488060cb4a8c0b2080\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'The most commonly used method of demonstrating substantial equivalence is through the submission \\\\nand FDA review and clearance of a Traditional 510(k).  Under 21 CFR 807.87, FDA established \\\\nbasic content requirements for 510(k)s to be submitted by device manufacturers in support of \\\\nsubstantial equivalence.  The Agency has provided a general framework on how to format an original \\\\nsubmission for a Traditional 510(k) in FDA’s Guidance for Industry and FDA Staff, “Format for\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 32, \\'page_label\\': \\'33\\', \\'_id\\': \\'76f18f08b9004cfeaebefadced101659\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'o A high level summary of the tests that were used to demonstrate substantial \\\\nequivalence should be included (e.g., fatigue testing, biocompatibility, etc.). \\\\no If a guidance document was referenced/used for the testing, the guidance document \\\\nshould be referenced in this section. \\\\no If an FDA recognized consensus standard (e.g., test method or guide) was used/relied \\\\nupon for testing, please list the standard connotation (e.g., ASTM FXXXX-last 2 \\\\nnumbers of the year). \\\\n \\\\n“(2) A brief discussion of the clinical tests submitted, referenced, or relied on in the premarket \\\\nnotification submission for a determination of substantial equivalence. This discussion shall \\\\ninclude, where applicable, a description of the subjects upon whom the device was tested, a \\\\ndiscussion of the safety or effectiveness data obtained from the testing, with specific reference \\\\nto adverse effects and complications, and any other information from the clinical testing\\'), Document(metadata={\\'producer\\': \\'Microsoft® Word 2010\\', \\'creator\\': \\'Microsoft® Word 2010\\', \\'creationdate\\': \\'2014-07-15T14:07:40-04:00\\', \\'author\\': \\'Loretta E Chi\\', \\'moddate\\': \\'2014-07-25T09:52:22-04:00\\', \\'nccl_054-77087048086\\': \\'NCCL-20071082023\\', \\'nccl_054-77087048087\\': \\'NCCL-69061003033\\', \\'nccl_054-77087048088\\': \\'NCCL008001-73068\\', \\'nccl_054-77087048089\\': \\'NCCL-106108-32097\\', \\'nccl_054-77087048090\\': \\'NCCL039029-65-121\\', \\'nccl_054-77087048091\\': \\'NCCL093-56013037\\', \\'nccl_054-77087048091014\\': \\'NCCL-14110020126\\', \\'nccl_054-77087048091015\\': \\'NCCL114071059-51\\', \\'nccl_054-77087048092\\': \\'NCCL-43-12-21087\\', \\'nccl_054-77087048092006\\': \\'NCCL083084036-120\\', \\'nccl_054-77087048092007\\': \\'NCCL-99045-48-33\\', \\'nccl_054-77087048092008\\': \\'NCCL-108-110124-47\\', \\'nccl_054-77087048092009\\': \\'NCCL056017-96008\\', \\'nccl_054-77087048092010\\': \\'NCCL-04-123-74-89\\', \\'nccl_054-77087048092011\\': \\'NCCL020-31092121\\', \\'nccl_054-77087048092012\\': \\'NCCL-115008-108-40\\', \\'nccl_054-77087048092013\\': \\'NCCL118091057103\\', \\'nccl_054-77087048092014\\': \\'NCCL-60-89107-51\\', \\'nccl_054-77087048092015\\': \\'NCCL-122-27051-80\\', \\'nccl_054-77087048093\\': \\'NCCL015005041-127\\', \\'nccl_054-77087048093006\\': \\'NCCL-94062079117\\', \\'nccl_054-77087048093007\\': \\'NCCL110021-118-75\\', \\'nccl_054-77087048093008\\': \\'NCCL113-104052-84\\', \\'nccl_054-77087048093009\\': \\'NCCL012113-85-01\\', \\'nccl_054-77087048093010\\': \\'NCCL005027-95-42\\', \\'nccl_054-77087048093011\\': \\'NCCL-03-97094-120\\', \\'nccl_054-77087048093012\\': \\'NCCL-26-44-109077\\', \\'nccl_054-77087048093013\\': \\'NCCL-47009054019\\', \\'nccl_054-77087048093014\\': \\'NCCL-71115-43123\\', \\'nccl_054-77087048093015\\': \\'NCCL-89007-23-116\\', \\'nccl_054-77087048094\\': \\'NCCL-51058-106-105\\', \\'nccl_054-77087048094006\\': \\'NCCL083116-93084\\', \\'nccl_054-77087048094007\\': \\'NCCL020069111048\\', \\'nccl_054-77087048094008\\': \\'NCCL-67051089-31\\', \\'nccl_054-77087048094009\\': \\'NCCL-119-76-81014\\', \\'nccl_054-77087048094010\\': \\'NCCL118-111-74077\\', \\'nccl_054-77087048094011\\': \\'NCCL112032062065\\', \\'nccl_054-77087048094012\\': \\'NCCL065078-77-02\\', \\'nccl_054-77087048094013\\': \\'NCCL062-03119043\\', \\'nccl_054-77087048094014\\': \\'NCCL-74086107057\\', \\'nccl_054-77087048094015\\': \\'NCCL-72-51-68112\\', \\'nccl_054-77087048095\\': \\'NCCL043-50-102-39\\', \\'nccl_docid\\': \\'19921\\', \\'title\\': \\'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\\', \\'source\\': \\'./data/510K - Evaluating Substantial Equivalence.pdf\\', \\'total_pages\\': 42, \\'page\\': 17, \\'page_label\\': \\'18\\', \\'_id\\': \\'02cb04efe196455bb6b323a51d4ff95e\\', \\'_collection_name\\': \\'guidelines\\'}, page_content=\\'equivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2) \\\\nof the FD&C Act provides that a predicate device may not have been removed from the market at the initiative of the Commissioner of \\\\nFood and Drugs or been determined to be misbranded or adulterated by a judicial order.  See also 21 CFR 807.100. \\\\n \\\\n20 This guidance is not intended to supplant either of the following guidance documents:  “Determination of Intended Use for 510(k) \\\\nDevices; Guidance for CDRH Staff (Update to K98-1)” \\\\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082162.htm) or “General/Specific \\\\nIntended Use” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm). \\\\n \\\\n21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”\\')]', name='retrieve_fda_guidelines', id='7568639d-f2ef-42e9-8860-3e06c6678755', tool_call_id='call_qYBqzbdFgJHoodM3eKLlSFpk'), ToolMessage(content=\"[Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 9, 'page_label': '10', '_id': 'b87fc760c2874fcaa2b4b99e72d92f59', '_collection_name': 'guidelines'}, page_content='significant change in the materials, design, energy source, or other features of the device from \\\\nthose of the predicate device. \\\\nSafety and effectiveness factor into both parts of the FDA’s review.  First, FDA must find that the \\\\nintended use of the device and its predicate are “the same.”  As discussed in the Intended Use Section \\\\nof this guidance, differences in the indications for use, such as the population for which a device is \\\\nintended or the disease a device is intended to treat do not necessarily result in a new intended use.  \\\\nSuch differences result in a new intended use when they affect (or may affect) the safety and/or \\\\neffectiveness of the new device as compared to the predicate device and the differences cannot be \\\\nadequately evaluated under the comparative standard of substantial equivalence. (See Section IV.D.)  \\\\n \\\\nSecond, when comparing a new device to a predicate device, FDA must find that the two devices'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 29, 'page_label': '30', '_id': '615f39dfbf0249e2baf89724c274d8fc', '_collection_name': 'guidelines'}, page_content='on safety and effectiveness.\\\\nDecision 5a\\\\nAre the methods \\\\nacceptable?\\\\nNSE NO\\\\nYES\\\\nEvaluate performance data.\\\\nDecision 5b\\\\nDo the data \\\\ndemonstrate substantial \\\\nequivalence?\\\\nNSE\\\\nSE\\\\nYES\\\\nSE = “Substantially Equivalent”\\\\nNSE = “Not Substantially Equivalent”\\\\nIFU = “Indications For Use”\\\\nThis Flowchart is not intended to be used as a ‘stand-alone’ document and should only be considered in conjunction with the accompanying text in \\\\nthis guidance.\\\\n Refer to Section IV.D. \\\\n(Intended Use) and\\\\n21 CFR 807.100(b)(1).  \\\\nRefer to Section IV.C. \\\\n(Predicate Devices) and \\\\n21 CFR 807.100(b)(3).\\\\nRefer to Section IV.E. \\\\n(Technological \\\\nCharacteristics) and 21 \\\\nCFR 807.100(b)(2)(i) and \\\\n(ii)(A). \\\\nNO\\\\nRefer to Section IV. \\\\nF (Requests for \\\\nPerformance Data) \\\\nand\\\\n21 CFR \\\\n807.100(b)(2)(ii)(B).\\\\nRefer to Section IV. \\\\nF (Requests for \\\\nPerformance Data) \\\\nand 21 CFR\\\\n807.100(b)(2)(ii)(B). \\\\nRefer to Sections \\\\nIV.E. (Technological \\\\nCharacteristics) and \\\\nIV.F. (Requests for \\\\nPerformance Data) \\\\nand\\\\n21 CFR'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 19, 'page_label': '20', '_id': 'e9752ea42e9d4c13adfd13aeb7637a80', '_collection_name': 'guidelines'}, page_content='of a new intended use.  Only a change in the indications for use that raises different questions of \\\\nsafety and effectiveness and therefore, precludes a meaningful comparison with the predicate device \\\\nconstitutes a new intended use.  FDA may find changes in indications for use of a device to constitute \\\\na new intended use when the changes raise a safety or effectiveness issue that was not raised by the \\\\npredicate device, or the changes have the potential to significantly increase a safety or effectiveness \\\\nconcern raised by the predicate device.\\\\n24  In the first case, reliance on a predicate device is inadequate \\\\nbecause the safety or effectiveness issue was not considered in reviewing the 510(k) for the predicate \\\\ndevice.  In the second case, although the safety or effectiveness issue may have been considered in \\\\nthe 510(k) for the predicate device, the finding of substantial equivalence for the predicate device'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18', '_id': '02cb04efe196455bb6b323a51d4ff95e', '_collection_name': 'guidelines'}, page_content='equivalence is claimed, any legally marketed Class II or Class I device may be used as a predicate device.  However, section 513(i)(2) \\\\nof the FD&C Act provides that a predicate device may not have been removed from the market at the initiative of the Commissioner of \\\\nFood and Drugs or been determined to be misbranded or adulterated by a judicial order.  See also 21 CFR 807.100. \\\\n \\\\n20 This guidance is not intended to supplant either of the following guidance documents:  “Determination of Intended Use for 510(k) \\\\nDevices; Guidance for CDRH Staff (Update to K98-1)” \\\\n(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082162.htm) or “General/Specific \\\\nIntended Use” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073944.htm). \\\\n \\\\n21 Refer to “Initial Results of 510(k) Audit: Analysis of Not Substantially Equivalent (NSE) Determinations”'), Document(metadata={'producer': 'Microsoft® Word 2010', 'creator': 'Microsoft® Word 2010', 'creationdate': '2014-07-15T14:07:40-04:00', 'author': 'Loretta E Chi', 'moddate': '2014-07-25T09:52:22-04:00', 'nccl_054-77087048086': 'NCCL-20071082023', 'nccl_054-77087048087': 'NCCL-69061003033', 'nccl_054-77087048088': 'NCCL008001-73068', 'nccl_054-77087048089': 'NCCL-106108-32097', 'nccl_054-77087048090': 'NCCL039029-65-121', 'nccl_054-77087048091': 'NCCL093-56013037', 'nccl_054-77087048091014': 'NCCL-14110020126', 'nccl_054-77087048091015': 'NCCL114071059-51', 'nccl_054-77087048092': 'NCCL-43-12-21087', 'nccl_054-77087048092006': 'NCCL083084036-120', 'nccl_054-77087048092007': 'NCCL-99045-48-33', 'nccl_054-77087048092008': 'NCCL-108-110124-47', 'nccl_054-77087048092009': 'NCCL056017-96008', 'nccl_054-77087048092010': 'NCCL-04-123-74-89', 'nccl_054-77087048092011': 'NCCL020-31092121', 'nccl_054-77087048092012': 'NCCL-115008-108-40', 'nccl_054-77087048092013': 'NCCL118091057103', 'nccl_054-77087048092014': 'NCCL-60-89107-51', 'nccl_054-77087048092015': 'NCCL-122-27051-80', 'nccl_054-77087048093': 'NCCL015005041-127', 'nccl_054-77087048093006': 'NCCL-94062079117', 'nccl_054-77087048093007': 'NCCL110021-118-75', 'nccl_054-77087048093008': 'NCCL113-104052-84', 'nccl_054-77087048093009': 'NCCL012113-85-01', 'nccl_054-77087048093010': 'NCCL005027-95-42', 'nccl_054-77087048093011': 'NCCL-03-97094-120', 'nccl_054-77087048093012': 'NCCL-26-44-109077', 'nccl_054-77087048093013': 'NCCL-47009054019', 'nccl_054-77087048093014': 'NCCL-71115-43123', 'nccl_054-77087048093015': 'NCCL-89007-23-116', 'nccl_054-77087048094': 'NCCL-51058-106-105', 'nccl_054-77087048094006': 'NCCL083116-93084', 'nccl_054-77087048094007': 'NCCL020069111048', 'nccl_054-77087048094008': 'NCCL-67051089-31', 'nccl_054-77087048094009': 'NCCL-119-76-81014', 'nccl_054-77087048094010': 'NCCL118-111-74077', 'nccl_054-77087048094011': 'NCCL112032062065', 'nccl_054-77087048094012': 'NCCL065078-77-02', 'nccl_054-77087048094013': 'NCCL062-03119043', 'nccl_054-77087048094014': 'NCCL-74086107057', 'nccl_054-77087048094015': 'NCCL-72-51-68112', 'nccl_054-77087048095': 'NCCL043-50-102-39', 'nccl_docid': '19921', 'title': 'The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]', 'source': './data/510K - Evaluating Substantial Equivalence.pdf', 'total_pages': 42, 'page': 17, 'page_label': '18', '_id': '2f9999c4bb764bb2a229e13c01f48acf', '_collection_name': 'guidelines'}, page_content='device is necessary and appropriate to support substantial equivalence.  Manufacturers should choose \\\\nthe most appropriate single or primary predicate for their new device, and should limit the multiple \\\\npredicates to those most helpful in facilitating review of the new device and to the minimum number \\\\nnecessary to support substantial equivalence.  Predicate device(s) relied upon for SE must be \\\\naccurately cited in the 510(k) Summary (see Appendix B) according to 21 CFR 807.92 (a)(3).  \\\\nReference devices also may be cited in the 510(k) Summary.   \\\\nD. Intended Use \\\\nUnder section 513(i) of the FD&C Act, FDA may only determine that a device is substantially \\\\nequivalent to a predicate device if it has the same intended use.20  (Refer to the 510(k) Decision-\\\\nMaking Flowchart in Appendix A).  A finding of NSE due to a new intended use is relatively rare.  \\\\nApproximately 10% of all NSE decisions are due to a new intended use.21  This type of NSE')]\", name='retrieve_fda_guidelines', id='2c4632a7-08d2-4a0d-832f-ceb93e739dd2', tool_call_id='call_MANISB7u7tm2DadEg8QNT9s0')]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_PCU9OTQVLnU1jrsilNWlSswM', 'function': {'arguments': '{\"query\":\"Indications for Use\"}', 'name': 'retrieve_predicate_device_details'}, 'type': 'function'}], 'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 20, 'prompt_tokens': 14263, 'total_tokens': 14283, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzeqC5kXEtYBTfrlay7cLHVYOLvsb', 'service_tier': 'default', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run--d9f54249-2fbc-421b-a907-74e222c5d8e3-0', tool_calls=[{'name': 'retrieve_predicate_device_details', 'args': {'query': 'Indications for Use'}, 'id': 'call_PCU9OTQVLnU1jrsilNWlSswM', 'type': 'tool_call'}], usage_metadata={'input_tokens': 14263, 'output_tokens': 20, 'total_tokens': 14283, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'action'\n",
      "[ToolMessage(content='[Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'f864264c22b54c0197ad2b4f98d58535\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'Device Name: Reliant Stent Graft Balloon Catheter\\\\nIndications For Use:\\\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\\\nvessels, or to expand vascular prostheses.\\\\nPrescription Use _X_--- AND/OR Over-The-Counter Use\\\\n(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)\\\\n(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE\\\\nIF NEEDED)\\\\nConcurrence of CDRH, Office of Device Evaluation (ODE)\\\\nPage I oft_\\\\n(Division Sign-Off)\\\\nOlvislon of C~rdiovascuIar Devices\\\\n5 IOk) Numlber _ 603_\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'909bc42f183c4ff78454d00b9f815622\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'to proceed to the market.\\\\nIf you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please\\\\ncontact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled,\\\\n\"Misbranding by reference to premarket notification\" (21CFR Part 807.97). You may obtain\\\\nother general information on your responsibilities under the Act from the Division of Small\\\\nManufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 cr\\\\n(301) 443-6597 or at its Internet address http://www.fda wv/cdrh/ds ma/dsnmain.html\\\\nSincerely yours,\\\\nBrain D. Zuckerman, M.D.\\\\nDirector\\\\nDivision of Cardiovascular Devices\\\\nOffice of Device Evaluation\\\\nCenter for Devices and\\\\nRadiological Health\\\\nEnclosure\\\\n\\\\x0cIndications for Use\\\\n510(k) Number (if known): not yet assigned ( & )5 CC I 3\\\\nDevice Name: Reliant Stent Graft Balloon Catheter\\\\nIndications For Use:\\\\nThe Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'9df95e0bf60944e9ab9bbf20e1476a5d\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'Regulation Number: 21 CFR 870.1250\\\\nRegulation Name: Percutaneous Catheter\\\\nRegulatory Class: Class 1L (Two)\\\\nProduct Code: DQY\\\\nDated: January 6, 2005\\\\nReceived: January 7, 2005\\\\nDear Mr. Mitchell:\\\\nWe have reviewed your Section 510(k) premarket notification of intent to market the device\\\\nreferenced above and have determined the device is substantially equivalent (for the indications\\\\nfor use stated in the enclosure) to legally marketed predicate devices marketed in interstate\\\\ncommerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to\\\\ndevices that have been reclassified in accordance with the provisions of the Federal Food, Drug,\\\\nand Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).\\\\nYou may, therefore, market the device, subject to the general controls provisions of the Act. The\\\\ngeneral controls provisions of the Act include requirements for annual registration, listing of\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'ea116e42f3ef47158e1c08bf2e5ff5dc\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'5 1 0(k) Pre-Market Notification APR 1 3 2005 lti\\\\nReliant Stent Graft Balloon Catheter\\\\nMedtronic, Inc.\\\\n5 10(k) Summary\\\\nSubmitter: Mcdtronic Vascular\\\\n3576 Unocal Place\\\\nSanta Rosa, CA 95403\\\\nUSA\\\\nContact Person: Willie Mitchell\\\\nAssociate Regulatory Affairs Specialist\\\\n(707) 591-2091\\\\n(707) 566-1432 - FAX\\\\nwillie.mitchell~medtronic.com\\\\nDate Prepared: January 6, 2005\\\\nTrade Name: Reliant Stent Graft Balloon Catheter\\\\nCommon Name: Balloon Catheter\\\\nClassification Percutaneous Catheter\\\\nName:\\\\nPredicate Devices: The CODA Balloon Catheter (K032869) manufactured by\\\\nCook Incorporated (vessel occlusion and expansion of\\\\nvascular prosthesis, product code DQY), and was cleared by\\\\nFDA on November 19, 2003.\\\\nThe Iliac Balloon Catheter (K003495) manufactured by\\\\nGuidant Corporation (prosthesis expansion, product code\\\\nDQY), and was cleared by FDA on February 7, 200 1.\\\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\\\nmanufactured by Cook Incorporated (vessel occlusion,\\'), Document(metadata={\\'producer\\': \\'\\', \\'creator\\': \\'\\', \\'creationdate\\': \\'\\', \\'source\\': \\'./data/510K_1.pdf\\', \\'total_pages\\': 4, \\'_id\\': \\'258d633b02474f99b65cf30feb5e51b7\\', \\'_collection_name\\': \\'predicate_device_501K\\'}, page_content=\\'DQY), and was cleared by FDA on February 7, 200 1.\\\\nThe Large Diameter Occlusion Balloon Catheter (K002286)\\\\nmanufactured by Cook Incorporated (vessel occlusion,\\\\nproduct code MJN), and was cleared by FDA on March 22,\\\\n2001.\\\\nSubstantial The Reliant Stent Graft Balloon Catheter is substantially\\\\nEquivalence: equivalent to the predicate devices listed above, as it is\\\\ncomparable with respect to their intended use, overall catheter\\\\nconfiguration, and performance characteristics.\\\\n\\\\x0cDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service\\\\nFood and Drug Administration\\\\n9200 Corporate Boulevard\\\\nA.PR 1 3 Z005 Rockville MD 20850\\\\nMedtronic Vascular\\\\nc/o Mr. Willie Mitchell\\\\nAssociate Regulatory Affairs Specialist\\\\n3576 Unocal Place\\\\nSanta Rosa, CA 95403\\\\nRe: K050038\\\\nReliant Stent Graft Balloon Catheter\\\\nRegulation Number: 21 CFR 870.1250\\\\nRegulation Name: Percutaneous Catheter\\\\nRegulatory Class: Class 1L (Two)\\\\nProduct Code: DQY\\\\nDated: January 6, 2005\\\\nReceived: January 7, 2005\\\\nDear Mr. Mitchell:\\')]', name='retrieve_predicate_device_details', id='aeebdecd-c92b-4e47-b44f-15c8a4196df6', tool_call_id='call_PCU9OTQVLnU1jrsilNWlSswM')]\n",
      "\n",
      "\n",
      "\n",
      "Receiving update from node: 'agent'\n",
      "[AIMessage(content='```json\\n{\\n  \"substantially_equivalent\": false,\\n  \"reasons\": [\\n    \"The new device is intended to \\\\\"expand vascular prostheses and deliver therapeutic agents into vessel walls,\\\\\" whereas the predicate device (Reliant Stent Graft Balloon Catheter) has an indication for \\\\\"temporary occlusion of large vessels or to expand vascular prostheses.\\\\\"\",\\n    \"The addition of \\'deliver therapeutic agents into vessel walls\\' in the new device\\'s intended use introduces a differing clinical purpose that was not stated for the predicate device, impacting the safety and effectiveness assessment.\",\\n    \"According to the FDA guidance, a new intended use is established if the differences in indications affect the safety and effectiveness of the device compared to the predicate, which is applicable in this case.\"\\n  ],\\n  \"citations\": [\\n    {\"tool\": \"fda_guidelines\", \"text\": \"FDA may only determine that a device is substantially equivalent to a predicate device if it has the same intended use.\"},\\n    {\"tool\": \"fda_guidelines\", \"text\": \"A finding of NSE due to a new intended use is relatively rare. Approximately 10% of all NSE decisions are due to a new intended use.\"},\\n    {\"tool\": \"predicate_device\", \"text\": \"The Reliant Stent Graft Balloon Catheter is intended for temporary occlusion of large vessels, or to expand vascular prostheses.\"}\\n  ],\\n  \"suggestions\": [\\n    \"Consider revising the new device\\'s indications to exclude the delivery of therapeutic agents, aligning it more closely with the predicate device\\'s indications to evaluate substantial equivalence.\",\\n    \"Alternatively, consult with the FDA through a Pre-Submission to discuss the new clinical purpose and how it affects the intended use.\"\\n  ]\\n}\\n```', additional_kwargs={'refusal': None}, response_metadata={'token_usage': {'completion_tokens': 359, 'prompt_tokens': 15842, 'total_tokens': 16201, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 14208}}, 'model_name': 'gpt-4o-mini-2024-07-18', 'system_fingerprint': 'fp_34a54ae93c', 'id': 'chatcmpl-BzeqENgx2BhB2xbAzS26fPWyBPOnQ', 'service_tier': 'default', 'finish_reason': 'stop', 'logprobs': None}, id='run--e8a143cd-fce3-47b3-abc4-d0fe3b53da44-0', usage_metadata={'input_tokens': 15842, 'output_tokens': 359, 'total_tokens': 16201, 'input_token_details': {'audio': 0, 'cache_read': 14208}, 'output_token_details': {'audio': 0, 'reasoning': 0}})]\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "query = \"“Used to expand vascular prostheses and deliver therapeutic agents into vessel walls.”\"\n",
    "input = create_initial_state(query)\n",
    "async for chunk in device_regulatory_agent.astream(input, stream_mode=\"updates\"):\n",
    "    for node, values in chunk.items():\n",
    "        print(f\"Receiving update from node: '{node}'\")\n",
    "        print(values[\"messages\"])\n",
    "        print(\"\\n\\n\")\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
